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There is growing epidemiological and experimental evidence implicating excess luminal iron in 
the context of colorectal cancer. High levels of dietary iron is thought to aid carcinogenesis, due to 
the formation of reactive oxygen species from the redox cycling of iron, which can cause oxidative 
tissue damage and disrupt cellular signalling pathways. Hence, it is proposed that removal of this 
excess iron will suppress the development of this cancer.  
A clinically used iron chelator deferasirox and a modified version of this ligand, were attempted to 
be conjugated onto biopolymers chitosan and alginate. These non-absorbable polymers were 
hypothesised to be undigested in the gastrointestinal tract, thus specifically capable of targeting 
and removing excess iron from the colon. These chelator incorporated polymer materials, be they 
conjugated polymers or functional material blends, were subsequently shown to have improved 
iron binding properties compared to the parent polymers. Culturing RKO colorectal cancer cells 
with iron and alginate-ligand material did not significantly affect intracellular iron uptake, however 
culturing RKO cells with iron and chitosan-ligand material elicited a suppression in iron mediated 
ferritin expression and overall intracellular iron status. Based on these in vitro results, that the 
material obtained from reaction of chitosan with ligand elicits the desired inhibition of iron uptake, 
the chitosan-ligand material was administered to a mouse model of colorectal cancer. Apc Hom 
Pten Hom mice show reduced mitosis and increased apoptosis of intestinal crypt cells, 





Whilst polymer characterisation was sometimes challenging, the advice of the PhD examiners 
proved highly informative. As such additional diffusion NMR characterisation experiments were 
run post viva voce on new batches of polymer derivative, with the aid of Dr Melanie Britton and 
Catherine Smith. Data generated in these additional experiments confirm conjugation of alginate-
ligand material but suggest that chitosan-ligand material is not covalently conjugated. In light of 
this new data, alternative interpretations of the results in this thesis are provided. However, due to 
time passed the batches used for these suggested experiments were not the same as those that 
underwent the majority of experiments in this thesis. Thus caution must be exercised when 
interpreting the data as batch-to-batch variation means that it is unclear whether conjugation 
occurred in previous batches of chitosan-ligand material or if it was a polymer-ligand mixture. 
Despite this it still remains exciting that the chitosan-ligand material, as a conjugated polymer or a 
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1 Introduction  
1.1 Biological role of iron  
Iron, a first row transition metal of the periodic table, is not only one of the most abundant elements 
on the Earth1 but is also an essential nutrient found in most living organisms.2 It is vital in many 
mammalian cellular processes including DNA synthesis, proliferation and growth3 and is also 
utilised in numerous enzymes through the formation of iron-sulphur clusters.4 Furthermore, it plays 
an imperative role in the transport and storage of oxygen in the iron containing metalloproteins 
haemoglobin and myoglobin.5  
Iron absorption in humans occurs in the duodenum with only 10% of dietary iron being absorbed.6 
This is a heavily regulated process since humans do not possess a physiological mechanism for 
excreting excess iron, therefore deviation from this tightly regulated process can be particularly 
harmful.7 Iron deficiency anaemia occurs when there is an inadequate amount of iron in the body 
to meet physiological demands, and can result in fatigue and compromised immunity.8 Conversely, 
iron overload can occur in patients suffering from hemochromatosis, which is a genetic disorder 
resulting in excessive accumulation of iron, and also in patients receiving long term blood 
transfusions for various blood disorders such as β-thalassemia.5 Iron overload can cause iron 
deposits to occur around vital organs causing tissue damage, contributing to heart and liver 
diseases.9, 10 Aside from the complications arising from iron overload, it has been also been 
observed that patients suffering from iron overload diseases are also at increased risk of liver and 
colorectal cancer (CRC).11  
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1.2 Iron and colorectal cancer 
Numerous factors are associated with an increased risk of colorectal cancer (CRC) which includes 
genetic predisposition, age, history of inflammatory bowel disease and an unhealthy lifestyle. 
However, iron has been recognised in the aetiology of CRC,7, 12, 13 which causes approximately 
16,000 deaths per year in the UK, making it the second most common cause of death from cancer 
in the UK.14  
1.2.1 Epidemiological evidence 
Many epidemiology studies have shown that there is a greater incidence of CRC in developed 
nations15, 16 with 60% of all cases occurring in Western Europe, North America and Australia 
(Figure 1).17 This has been specifically associated with an iron rich diet comprising of red and 
processed meat which are rich sources of haem containing compounds.7, 13 Therefore, a high dietary 
iron intake has been identified as CRC risk factor.18 
 
Figure 1 Map showing colorectal cancer incidence in different regions of the world. More developed regions including Australia, 
New Zealand, Europe and North America have significantly greater cancer incidence than less developed regions.  
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1.2.2 Iron metabolism and regulation in cancer 
Iron absorption in humans principally happens in the duodenum (the first section of the small 
intestine), where dietary iron, mostly in the ferric (Fe (III)) form, is absorbed through the action of 
a reductase, duodenal cytochrome b (DCYTB) which reduces ferric (Fe (III)) iron to ferrous (Fe 
(II)) iron. Divalent metal transporter 1 (DMT1) enzyme transports ferrous iron into the enterocytes, 
and exits through the action of an iron efflux pump ferroportin and the oxidase hephaestin which 
oxides ferrous to ferric iron, which is then loaded onto transferrin (TF).19 This circulates in the 
bloodstream to deliver iron to sites of use (Figure 2). Hepcidin (HP), a peptide hormone produced 
by the liver is the ‘master regulator’ of systemic iron homeostasis.20 Hepcidin is expressed in 
response to excess iron and binds to ferroportin, preventing iron form being exported from 
enterocytes.  
 
Figure 2 Iron homeostasis in humans. (Reprinted with permission from Macmillan Publishers Ltd, Copyright 2013.) 
When the transferrin bound iron reaches a site of use, it binds to transferrin receptor 1 (TFR1) on 
the plasma membrane of cells and is endocytosed, where ferric iron is released and reduced to 
ferrous iron by the ferrireductase STEAP3. DMT1 transports ferrous iron out of the endosome and 
into the labile iron pool, and from here iron is taken to multiple destinations for various applications 
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including DNA synthesis and repair, energy generation by mitochondria and haem synthesis.2 
Excess iron is stored in the iron storage protein ferritin. Iron leaves the cell through ferroportin, 
under the action of an oxidase such as hephaestin or ceruloplasmin which converts ferrous to ferric 
iron for loading onto transferrin (Figure 3).19 
 
Figure 3 Iron metabolism in mammalian cells. (Reprinted with permission from Macmillan Publishers Ltd, Copyright 2013.) 
Cancer cells have amplified amounts of metabolically available iron due to increasing iron uptake 
via TFR1 and deceasing iron storage in ferritin.21 Iron efflux via ferroportin is also reduced by the 
upregulation of hepcidin leading to ferroportin degradation.22 Increased intracellular iron levels can 
fuel proliferation of cancer cells.23 Furthermore, adenomatous polyposis coli (Apc) gene is a 
tumour suppressor gene which is mutated or deleted in the majority of CRC cases.24 This genetic 
aberration is known to activate oncogenic signalling pathways,25 and is an early event in the 
adenoma to carcinoma sequence, resulting in multiple intestinal polyps which progress to 
cancerous tumours. It has been shown that following Apc deletion, there is a rapid induction of 
iron import proteins TFR1 and DMT1, which suggests an intimate relationship between iron and 
CRC, in the background of Apc deletion.26  
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1.2.3 In vivo evidence 
Mouse model studies were conducted by Radulescu et al. using Apcmin/+ mice which carry the 
germline Apc mutation and are representative of early stage CRC as they develop multiple 
intestinal adenomas.26 When these mice were fed an iron rich diet, the tumour burden increased 
significantly in both tumour number and size, whereas mice fed an iron deficient diet had a greatly 
reduced tumour burden compared to the controls. In order to elucidate the role of luminal iron as 
opposed to systemic iron, mice were given intravenous iron supplementation to induce systemic 
iron overload whilst on an iron deficient diet. These mice still showed a decreased tumour burden 
which indicates that systemic iron overload does not affect CRC, whereas luminal iron levels are 
critical.26  
Patients suffering from ulcerative colitis and Crohn’s disease are also at risk of anaemia due to 
persistent colonic blood loss and are often recommended iron rich diets as well as oral iron 
supplements in order to counteract the resultant loss of iron from the body.27 However, recent 
studies have shown that an iron-enriched diet not only exaggerates ulcerative colitis symptoms, but 
also elevates the development of ulcerative colitis related colorectal carcinoma.6 It has also been 
shown that a reduction of luminal iron leads to a lowering of ileitis associated with Crohn’s disease 
and offers significant alterations to gut microbiota.28  
1.3 The influence of iron in oxidative stress 
The inherent ability of iron to gain and loose electrons, the very attribute that makes iron useful 
biologically, is also the attribute which contributes towards the toxicity of iron when present in 
excess. The ability to redox cycle between two stable oxidation states, ferric (Fe (III)) and ferrous 
iron (Fe (II)), allows it to partake in potentially deleterious reactions which generate reactive 
oxygen species (ROS) such as the hydroxyl radical (Scheme 1).29 This can interact with most 
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biological molecules causing oxidative tissue damage, and can also initiate lipid peroxidation 
leading to the loss of cell membrane structure and function, which is thought to cause the formation 
of cancerous cells.30 In cases such as transfusion induced iron overload, the excess iron can lead to 
free radical induced tissue damage which can prove to be fatal without chelation therapy.31 
 
Scheme 1 The Haber-Weiss reaction generates toxic hydroxyl radical species via Fenton chemistry enabled by redox cycling by Fe 
(II) and Fe (III) in the presence of superoxide radical (O2-.) and hydrogen peroxide (H2O2). 
1.4 Iron chelation therapy 
Metal chelation therapy was initially developed in the early 1900s to counteract the toxicity of 
drugs containing arsenic and antimony, which were frequently used in the treatment of parasitic 
diseases. The arrival of the industrial revolution resulted in a large increase in cases of accidental 
heavy metal exposure, in addition to chemical warfare which instigated the development of 
chelators for mercury and lead poisoning.32 
Iron chelators have emerged to be of importance in the treatment of iron overload disorders and 
blood conditions such as β-thalassemia which is a genetic defect affecting haemoglobin, in which 
long term blood transfusions are required leading to iron overload.31 Iron chelators have also been 
investigated as therapeutic agents for degenerative diseases such as Alzheimer’s Disease, 
Parkinson’s Disease, and Friedreich’s Ataxia. It is proposed that one of the causes of such 
neurodegenerative diseases is the accumulation of iron in the brain leading to oxidative stress and 
tissue damage via redox cycling.33  
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An emerging application of iron chelators is in the treatment of cancer, whereby depleting iron 
from proliferating cancer cells deprives these cells of an essential nutrient needed for cell 
replication, therefore can inhibit or retard tumour growth (Figure 4).21  
 
Figure 4 A series of aroylhydrazones and thiosemicarbazones that are known to have potent anti-tumour activity due to their in vivo 
iron chelation and ROS promotion properties.  
In addition, kinetically labile bidentate or tridentate chelators, or those containing soft donor atoms 
which have lower redox potentials can be used to exploit the redox property of iron to target cancer 
cells.34 The highly reactive nature of ROS species can be harmful, as aforementioned, however the 
same property of ROS can be used against cancer cells as these iron chelators can be used to 
promote oxidative damage and subsequent cancer cell death.35 This is particularly advantageous 
when tumours develop resistance to standard chemotherapeutics and provides an alternate mode of 
treatment. 
1.5 Iron chelator design 
There are numerous factors that need to be considered in designing therapeutic iron chelators. 
Hard-soft-acid-base (HSAB) theory is of importance when considering the number and type of 
ligands that are appropriate for chelation. Hard acids and bases have small atomic or ionic radius 
and high oxidation states so that they are charge dense and have low polarizability, whereas soft 
acids and bases have larger atomic or ionic radius and low oxidation states with high polarizability. 
In terms of metal chelation, this refers to the donation of electron density from the ligand to the 
empty d-orbitals of the metal,32 with possible back donation from metal to ligand.36 Fe (III) is a 
hard metal ion which will bind preferentially to hard donors such as oxygen in catechol and 
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carboxylate groups, as observed in [Fe(C2O4)3]
3+ in which the hard oxygen donors of the oxalate 
groups stabilise ferric iron (Figure 5).37 However, Fe (II) is a borderline metal ion with preferential 
binding to soft donor atoms such as nitrogen,38 such as in [Fe(bpy)3]
2+ which is a stable ferrous 
iron complex with donation from soft nitrogen donor atoms and back donation to low lying π* 
orbitals (Figure 5).39  
 
Figure 5 Ferrous bipyridine and ferric oxalate complexes.  
The thermodynamic stability of the iron complex is also an important factor. The chelate effect 
states that as the denticity of the ligand is increased the resultant complex will be more 
thermodynamically stable due to a favourable entropy change upon exchange of many monodentate 
ligands of a solvated metal ion for fewer multidentate ligands.32 Also, the size and number of 
chelate rings formed is driven by thermodynamic factors as the most favourable chelate ring size 
is five or six membered, and the number of chelate rings formed is five for an octahedral complex 
(Figure 6).40  
 
Figure 6 The formation of chelate rings with bi-, tri- and hexadentate ligands. 
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Thus, since Fe (III) is a high spin metal with octahedral coordination sphere, the thermodynamic 
stability of its complex can be maximised by utilising a hexadentate ligand which will form five 
chelate rings. Iron chelators designed for therapeutic use must be selective towards iron only so as 
to prevent deficiencies of other biologically important metals within the body. Whilst it is possible 
to design ligands for preferential Fe (II) chelation with respect to Fe (III), such ligands can bind to 
other divalent metals such as Cu (II) and Zn (II). Similarly, Fe (III) chelators containing oxygen 
donor ligands can have an affinity for other trivalent metals such as Al (III) and Ga (III).40 
Moreover, ligands with a high affinity for Fe (III) can bind Fe (II) and promote autoxidation of Fe 
(II) to Fe (III) in aerobic conditions, suggesting that under physiological conditions, a highly Fe 
(III) selective chelator can bind both Fe (II) and Fe (III).41  
Iron must be tightly bound once chelated in order to minimise exposure to oxygen or hydrogen 
peroxide to prevent the generation of harmful ROS. Most hexadentate ligands such as 
desferrioxamine (DFO) (Section 1.6.1) encapsulate Fe (III) by occupying the coordination sphere 
of the metal ion resulting in a kinetically inert complex diminishing ROS production.42 However, 
ethylenediaminetetraacetic acid (EDTA) (Section 1.6.2) is more kinetically labile with a possible 
seventh coordination site occupied by water, which can exchange rapidly with oxygen and 
hydrogen peroxide leading to enhanced ROS production.43  
1.5.1 Siderophores: Enterobactin 
Due to the importance of iron in many metabolic processes, molecules of low molecular weight 
and high Fe (III) selectivity called siderophores are produced by microbes in response to iron 
deficiency in order to scavenge iron from the environment for uptake as soluble Fe (III) 
complexes.44 Siderophores can generally be divided into two groups depending upon the structural 
functionality that is used to chelate iron: catecholamides or hydroxamates.45 Since Fe (III) is a 
charge dense, hard lewis acid, a hard lewis base such as oxygen is preferred for binding.  
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Enterobactin, 1 is a naturally occurring siderophore most commonly found in gram-negative 
bacteria such as Escherichia coli and Salmonella typhimurium.44 The binding affinity for Fe (III) 
is K = 1052 and so it is regarded as the strongest known siderophore.46 
 
Scheme 2 Structure of enterobactin 1 and changes in conformation of catechol units by rotation about C-C bond driven by hydrogen 
bonding.  
Enterobactin consists of three catecholate functionalities linked by amide bonds to a cyclic 
trilactone scaffold (Scheme 2). Fe (III) is bound by the catechol groups which form a stable high-
spin hexacoordinate octahedral complex; the entropy difference upon binding is minimised by 
utilising a hexadentae ligand as opposed to bi- or tridentate ligands.  
 
Figure 7 Model of enterobactin showing hydrogen bonding within uncomplexed structure (left) and in that of Fe (III) complex 
(right) in which grey is carbon, blue is nitrogen, red is oxygen, white is hydrogen and dotted lines represent hydrogen bonds 
(Copyright 2003 National Academy of Sciences, USA). 
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Hydrogen bonding is important as catechol groups are effectively locked in one of two 
conformations. Interconversion between conformations is achieved upon metal complexation, in 
which deprotonation of catechols are required (Figure 7).47 The use of enterobactin for iron 
chelation therapy has been investigated but is prohibited due to high toxicity encountered in animal 
studies resulting in inflammation and sepsis, associated with enterobactin’s ability to stimulate 
microbial growth.45 
1.6 Iron chelators in clinical use 
1.6.1 Desferrioxamine 
Desferrioxamine (DFO), 2 is a naturally occurring siderophore produced by Streptomyces pilosus 
(Figure 8) and has been the leading Fe (III) chelator in clinical use for the treatment of chronic iron 
overload since mid-1960s.48  
 
Figure 8 Structure of DFO 2 and its ferric iron complex 2-Fe. 
It is a hexadentate hydroxamate chelator with good affinity for Fe (III) over other trivalent species 
(Table 1), binding ferric iron in a 1:1 molar ratio. Its hydrophilic nature means that it has poor oral 
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bioavailability and must be administered subcutaneously or intravenously for 8-12 hours per day, 
5-7 days a week. Hence, treatment by DFO is expensive and often has poor patient compliance.34 
1.6.2 Aminocarboxylates 
Ethylenediaminetetraacetic acid (EDTA), 3 is a synthetic hexadentate chelator binding through two 
amine nitrogens and carboxylates, although an additional water molecule may also coordinate 
forming a seven coordinate complex. Diethylenetriaminepentaacetic acid (DTPA), 4 is an 
expanded version of EDTA and is potentially an oxadentate ligand (Figure 9).49 Both bind with 
excellent affinity for Fe (III) and consequently have been extensively investigated for clinical use, 
being administered to patients who are intolerant to DFO. However, their lack of selectivity for Fe 
(III) renders them unsuitable as they also have good affinity for Zn (II) leading to zinc depletion 
(Table 1), as well as the formation of labile iron complexes resulting in the formation of toxic 
ROS.40 
 
Figure 9 Structure of EDTA 3 and its iron complex 3-Fe, and DTPA 4 and its iron complex 4-Fe. 
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In addition to chelation therapy, the non-specific metal binding ability of EDTA and DTPA renders 
them useful for other applications such as sequestering of metals in textiles, paper and food 
industries.50 Titrations with EDTA is often used to quantify metal ions in solution based on the 
stoichiometric formation of metal-EDTA complex.51 Furthermore,  EDTA acts as an anticoagulant 
in blood samples,52 and it can also be used to deactivate metal dependant enzymes by using in 
excess.53  
Table 1 Log cumulative stability constants of various cations with ligands. 
 Log Cumulative Stability Constants 
Ligand Fe (III) Al (III) Ga (III) Cu (II) Zn (II) Fe (II) 
DFO 30.6 25.0 27.6 14.1 11.1 7.2 
EDTA 25.1 16.5 21.0 18.8 16.5 14.3 
DTPA 28.0 18.6 25.5 21.6 18.4 16.5 
Deferiprone 37.2 35.8 32.6 21.7 13.5 12.1 
 
1.6.3 Deferiprone (L1, Ferriprox®) 
Deferiprone, 5 belongs to the bidentate hydroxypyridone family extensively investigated by Hider 
and co-workers for their iron chelation properties.33 Binding of Fe (III) occurs in a 3:1 molar ratio 
via the O-donors (Figure 10).  
 
Figure 10 Structure of deferiprone 5 and the ferric iron complex 5-Fe. 
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It was developed and quickly applied for therapeutic treatment of iron overload in the early 1980s 
with the main advantage of deferiprone being that it is available for oral administration.54 
Unfortunately, deferiprone is only effective at relatively large doses and can lead to side effects, 
most commonly abdominal pain and nausea. It has also been associated with more severe side 
effects leading to acute conditions such as agranulocytosis in which white blood cell count is 
extremely diminished such that the immune system is compromised, and arthropathy which causes 
inflammation of joints.55 
1.6.4 Deferasirox (ICL670A, Exjade®) 
Deferasirox, 6 is a tridentate chelator with ligand donation arising from the triazole nitrogen and 
two phenolate oxygens binding in a 2:1 molar ratio with Fe (III) (Figure 11). It has great selectivity 
for Fe (III) over other divalent ions and is hydrophobic, lending to its oral bioavailability.56 
 
Figure 11 Deferasirox 6 and the ferric iron complex 6-Fe. 
As Fe (III) is best chelated by oxygen containing ligands (HSAB theory), it would be expected that 
the presence of a borderline donor such as nitrogen would diminish Fe (III) selectivity in favour of 
divalent metal cations. However, if steric properties of the complex are considered, the ligand-
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metal unit is planar with O-M-O bond angle of 180° leading to short bond lengths for M-O and M-
N to be 1.60 Å and 1.90 Å respectively.57 Such small bond lengths can only be achieved by the 
binding of small metal ions such as Fe (III). Furthermore, the formation of a six membered chelate 
ring is also preferred by smaller metal ions. The intrinsic steric strain of the complex system 
increases as the size of the metal ion is increased contributing to the selectivity of the ligand for Fe 
(III). Deferasirox also has a relatively good affinity for Al (III) owing to its small ionic radius, but 
low affinity for other divalent ions (Table 2).58 This is currently the leading therapeutic agent for 
chronic iron overload in favour of DFO and deferiprone due to its oral bioavailability and absence 
of severe side effects.59  
Table 2 Formation constants for [MHxLy] in H2O/ DMSO, where M refers to the metal cation, L refers to deferasirox, and H refers 
to the degree of protonation of the ligand at the carboxylic acid. 
 Log Formation Constant 
 Mg (II) Ca (II) Cu (II) Zn (II) Al (III) Fe (III) 
[ML] 7.6 5.5 18.8 13.3 19.8 23.3 
[M(HL)]     24.1 27.5 
[ML2]   23.9 17.5 34.0 38.6 
[ML(HL)]     39.4 44.4 
[M(HL)2]     44.7 48.7 
 
Deferasirox has also been investigated as a therapeutic against neurodegenerative diseases. 
Kamalinia et al. conjugated deferasirox to lactoferrin in order to improve the water solubility and 
brain permeability of the ligand. Rat model studies using this compound confirmed the 
neuroprotective properties of iron chelation in the brain.60 There has also been growing interest in 
the anti-neoplastic activity of deferasirox,61 as it has been shown to overcome cisplatin resistance 
to inhibit oesophageal cancer growth,62 and is also effective against human lung tumour xenografts 
in murine models.63 Although anti-neoplastic data of deferasirox in humans is currently limited, it 
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is clear that due to its oral bioavailability, safety profile, and in vitro anti-tumour activity, 
deferasirox is a potential chemotherapeutic for the treatment of cancer. 
1.7 Macromolecular iron chelators 
Polymeric chelators have applications in water purification,64 metal recovery65 and pollution 
regulation.66 Macromolecular iron chelators for pharmaceutical use have also been reported, which 
display unique properties compared to their small molecule counterparts. The high molecular 
weight renders them non-absorbable in the gastrointestinal tract if taken orally, and increases their 
blood serum half-life if given intravenously, and they have also been demonstrated to have a lower 
toxicity profile compared to small molecule chelators.67 
1.7.1 Polymeric iron chelators 
Current methods of iron chelation therapy for chronic iron overload often has poor patient 
compliance due to the frequency of administration and monitoring required.5 In particular, DFO 
can pose severe problems as the dosage is limited by its acute toxicity and adverse effects on blood 
pressure which can lead to hypotension. It also has a short plasma half-life so it must be 
administered by prolonged subcutaneous infusions, which can be uncomfortable or impractical for 
the patient. To circumvent these problems, a high molecular weight iron chelator was developed 
by covalently attaching DFO to biopolymers dextran and starch. This was achieved by oxidation 
of the alcohol groups of the polysaccharide by sodium metaperiodate to yield aldehydes. DFO was 
added to the activated polysaccharide, and the resultant imine was reduced by cyanoborohydride. 
Any remaining aldehyde groups were reduced by sodium borohydride, and the reaction mixture 
was purified by extensive diafiltration to yield compound 7 in Scheme 3.68  
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Scheme 3 Synthesis of 7 starch-DFO conjugate.  
The degree of incorporation was calculated to be 20-30% for dextran-DFO and 10-20% for starch-
DFO. These substituted polymers showed greatly reduced toxicity in mice and increased plasma 
half-life of over tenfold compared to free DFO, and any adverse effects on blood pressure was 
negated.69  
The starch-DFO conjugate was tested in Phase 1B clinical trial with 21 β-thalassaemia patients 
suffering from transfusion induced iron overload. This was a single dose study where the patients 
were given one hour intravenous infusion of the drug at various concentrations ranging 150-900 
mg/kg. The starch-DFO conjugate was well tolerated with only four of the patients exhibiting mild 
urticarial reactions. Plasma and urine iron content were monitored which showed prolonged urinary 
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iron excretion over seven days, with a linear dose response relationship.70 Therefore, these 
substituted polymers have an iron binding capacity that is identical to the free drug with reduced 
acute toxicity and increased plasma half-life, allowing higher doses of the active drug to be 
administered at a lower frequency of administration. 
Other examples of DFO based macromolecular chelators include addition of a DFO polymer 
conjugate to polyethelene glycol (PEG) methacrylate by reversible addition fragment chain transfer 
(RAFT) copolymerisation (Figure 12) to give 8. This polymer also had improved vascular retention 
and in vitro cytotoxicity. The DFO moiety is attached to the polymer by an amide linkage, whereas 
the ester linkage to PEG can be hydrolysed, which will decrease the polymer size enabling effective 
renal clearance for excretion of the iron bound polymer complex in urine.71 
 
Figure 12 DFO polymer with PEG groups. 
DFO immobilised nylon 6,6 chelate fibres were also synthesised which show good affinity for high 
valence metal ions.72 Furthermore, the hydroxamine acid moiety of DFO was exploited to make 
polymeric hydroxamine acid iron chelators such as 9, 10 and 11 for the treatment of iron overload, 
which show improved iron binding compared to DFO due to cooperative binding from a polymeric 
structure (Figure 13).73 
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Figure 13 Hydroxamine acid based polymers. 
Enterobactin inspired hydrogel was made by Berkland and co-workers in which the catechol iron 
binding domain was attached to polyallamine via NHS/DCC peptide coupling (Scheme 4) to yield 
12. This afforded improved ferric iron chelation compared to polyallyamine alone, but it also had 
good affinity towards other divalent metals such as Ni (II), Mn (II) and Cu (II) which may be 
problematic for application in chelation therapy.74 
 
Scheme 4 Synthesis of enterobactin mimetic hydrogel. 
Although bidentate chelators may be more readily available or synthesised, it is more difficult to 
form an ideal octahedral iron complex when in a polymeric chain. Hexadentate chelators are 
entropically favoured and form stable iron complexes, and this property was utilised by Zhou et al. 
by preparing 3-hdroxypyridin-4-one hexadentate ligands via a multistep synthesis. This was 
incorporated into a block copolymer to form a highly iron selective reusable polymer. In vitro 
perfusion studies using rat intestines suggest that this polymer can be used to remove intestinal iron 
for patients with heamochromotosis.75  
1.7.2 Dendritic iron chelators 
Dendrimers are repetitively branched molecules with functional groups on the molecular surface, 
and are usually classified by generation which refers to the number of repeating branching units 
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from the core.76 Although polymers can be easier to synthesise and purify, dendrimers offer the 
advantage of having a precise molecular weight. Divergent and convergent synthetic strategies 
were employed to decorate a first and second generation dendrimer respectively with hexadentate 
ligands, which are effectively three equivalent bidentate 3-hydroxypyridin-4-one moieties (Scheme 
5).77 Dendrimer-Fe complexes were observed by MALDI mass spectrometric analysis. Iron 
chelation was also confirmed by titration methods.78 
 
Scheme 5 Synthesis of first generation dendrimer containing hexadentate ligands. 
DFO appended dendrimers have also been developed by Lim et al. which is accessed from a 
commercially available third generation dendrimer in seven steps, and 35% overall yield containing 
twelve DFO groups.79 The concise structure of dendritic-DFO may afford more robust 




Alginic acids (alginates) are hetropolysaccharides distributed widely in nature, most commonly 
found in marine brown algae and some bacteria.80 They consist of (1-4) linked β-D-mannuronic 
acid (M) and α-L-guluronic acid (G) residues (Figure 14) occurring in MM, GG or MG block 
copolymeric sequence.81 The physical properties of alginates can differ depending upon the 
average molecular weight and distribution of the polymer, as well as the sequence of M and G 
residues.82  
 
Figure 14 Alginate polymer chain containing G and M residues. 
1.8.1 Egg box structure and cation binding 
The most important physical property of alginates is the ability to form gels in the presence of 
cations.83 Alginates are well known to bind Ca (II) with G blocks having a greater selectivity for 
Ca (II) than M block or MG heteroblock. This can be explained in terms of molecular conformation 
as when G blocks are packed together, cavities can form into which Ca (II) ions can insert and bind. 
This is known as the egg box model (Figure 15).84 Additionally, Wang et al. have shown that there 
is strong autocooperative binding between Ca (II) and G residues in which all functional groups 
including hydroxyl and carboxyl groups are involved in binding, thus supporting the egg box 
model.85 Ca (II) has a weaker association with the M residues as these do not pack into a regular 
egg box structure.86  
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Figure 15 a) The regular packing of G blocks from two alginate strands results in cavities which Ca (II) cations can occupy by 
interacting with all carboxyl and hydroxyl groups, b) a schematic representation of poly-G units in which the grey spheres represent 
Ca (II) ions.  
Alginates have many applications in which this gelling property is exploited. They are commonly 
used as a gelling and thickening agent in the food industry as well as in many biomedical 
applications such as wound dressings, dental impression materials, drug delivery and formulations 
preventing gastric reflux.87 Indigestible viscous polysaccharides such as alginates are non-
absorbable in the gastrointestinal tract88 and are also known to lower serum cholesterol levels due 
to their ability to disperse in water.89  
Alginates have gained recent attention as potential non-absorbable iron chelators for bowel cancer 
therapy as they do have a propensity for binding other cations such as Fe (II). The ability to bind 
iron was demonstrated to be related to M:G ratio, with a high M:G ratio displaying high iron 
binding and reduced calcium binding. Further study using mouse models of colorectal 
tumorigenesis showed that alginate treatment was able to reduce tumour burden in APCmin/+ mice.90 
However, the main limitation of this approach is that iron binding by alginate is not necessarily 
specific as it can also bind other physiologically relevant metals such as calcium and cause 
unwanted side effects from calcium deficiency.  
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1.8.2 Chemical modifications of alginate 
Current interest in alginates include chemical modifications of the polymer, especially that of the 
carboxylic group for numerous applications. The ability of alginates to form hydrogels means that 
they have been extensively used in medicine as synthetic extracellular matrices (ECM) for cell 
immobilisation and transplantation in tissue engineering.91 However, the mechanical properties of 
hydrogels formed in the presence of divalent cations decays over time due to the loss of cations to 
the surrounding medium as well as exchange with other cations, which impose significant 
limitations to their biomedical use. This was overcome by covalently coupling cross-linkers such 
as polyethylene glycol diamines between alginate chains utilising the carboxylic group and aqueous 
carbodiimide chemistry to offer greater control over its mechanical properties.92 Similarly, 
alginates can be coupled to short peptides91 and galactose moieties93 to improve cell anchorage for 
ECM applications. Furthermore, biotin-alginate conjugate 15 has been synthesised to probe 
streptavidin-biotin interaction within cells for use as biosensors (Figure 16), which was 
characterised by FTIR, 13C NMR and fluorescence spectroscopy.82 
 
Figure 16 Alginate-biotin conjugate for use as biosensors. 
Dopamine modified alginate 16 was synthesised by activation of carboxylic group of alginate by 
NHS/EDAC coupling chemistry, followed by addition of dopamine (Figure 17) which was 
characterised by UV-vis and florescence spectroscopy, elemental analysis and imaging methods.94 
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This was then alternatively deposited onto CaCO3 templates with titanium (IV) 
bis(ammoniumlactato) dihydroxide, so that alginate-titanium microcapsules can be obtained upon 
removal of the template. This is achieved by the coordination of the catechol moiety to Ti (IV). 
Similar coupling chemistry was employed to incorporate cystine onto alginate to stabilise gold 
nano-particles for use as imaging agents.95 
 
Figure 17 Dopamine modified alginate used to bind to Ti (VI). 
1.9 Chitosan 
Chitosan is a linear polysaccaharide containing randomly distributed (1-4) linked β-D-
glucosamine.96 It is derived by the deacytalation of chitin which is found in the exoskeleton of 
crustaceans such as crabs and shrimps, and also in the cell walls of fungi, and is second only to 
cellulose in terms of the most abundant biopolymer in nature.97 Chitosan is known to be highly 
adsorbant of heavy metals such as Cd, Cr, Hg and Pb compared to chitin due to coordination from 
the free amino groups exposed during the deacytalation process, however sorption properties will 
depend upon the degree of deacytalation and amino group content.98 The key structural difference 
between alginate and chitosan is the presence of a primary amine group in place of the carboxylic 
acid group (Figure 18); however chitosan is also known to form hydrogels in aqueous media 
lending to similar physical properties and applications. 
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Figure 18 The structure of cellulose (top), chitin (middle) and chitosan (bottom). 
The digestion of chitosan by human digestive enzymes and colonic bacteria is unclear. One study 
suggests that non-crosslinked chitosan is readily digested by pancreatic and colonic bacteria, 
whereas crosslinked chitosan is more resistant.99 Moreover, chitosan itself may influence the 
concentration of certain types of colonic bacteria present, which was found to be dependent upon 
the molecular weight of the chitosan.100 
1.9.1 Chemical modifications of chitosan 
Protonation of the amino group forms pH sensitive hydrogels101 that are biodegradable and 
biocompatible enabling applications in tissue engineering and biotechnology.102 Furthermore, cross 
linked chitosan has been extensively investigated as a drug delivery agent as it is non-toxic if orally 
ingested and hydrogels enable sustained and controlled drug delivery.103 Modified forms of 
chitosan beads which allow selective sorption of Fe (III) is also of interest with the potential 
application of iron removal from contaminated and waste water.104  
Chemical modification of chitosan utilising the amine functionality is widely reported: N-
carboxymethyl chitosan synthesized from chitosan and chloroacetic acid105 or glyoxylic acid106 is 
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a common ingredient in cosmetic hydrating creams due to its moisturising properties on skin.96 
Chitosan bound to sugars such as D- and L- fructose as reported by Morimoto and co-workers were 
investigated for biological interactions with lectins and canine polymorphonuclear leukocyte 
(PMN) cells.107 Dendrimers, which are known to have viral inhibiting properties, containing an 
aldehyde moiety and spacers are also attached to chitosan by reductive N-alkylation.108 
Furthermore, chitosan linked to cyclodextrins have gained prominence due to the hydrophobic 
nature of the cylclodextrin core, allowing selective binding small molecules with potential 
applications in drug delivery and cosmetics.109 
 
Figure 19 Chitosan succinate and hydroxymated chitosan succinate used to cross link with Fe (III). 
Metal binding of modified chitosan is also used to form cross linked polymer beads for drug 
delivery; chitosan succinate 17 and hydroxamated chitosan succinate 18 (Figure 19) were prepared, 
principally characterised by IR spectroscopy, and cross linked by addition of FeCl3 due to chelation 
by O-donor groups of succinate for prolonged drug delivery applications in which iron leeching 
was found to be minimal, suggesting tight coordination of ferric iron.110 
1.10  Conclusion 
With the growing prevalence of colorectal cancer in developed countries, the emergence of iron 
chelators as a potential therapeutic and preventative agent is of great importance. The current 
course of treatment for colorectal cancer is invasive surgery to remove cancerous tissue and 
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chemotherapy which has many unpleasant side effects. The use of non-absorbable backbones such 
as alginate and chitosan attached to chelators will enable targeted chelation therapy and may 
provide an additional option for treatment. Due to the increasing cost of cancer care, the 
development of cancer preventative agents could also contribute towards lowering cancer 




2 Project overview and Aims 
Due to the innate association between luminal iron and colorectal cancer, the main objective of this 
project is to design and synthesise an iron chelator which can be utilised to specifically target and 
remove excess iron from the colon. This can be used as a therapeutic agent for those already 
affected with the disease or as a preventative agent for those at increased risk of the disease 
(Scheme 6). The extent of redox cycling between ferrous (Fe (II)) and ferric states (Fe (III)) of iron 
is unknown under physiological conditions so both states of iron will be taken into account. The 
iron chelator must bind iron selectively in the presence of other physiologically relevant ions and 
offer good chelation to supress and minimise redox cycling of iron.  
 
Scheme 6 The development of ligand (L) attached to a non-absorbable backbone (NAB) for chelation of iron. 
Consequently, the proposed system should deliver iron chelators to the colon and conjugation with 
non-absorbable polymer conjugates represent an ideal platform to achieve this. However, aggregate 
and salt-like systems for colonic ligand delivery may also provide an alternative approach. It is 
important that the chelator is not digested and absorbed into the blood stream as this may cause 
systemic iron deficiency and associated side effects. This will be enabled by a targeted approach 
in which the chelator should specifically remove iron from the bowel. Finally, iron binding studies 
of the polymer materials will establish the iron binding strength of the polymers which will 
contribute to in vitro and in vivo studies in which the toxicity and chelation properties of these 




The state-of-the-art evidence discussed previously (Chapter 1) led to the conclusion that excess 
free luminal iron is a driver of carcinogenesis in the colon. Chelators developed thus far are 
predominantly used for the removal of systemic, plasma circulating iron and are often orally active 
with limited toxicity. However, the design of an iron chelator that will sequester luminal iron 
should be non-absorbable and non-fermentable by the microbiota in the gastrointestinal tract so 
that iron removal occurs specifically in the colon, to prevent systemic iron deficiency by absorption 
of the iron chelator into the bloodstream. Furthermore, iron must be bound selectively by ligands 
ideally removing excess luminal iron via excretion; removal of non-target physiologically 
important metals may potentially be deleterious. 
Clinically used iron chelators such as desferrioxamine, deferiprone and deferasirox were 
considered as their iron binding properties and toxicity profiles are well characterised. Additionally, 
such chelators have already undergone rigorous clinical trials in humans to assess safety and 
tolerability. Desferrioxamine and deferiprone both have low tolerability, risk of side effects, and a 
chemical structure that cannot be easily altered without affecting the key iron binding 
functionalities. Therefore, deferasirox 6 (ICL670A, Exjade®, Figure 20) was chosen as a suitable 
iron chelator for investigation in the role of CRC therapy due to its high affinity and selectivity of 
iron over other physiologically relevant metals, a facile two step synthesis from commercially 
available starting materials, and a chemical structure that lends itself for further chemical 
manipulation. Deferasirox is also known to exhibit anti-neoplastic effects against specific 
cancerous tumours (Section 1.6.4).   
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Figure 20 Structure of deferasirox 6. 
In order for this chelator to be non-absorbable in the gastrointestinal tract, the design proposed 
allows attachment to a polymeric backbone, which should also be non-toxic and safe to consume.  
Naturally occurring polymers were considered, in particular alginate and chitosan which are 
already used in many food products as thickening agents so are approved for human consumption. 
They also have chemical moieties that can be utilised to attach deferasirox to afford non-absorbable 
iron chelators. As such, investigations in the use of this ligand and these polymers, whether as 
conjugates or hybrid material presents a reasonable strategy for moving forwards towards the clinic 
given they have independent low toxicity.  
3.2 Ligand synthesis and modifications 
The synthesis of deferasirox 6 was based on work by Steinhauser et al.57 and began with 
commercially available salicylic acid 19 and salicylic amide 20 to afford intermediate 21 via the 
formation of the acid chloride, which aids cyclisation. This was further reacted with 4-
hydrazinobenzoic acid 23 in which the hydrazine attacks the electrophilic sites of the carbonyl and 
imine carbons to produce the triazole 6 in 99% yield (Scheme 7). It was discovered during synthesis 
that intermediate 21 readily decomposes in the presence of moisture into 22 which was very 
difficult to remove from the mixture by column chromatography or recrystallisation. Therefore, 21 
was synthesised and immediately used in the next step of ligand formation.  
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Scheme 7 Two-step synthesis leading to the formation of deferasirox 6.  
Since the iron binding capacity of deferasirox comes from the phenolic oxygens and nitrogen of 
the triazole, this part of the molecule must be left unmodified for it to be an effective ligand. 
However, attachment to a non-absorbable backbone can occur through utilisation of the carboxylic 
acid or by exchanging 23 with hydrazines that contain different functionalities. In the first instance, 
alginate which contains carboxylic acid groups was identified as a suitable non-absorbable 
backbone. Carbodiimide mediated cross coupling reactions utilising the free carboxylic acid groups 
of alginates with amines are well known and documented (Section 1.8.2). Hence, it was proposed 
that the carboxylic acid group of ligand 6 can be chemically modified to an amine for further 
coupling to alginate. 
Initial attempts were based on the synthesis of N-protected aminophthalimides with the removal of 
the phthaloyl group leading to the corresponding hydrazine 25, by Brosse et al.112 1,1’-
carbonyldiimidazole (CDI) is a highly reactive carbonylating agent used to activate carboxylic 
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acids via the formation of the reactive N-acylimidazole intermediate, with the release of carbon 
dioxide as the entropic driving force. This can further react with N-amiophthalimide to afford the 
product 24. The removal of the phthaloyl group using hydrazine hydrate as a nucleophilic agent to 
give the corresponding hydrazine 25 (Scheme 8) would have allowed direct coupling of the product 
to alginate in a similar method to that described by Polyak et al.82  
 
Scheme 8 CDI mediated amide formation of 6 followed by a proposed reaction with hydrazine hydrate.  
However, 24 could not be isolated from the reaction mixture after column chromatography despite 
mass spectrometry (MS) evidence for product formation (Figure 21). This was repeated using 
benzoic acid as a model reaction but similar purification problems were encountered. 
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Figure 21 Mass spectra of reaction mixture showing unreacted starting material 6 + K+ and product 24 + K+ 
Alternatively, different hydrazines can be used to incorporate different functionalities and as such 
4-nitrophenyl hydrazine 26 was reacted with intermediate 21 to give product 27 in 86% yield 
(Scheme 9).  
 









Reduction of the nitro group in 27 was attempted utilising two different methods to try and form 
the corresponding amine (Scheme 9). Hydrogenation was attempted with Pd/C catalyst and 
hydrogen gas in a sealed reaction vessel, however this gave a mixture of compounds that could not 
be separated by column chromatography. Therefore, the reduction was tried with Sn/HCl, and 
although there was evidence for product 28 formation by MS (Figure 22), it could not be isolated 
in good purity or yield.  
 
Figure 22 Mass spectra of reaction mixture after reduction of 27 to 28 by Sn/HCl showing product 28 +H+ as main peak. 
The carboxylic acid group on ligand 6 can also be utilised in NHS/DCC mediated coupling 
reactions with amines to afford amides. Hence, it was proposed that reacting 6 with excess diamine 
would incorporate a free amine for further coupling to the carboxylic groups of alginate. Amide 
formation with 6 was initially tested using isopropylamine to establish the protocol which gave 29a 
in 83% yield after column chromatography. Consequently, numerous diamines were used in the 






Scheme 10 Amide formation with isopropyl amine (top) to yield 29a, and other amines tried in this reaction (bottom).  
 
 

















a) b) c) d) 
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However, despite mass spectrometry evidence for product formation 29b-e (Figure 23), isolation 
of products proved to be problematic. Column chromatography using silica was investigated with 
a range of eluent conditions but products seemed to stick or streak on silica, despite using very 
polar eluent conditions (e.g. 5% MeOH, 1% NEt3 in CHCl3). Precipitations and recrystallisations 
were attempted, however clean products were unable to be isolated due to the persistent 
contamination of amine or urea side product from DCC coupling. In order to overcome the isolation 
problems encountered, a mono-Boc protection of a diamine was proposed so that an excess of 
diamine would not have to be used in reaction with the ligand, as this was very difficult to remove 
at the end of the reaction (Scheme 11).  
 
Scheme 11 Synthesis of amine appended ligand 33 from Boc protected amine 31 and acid chloride 32.  
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Scheme 12 The mechanism for the formation of 33 from 31 and 32. 
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In addition, thionyl chloride was used to convert the carboxylic acid group of 6 into an acid chloride 
so that this could be reacted with the amine. This would circumvent the use of NHS/DCC coupling 
method, so would avoid contamination from the urea side product. Initial attempts at formation of 
32 gave incomplete conversion after refluxing for 7 hours; hence a longer reaction time of 22 hours 
was required to obtain full conversion to the acid chloride. In order to aid the water solubility of 
the modified polymer, it was proposed that a glycol linker between the polymer and ligand would 
be beneficial. For that reason, 2,2 (ethylenedioxy)bis(ethylamine) was mono-Boc protected to give 
31 and subsequently reacted with 32. The Boc protected amine group was deprotected by stirring 
in TFA/DCM to give 33 in 96% yield (Scheme 11). The mechanism is shown in Scheme 12. This 
amine appended ligand was now suitable for reacting with carboxylic acid groups of alginate.  
Although there is greater literature precedent for carbodiimide-mediated amide formation reactions 
with alginate, esterification reactions utilising the carboxylic acid moiety of the alginate also 
seemed chemically accessible. Esterification reactions were first tested with the ligand to check for 
viability. Therefore, deferasirox 6 was refluxed in methanol and ethanol with sulphuric acid to give 
the corresponding methyl and ethyl esters 34 and 35 in 99% yield (Scheme 13). 
 
Scheme 13 Formation of methyl ester 34 and ethyl ester 35. 
Furthermore, intermediate 21 was reacted with 2-hydroxyethyl hydrazine 36 to give an alcohol 
appended version of the ligand 37 in 43% yield (Scheme 14). Nucleophilic attack of the primary 
amine of 36 into the electrophilic imine site of 21 is followed by the activation of the carbonyl by 
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protonation. This undergoes a second nucleophilic attack by the secondary amine of 36 leading to 
cyclisation to form a five membered ring, and further loss of a water molecule leads to a 
thermodynamically stable aromatic triazole product 37.  
 
Scheme 14 Reaction conditions for the formation of alcohol appended ligand 37 (top) and the proposed mechanism for the formation 
of 37 from 21 and 36 (bottom).  
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This was used in a Steiglish esterification with benzoic acid, and after purification by column 
chromatography the desired ester 38 was isolated in 18% yield (Scheme 15). The poor yield may 
be due to the mild reaction conditions employed, as the starting material 37 was also isolated from 
the column. However, for the purpose of a model reaction, it was performed at room temperature 
so that the conditions would be transferable to alginate. Nevertheless, the formation of an ester 
linkage using 37 was confirmed as product 38 was isolated from the reaction mixture. 
 
Scheme 15 Formation of ester 38 from 37. 
Additionally, with the alcohol appended ligand 37 in hand it was thought that the alcohol group 
could be tosylated or mesylated into a good leaving group for further reactions with nucleophiles. 
Therefore, tosylation of the primary alcohol of 37 was attempted initially with 1.20 equivalents of 
TsCl, however, after purification by column chromatography, two products 39 and 40 were isolated 
in 20% and 12% yield respectively (Scheme 16).  
 
Scheme 16 Tosylation of 37 resulted in two products 39 and 40. 
The position of the second tosylation on 40 was confirmed by Nuclear Overhauser Effect (nOe) 
studies. Irradiation of protons α to sulphur of tosyl groups resulted in nOe to protons shown (Figure 
24) confirming tosylation of primary alcohol and one of the phenolic rings.  
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Figure 24 Observed nOe in 40 to confirm positions of tosyl groups 
The primary alcohol should be chemically more nucleophilic and reactive than the phenolic alcohol 
as the O lone pair of electrons can be conjugated into the aromatic system, so the reaction was 
repeated using 1.00 equivalent of TsCl to minimise the formation of 40. Although the extent of the 
second tosylation occurring seemed to decrease, mixtures of 39 and 40 were still isolated in 43% 
and 7% yield respectively. A similar reaction using 1.00 equivalent of MsCl was attempted, 
however mixtures of products still seemed to occur as confirmed by crude 1H NMR spectroscopy 
and mass spectroscopy. In this instance, the compounds could not be separated by column 
chromatography. 
The tosylated product 39 was further reacted with excess p-xylenediamine, however 37 was 
isolated with quantitative mass recovery in which the diamine had failed to react with the tosylate, 
and in addition the tosyl group had reverted back to the alcohol. Due to the poor reactivity of 39 
under the conditions employed, this avenue of investigation was not pursued.  
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3.3 Polymer reactions 
3.3.1 Polymer-deferasirox conjugates 
After the successful esterification of 37 with benzoic acid to give 38, similar conditions were 
employed to attempt to couple 37 to alginate. Alginate is water soluble and does not dissolve in 
organic solvents, whereas 37 is organo-soluble with poor water solubility. Therefore, in the first 
attempt 37 was dissolved in a few drops of DMSO and added to an aqueous solution containing 
alginate, DCC and DMAP (Scheme 17).  
 
Scheme 17 Attempted esterification reaction with alginate and 37. 
However, upon addition the solution turned cloudy indicating precipitation of the ligand in aqueous 
media, and DCC is also poorly soluble in water. The reaction was repeated using 1:1 THF:H2O 
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mix, however DCC was still poorly soluble. Therefore, in the final attempt EDAC.HCl was used 
instead in 1:5 THF:H2O solvent mix.  
In all cases, the purification protocol involved dialysis in which the reaction medium was 
transferred to cellulose membrane tubing. This was then suspended in deionised water for three 
days, with the water being changed regularly. This should ensure that polymeric alginate remains 
inside the tubing, whilst all other soluble small molecules can freely cross the membrane barrier 
into the surrounding water to only leave the desired alginate product in the tubing.  
Characterisation of the alginate product proved problematic as matrix-assisted laser 
desorption/ionisation (MALDI) or electrospray mass spectra was not obtainable so the change in 
molecular weight upon desired modification could not be monitored. Proton NMR spectroscopy 
indicated a lack of aromatic protons suggesting that product 41 was not formed, and IR 
spectroscopy was used to determine the frequency of the ester band (~1735 - 1750 cm-1) which 
would have been diagnostic of product formation, however this was not observed. Ultimately, UV-
vis spectroscopy was used to shed light into the electronic properties in solution. A spectrum of 
unmodified alginate was compared to that obtained after the reaction. With modification, the 
spectrum should differ due to the incorporation of 37 which contains an aromatic conjugated 
system. However, it was found that the spectrum of the unmodified alginate were identical to those 
obtained after all reactions, thus conclusively indicating the absence of ligand 37 on alginate 
(Figure 25). This may be due to alginate itself containing secondary alcohol groups which may be 
of similar reactivity to the primary alcohol group of 37, therefore this alcohol is not nucleophilic 
enough in the alginate environment to attack the reactive intermediate in order to form the ester.  
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Figure 25 UV-vis spectra of alginate and attempted product 41 both showing an absorbance at 265 nm indicating that no 
modifications were made to alginate and compound 41 was not formed.  
Amide formations using amines may be a more viable route as N-lone pair electrons are higher in 
energy than O-lone pair electrons, rendering amines more nucleophilic than alcohols. Hence, the 
water soluble amine appended ligand 33 was reacted with alginate using similar NHS/EDAC.HCl 
coupling chemistry to yield product 42, Exalg (Scheme 18). After stirring at room temperature for 
16 hours, the resulting precipitate was isolated by centrifuge. Characterisation by proton NMR 
spectroscopy showed distinctive peaks in the aromatic region of 7 – 8 ppm indicative of ligand 
incorporation into the material (Section 4.3, page 53). Characterisation by IR spectroscopy showed 
an amide band at 1634 cm-1 (Section 4.2, page 51), and UV-vis spectroscopy also showed 
distinctive peaks at 247 and 301 nm from the incorporated ligand (Section 4.4, page 60). Full 
characterisation is discussed in Chapter 4. Alginate (LFR5/60) has 65% G composition, however 



























Scheme 18 Synthesis of alginate-ligand conjugate 42 Exalg. 
In addition to alginate, chitosan was also identified as a suitable biopolymer for application as a 
non-absorbable backbone. Chitosan contains primary amine groups, which could be utilised in 
carbodiimide mediated cross coupling with deferasirox 6. Chitosan is soluble in weakly acidic 
aqueous media whereas 6 is soluble in organic solvents. Therefore, 6 was dissolved in DMSO and 
then added to an aqueous solution containing chitosan, EDAC.HCl and NHS which was 
subsequently stirred at room temperature for 16 hours (Scheme 19). This was further dialysed in 
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water at ambient temperature for three days, and water was removed in vacuo to yield a product 
believed to be 43, Exkite as a brown film.  
 
Scheme 19 Synthesis of chitosan-ligand conjugate 43 Exkite. 
As chitosan is derived from chitin which contains N-acylated groups, chitosan will always contain 
a minor component of the N-acylated group as the deacylation process rarely goes to completion. 
The proton NMR spectrum of the Exkite product showed distinct resonances in the aromatic region 
(7 - 8 ppm) compared to that of chitosan alone indicating the presence of ligand 6 (Section 4.3, 
page 53). Full characterisation of this polymer is discussed in Chapter 4. 
3.3.2 Polymer-catechol conjugates 
Catechol groups are widely found in siderophores such as enterobactin and are known to have good 
affinity for Fe (III) due to HSAB theory in which small charge dense cations bind well to hard 
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oxygen donors. Therefore, coupling catechol groups to chitosan and alginate were attempted by 
using similar methods. Alginate was reacted with 44 in an aqueous solution (Scheme 20), and 
chitosan was reacted with 46 in 1:1 H2O:EtOH to aid the solution of 46 in the presence of NHS 
and EDAC.HCl coupling reagents (Scheme 21).  
 
Scheme 20 Synthesis of alginate-catechol polymer 45. 
After purification by dialysis in water at ambient temperature over three days, the resulting 
products 45 and 47 were isolated by lyophilisation. However, the poor solubility of 45 and 47 made 
characterisation of the polymers extremely difficult. Elemental analysis suggested ligand 
incorporation for both polymers due to the significant difference in elemental composition between 
unmodified and modified polymers. In particular, alginate alone does not contain any nitrogen 
however, after modification there was an increase in nitrogen composition to 5.28% which could 
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have only come from the ligand. Despite these promising results, these polymers were not carried 
forward for further investigations due to their poor solubility. 
 
Scheme 21 Synthesis of chitosan-catechol polymer 47. 
3.4 Dendrimer reactions 
Poly(aminoamide) (PAMAM) dendrimer is a class of spherical dendrimer that consists of repeating 
branching units containing amine and amide functionalities. They have been extensively studied 
for many different applications including drug delivery and nanotechnology, and are known to have 
good biocompatibility.76 Furthermore, the defined structure allows for structural control during 
synthesis and low polydispersity compared to polymers. PAMAM dendrimers are functionalised 
with amines on the surface, hence it was envisaged that this could be reacted with deferasirox 
ligand to produce iron binding dendrimers. 
For proof of concept, a commercially available generation zero (G0) PAMAM dendrimer was 
chosen and this was initially reacted with four equivalents of acid chloride functionalised ligand 
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32, with triethylamine in DCM at room temperature for 16 hours. However, monitoring by TLC 
showed numerous spots that were very difficult to separate by column chromatography. It was 
thought that the acid chloride moiety may have been too reactive and may have added multiple 
times to the dendrimer causing numerous addition products. 
 
Scheme 22 A synthetic route to compound 48. 
Therefore, in order to better control the addition of the ligand, carbodiimide chemistry was 
employed. The dendrimer was added to four equivalents deferasirox 6, DCC and NHS in DMF, 
and was stirred at room temperature for two days (Scheme 22). After purification by repeated 
precipitation in MeOH/DCM, a product with the mono-addition of the ligand was observed by 1H 
NMR spectroscopy and mass spectrometry. In order to drive the reaction to completion, the 
reaction was repeated with heating for 16 hours, however this also gave multiple products by TLC 
that were difficult to separate. In the next attempt, six equivalents of deferasirox 6, NHS and DCC 
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were used and the reaction mixture in DMF was heated at reflux for five days. After purification 
by column chromatography, none of the compounds seen previously were observed, possibly due 
to the decomposition of the dendrimer when heated for a prolonged period of time in DMF. The 
reaction was repeated in DCM which has a lower boiling point at 40 °C, however the product could 
not be isolated despite conducting column chromatography of the reaction material twice. In a final 
attempt, HOBt with DCC was used instead of NHS, and the reaction mixture in DMF was stirred 
at room temperature for three days, but there was no evidence for product formation by 1H NMR 
spectroscopy or mass spectroscopy.  
Reactions with the dendrimer were extremely difficult to control due to incomplete additions of 
the ligand to give mono-, bi- and tri- addition products, which also hampered the purification 
process due to a mixture of compounds being produced that were very similar in size and polarity. 
Reaction conditions were probed to force the reaction to completion, but addition of four ligands 
to a dendrimer was still difficult to achieve and even more difficult to isolate. 
3.5 Summary 
Deferasirox ligand was synthesised in two steps from commercially available starting materials. 
The carboxylic acid moiety of this ligand was utilised and reacted with diamines in order to produce 
amine appended ligands but products were difficult to isolate. Therefore, Boc-protected amine 31 
was used and reacted with the acid chloride of deferasirox to yield amine appended ligand 33. This 
was further utilised in NHS/EDAC.HCl mediated reaction with alginate to produce a material 
identified as Exalg 42. Deferasirox 6 itself was reacted with chitosan to give a material named 
Exkite 43. Catechol containing compounds were also reacted with alginate and chitosan but 
products were poorly soluble and difficult to characterise. Additionally, reactions of deferasirox 6 
with dendrimers were challenging to control and the desired products could not be isolated with a 
satisfactory purity or yield.  
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4 Polymer Characterisation  
4.1 Background 
Numerous methods were employed in an attempt to characterise the modified polymers Exkite 
(Scheme 19) and Exalg (Scheme 18). Due to their poor solubility in aqueous media, traditional 
polymer characterisation methods such as gel permeation chromatography (GPC) and size 
exclusion chromatography (SEC) were not feasible. However, efforts were focused on qualitative 
and quantitative analysis of the polymers, in particular calculating the amount of ligand 
incorporation or ligand loading of the polymer material that was believed to be modified.  
In order to further investigate the effects of ligand loading and subsequent iron binding properties, 
alginate was also reacted with varying amount of ligand 33 from 0.25 equiv to 1.25 equiv to give 
the corresponding products Exalg0.25, Exalg0.50, Exalg0.75, Exalg1.00 and Exalg1.25 (Scheme 23). The 
ligand loading of Exalg in particular was investigated due to the poor iron binding properties of 
Exalg compared to Exkite (see Chapter 5).  
 
Scheme 23 Synthesis of Exalg with varying equivalences of ligand 33. 
4.2 Infrared Spectroscopy 
Infrared (IR) spectroscopy is used in the qualitative characterisation of organic molecules and 
polymers to determine distinctive functional groups or bonds within the molecule by studying 
fundamental vibrations of covalent bonds.113 The IR spectrum of sodium alginate alone shows a 
broad –OH peak at 3255 cm-1, and a carbonyl peak corresponding to the carboxylic acid salt at 
1594 cm-1. The ligand 33 also shows –OH absorption at 3200 cm-1, -CH absorption at 3000 cm-1 
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and carbonyl peak from the amide at 1645 cm-1. After ligand incorporation, Exalg has distinctive 
peaks at 3295 cm-1 and 3000 cm-1 corresponding to –OH and –CH absorption, and a strong carbonyl 
amide absorption at 1636 cm-1 resulting from C=O vibration. Furthermore, the fingerprint region 
of Exalg is also very similar to that of ligand 33 which is also indicative of ligand incorporation 
(Figure 26). 
 
Figure 26 IR spectra of alginate, ligand 33 and Exalg.  
Similarly, chitosan alone exhibits –OH/-NH and –CH absorption at 3353 cm-1 and 3000 cm-1 
respectively, and amine N-H bend absorption at 1652 cm-1. Deferasirox 6 shows broad –OH 
absorption at 3000 cm-1 which is overlapped with the C-H peak at 2980 cm-1, and a carbonyl C=O 
peak at 1683 cm-1 which is at a lowered frequency of absorption due to conjugation of the carbonyl 
with the aromatic ring. After ligand addition, Exkite also shows –OH absorption and overlapped –
CH absorptions at 3379 cm-1 and 2985 cm-1. The carbonyl absorption at 1623 cm-1, shifted 
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approximately 60 cm-1 from the carbonyl of deferasirox 6, indicates amide formation and the 
fingerprint region also resembles that of the ligand 6 (Figure 27). 
 
Figure 27 IR spectra of chitosan, deferasirox 6, and Exkite. 
4.3 Nuclear Magnetic Resonance Spectroscopy  
Nuclear magnetic resonance (NMR) spectroscopy is universally utilised for the elucidation of 
structures of organic compounds as it allows the detection of atomic nuclei and the relative 
chemical environment that they are in.114 A large range of solvents were investigated for NMR 
spectroscopic studies and it was found that Exalg is soluble in d6-DMSO and Exkite is soluble in 
d-TFA. The analysis of 1H NMR spectra of Exkite (Figure 28) and Exalg (Figure 29) show clear 
aromatic protons that can be integrated to correspond to the twelve aromatic protons of deferasirox 
ligand 6 and modified ligand 33. There are also broad undefined peaks at 2.00 - 5.50 ppm from the 
aliphatic protons of chitosan and alginate polymer backbones.  
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Figure 28 1H NMR spectrum of Exkite in d-TFA (residual signal at 11.50 ppm not shown). 
 
Figure 29 1H NMR spectrum of Exalg in d6-DMSO. 
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Quantitative information was also extracted from the 1H NMR spectra to determine the percentage 
of ligand incorporation into the polymer backbones by integrating the relative aromatic and 
aliphatic regions. The ligand is the source of aromatic protons so comparison of this integral to that 
of aliphatic protons from the polymer backbone enabled the calculation of percentage incorporation 
of polymers (Table 3).   
Table 3 Percentage incorporation of polymers as calculated by proton NMR spectra integrations. 
Entry Compound Ligand equiv % Incorporation by inspection of 1H NMR 
spectra 
1 Exkite 1.00 37 
2 Exalg0.25 0.25 25 
3 Exalg0.50 0.50 27 
4 Exalg0.75 0.75 19 
5 Exalg1.00 1.00 26 
6 Exalg1.25 1.25 20 
 
The percentage incorporation was calculated to be 37% for Exkite and 19-27% for Exalg series, 
with the highest incorporation estimated for Exalg0.50 and the lowest modification for Exalg0.75. 
However, the main limitation of this method is that due to the hygroscopic nature of DMSO, in d6-
DMSO the residual 1H NMR signal for H2O occurs at 3.30 ppm which is in the aliphatic range that 
was integrated. This signal could not be distinguished from those resulting from alginate due to the 
broad peaks obtained, and so was included in the aliphatic integrations which may contribute 
towards overestimation of the aliphatic integration, so will give a lower percentage modification 
than in actuality. The residual solvent effects can be overcome by using solid state NMR 
spectroscopy, which is widely applied in polymer chemistry to negate the poor solubility of some 
polymers in deuterated solvents,115 and for the determination of 13C NMR spectroscopy which 
typically requires a greater concentration of compound in solution state NMR.116 Alternatively, the 
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polymers can be subject to acid hydrolysis and the resulting monomers can be analysed by solution 
state NMR spectroscopy which will allow more detailed characterisation and quantification,114 
however oligomers of differing sizes may broaden the spectra.  
4.3.1 Diffusion NMR Spectroscopy 
Diffusion NMR experiments were conducted and data fitted by Catherine Smith with assistance from Daniel Payne 
and advice from Dr Melanie Britton. This experiment was done at the recommendation of PhD examiners to improve 
understanding of conjugation between the polymer and ligand. As these experiments were done post viva voce, the 
original materials used in the majority of the thesis were unavailable and so these experiments were conducted on 
different batches of material. Therefore, batch-to-batch variation must be taken into consideration and caution 
exercised in the interpretation of these results in the context of the remainder of the results presented in this thesis.  
Self-diffusion is the random translational motion of molecules driven by internal thermal energy.117 
This is dependent on physical parameters in solution state such as size and shape of molecules, 
temperature and viscosity. The Stokes-Einstein equation can be used to describe the self-diffusion 





Equation 1 The Stokes-Einstein equation in which D is the self-diffusion coefficient, k is the Boltzmann constant, T is temperature, 
η is viscosity of the liquid, and rs is the hydrodynamic radius of the molecule 
Translational diffusion of molecules can be measured by pulsed field gradient NMR spectroscopy, 
in which a magnetic field gradient is applied to the sample in combination with radio-frequency 
pulses as used in routine NMR.119 The magnetic gradient pulse is used to phase shift the 
magnetisation and after a period of time, a second gradient pulse is used to refocus the signal. This 
refocusing is only achieved for nuclei that have not moved significantly up or down the NMR tube, 
therefore diffusion reduces the intensity of the resulting signal. By repeating the pulse sequence 
and incrementing the gradient strength whilst keeping all other NMR parameters constant, the 
diffusion coefficient of the sample can be calculated from the signal decay with respect to the 
gradient strength.120 The utilisation of diffusion NMR spectroscopy is widespread as it is non-
invasive and can be performed on dilute solutions so is particularly suited to studying molecular 
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dynamics in biological systems.121, 122 It is also applied for the study of host and guest interactions 
in supramolecular chemistry. In the uncomplexed state the host and guest will have different 
diffusion coefficients depending on their individual size and shape. However, in a complex the host 
and guest will have the same diffusion coefficient as if they are tightly bound, they will diffuse as 
a single entity.123 Thus, diffusion NMR can also be used to measure the association of complexes 
in self-assembly systems.124 Furthermore, diffusion NMR may aid the characterisation of 
dendrimers in which the self-diffusion coefficient can be used to calculate the effective radii of 
spherical dendrimers via the Stokes-Einstein equation.125 Similarly, modification of polymers can 
be monitored by diffusion NMR as the change in molecular size will affect the self-diffusion 
coefficient so can shed light on key structural properties.126, 127  
Diffusion NMR was employed on Exkite and Exalg to determine the effective association of ligands 
6 and 33 on chitosan and alginate polymers respectively. A pulsed gradient stimulated echo 
(PGSTE) experiment was performed and the signal loss with increasing gradient strength was fitted 
to the Stejskal-Tanner equation (Equation 2).128 Where a monoexponential fit was poor, a 
biexponential fit was performed, producing two diffusion coefficients.129 The biexponential fit is 
used when two entities within the sample have overlapping NMR signals and this fitting of data 
allows the determination of both diffusion coefficients that correspond to the two entities within 
that integration range.130  
𝑆(𝑮)
𝑆(0)




Equation 2 The Stejskal-Tanner equation where 
𝑆(𝑮)
𝑆(0)
  is the signal decal,  𝛾 is the gyromagnetic ratio and 𝐷 is the self-diffusion 
coefficient. 
The diffusion coefficient of the ligand and polymer were calculated separately from the respective 
integrated range in 1H NMR spectra of Exkite and Exalg. The values obtained for the polymer were 
compared to the ligand to determine whether the ligand was associated with the polymer. 
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Table 4 The self-diffusion coefficients for Exalg NMR sample calculated by monoexponential and biexponential fits resulting in 
two values; the best fit for each integrated value is shown in blue.  





Mono Bi (1) Bi (2) 
1 2.58 – 3.55 Exalg polymer 1.68 4.61 1.12 
2 6.56 – 8.20 Exalg ligand 1.07   
3 2.50 d6-DMSO 3.16 5.10 1.70 
4 3.30 Water 4.47 6.27 1.02 
 
Analysis of the Exalg sample shows that the best fit value of the self-diffusion coefficient for Exalg 
polymer integral is 1.12 x 10-10 m2 s-1 which is comparable to that obtained for Exalg ligand integral 
at 1.07 x 10-10 m2 s-1 (Table 4). This strongly suggests that the ligand and polymer are associated 
covalently as the similarity in their self-diffusion coefficients is indicative of both components 
moving together. This is similar to the approach used in determining host/guest complexation as 
similar diffusion coefficients obtained from the integrals of host and guest in a sample is indicative 
of association.131 The values obtained for DMSO and water are larger as smaller molecules are 
likely to be moving faster in solution.132 As the self-diffusion coefficient for Exalg ligand is also 
smaller, this also suggests that the ligand is part of the larger entity of the polymer.  
Table 5 The self-diffusion coefficients for Exkite NMR sample calculated by monoexponential and biexponential fits resulting in 
two values; the best fit for each integrated value is shown in blue. Samples made up in d-TFA were spiked with d6-DMSO for 
reference. 





Mono Bi (1) Bi (2) 
1 2.70 – 5.30 Exkite polymer 1.14 4.01 0.70 
2 6.80 – 8.40 Exkite ligand 2.16   
3 2.50 d6-DMSO 3.12 4.22 1.05 
4 11.50 d-TFA 6.13   
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However, the self-diffusion coefficient calculated for Exkite polymer integral is 0.70 x 10-10 m2 s-1 
which is significantly smaller than that calculated for Exkite ligand integral at 2.16 x 10-10 m2 s-1 
(Table 5). This suggests that the chitosan polymer and ligand are not associated in solution in this 
particular sample tested. This may be due to a poor attachment of ligand 6 to chitosan during the 
synthesis resulting in a mixture of chitosan and ligand rather than modification of the polymer itself. 
Alternatively, the NMR sample was dissolved in d-TFA due to the poor solubility of the sample, 
however the strongly acidic nature of the solvent may have hydrolysed the amide conjugation 
between the ligand and polymer. This result is reflective of one NMR sample prepared in d-TFA; 
more can be learnt about the polymer-ligand conjugation if other solvent systems are attempted on 
multiple batches of Exkite. However, it is not surprising that there is batch to batch variation as this 
is a well-known and documented phenomena of conjugated polymer synthesis.133, 134 The diffusion 
NMR data suggests that the ligand is present in the batch of Exkite material tested but is not 
covalently attached to chitosan. Therefore, it is plausible that that chitosan and ligand 6 are 
interacting electrostatically in a salt form of Exkite (Figure 30) by the protonation of the amine 
group of chitosan and deprotonation of the carboxylic acid of ligand 6. 
 
Figure 30 Salt form of Exkite 
Indeed, drugs which employ supramolecular interactions in which reversible, non-covalent bonds 
are exploited are emerging to be of importance for controlled drug delivery: block co-polymer 
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micelles,135 vesicles136 and self-assembled nanoparticles137 can be used to encapsulate hydrophobic 
or hydrophilic drugs to enhance solubility and deliver at sites of use as supramolecular functional 
material aggregates. In addition, salt formation is a common and effective method of improving 
drug solubility and dissolution rates across membranes.138 Therefore, as the electrostatic salt 
interaction is likely to withstand the low pH of the stomach,139 the salt form of Exkite may offer an 
alternate mode of delivery of the iron chelator to the colon which can be compared to the covalent 
binding of ligand to alginate in Exalg. 
4.4 Ultraviolet-visible Spectroscopy 
Ultraviolet-visible (UV-vis) spectroscopy measures the electronic transitions in a molecule 
between the ground state and excited state (HOMO-LUMO gap) and can be used in the 
characterisation of analytes, as specific electronic transitions in different molecules can give 
absorbance at specific wavelengths.140  
Alginate has a distinctive absorption at 265 nm, likely arising from the π to π* transition of the 
carbonyl from the carboxylic acid. Aromatic organic molecules with a high degree of conjugation 
can also show π to π* transitions such as in ligand 33 which shows peaks at 245 nm and 300 nm. 
After modification, Exalg also shows similar peaks at 247 nm and 302 nm indicative of ligand 






















Figure 31 UV-vis spectra of ligand 33 (0.015 mM in water) with absorbance at 245 nm and 300 nm, alginate (0.10% w/v in water) 
with absorbance at 265 nm and Exalg (0.01% w/v dissolved in 1% v/v DMSO in water) with absorbance at 247 nm and 302 nm. 
Chitosan itself does not have a distinguishing absorbance at a specific wavelength, however 
deferasirox ligand 6 absorbs at 245 nm and 315 nm. Exkite also shows similar peaks at 248 and 





















Figure 32 UV-vis spectra of chitosan (0.15% w/v dissolved in 1% v/v acetic acid in water) showing no obvious absorbance, 
deferasirox ligand 6 (0.04 mM in 0.1 M NaOH solution) with absorbance at 245 nm and 315 nm, and Exkite (0.10% w/v in 1M HCl 
solution) with absorbance at 248 nm and 305 nm. 
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4.4.1 Phenol/Sulphuric acid assay (PSAA) 
Measurements of UV-vis spectroscopy can be used quantitatively as the Beer-Lambert law 
(Equation 3) states that the absorbance (A) is directly proportional to the concentration (c) of the 
analyte in solution and the path length (l).141 Thus, if the path length (l) and molar extinction 
coefficient (ε) are known it is possible to calculate the concentration of the analyte from the 
observed absorbance. 
𝐴 = 𝜖𝑐𝑙 
Equation 3 The Beer-Lambert law 
It is possible to construct calibration curves to calculate the molar extinction coefficient, ε for the 
ligands by measuring absorbance at specific wavelengths at different concentrations of the ligands. 
Therefore, calibration curves for deferasirox 6 (Graph 1) and ligand 33 (Graph 2) were plotted by 
measuring the absorbance at λmax for known concentrations of the ligands.  
 
Graph 1 Calibration curve constructed for deferasirox ligand 6 (in 0.1M NaOH) by measuring absorbance at λmax 315 nm and 245 
nm with increasing ligand concentration. All measurements were taken in triplicate, expressed as mean ± SEM. 
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Graph 2 Calibration curve constructed for ligand 33 (in water) by measuring absorbance at λmax 300 nm and 245 nm with increasing 
ligand concentration. All measurements were taken in triplicate, expressed as mean ± SEM. 
The calibration curves were used to compare the absorbance observed for Exkite or Exalg at the 
same wavelengths in order to determine the concentration of the ligand in the modified polymers. 
However, in order to determine the percentage modification of the polymers, the concentration of 
the polysaccharides also need to be known. Although it is possible to construct a similar calibration 
curve for alginate due to its absorbance at 265 nm, this absorbance is not observed in Exalg as it is 
superimposed by the ligand peaks. Also, chitosan itself does not show any absorbance in the UV-
vis spectra so this cannot be quantified using this method. Therefore, phenol/sulphuric acid assay 
(PSAA) was used for the quantitative determination of polysaccharides. Concentrated sulphuric 
acid hydrolyses polysaccharides into monosaccharides, which condense to form a furfural product. 
This further reacts with phenol to produce an orange/yellow compound (Scheme 24).142 The colour 
produced is stable and gives a definite absorption in the UV-vis spectrum, and the intensity of the 
colour produced at a constant phenol concentration is directly proportional to the amount of sugar 
or polysaccharide in solution. 
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Scheme 24 Alginate treated with sulphuric acid and phenol produces a coloured furfural product, which can be used to measure 
carbohydrate concentration by UV-vis spectroscopy.  
A calibration curve was constructed for alginate and chitosan in which known concentrations of 
polymer were treated with sulphuric acid and phenol, and then a UV-vis spectrum was taken to 
plot concentration vs. absorbance at λmax 480 nm for alginate and 490 nm for chitosan (Graph 3). 
 
Graph 3 Calibration curve obtained for alginate at 480 nm and chitosan at 490 nm after treatment with phenol and sulphuric acid. 
Measurements were taken in triplicate and expressed as mean ± SEM. 
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A solution of Exalg was treated in the same way and the absorbance of the resulting peak at 480 
nm (Figure 33) was compared to the calibration curve to calculate the concentration of alginate in 
solution. Unfortunately, when Exkite underwent the phenol and sulphuric acid treatment, an 
appreciable peak at 480 nm was not observed. This may be due to the fact that the poor solubility 
of Exkite meant that this was dissolved in dilute hydrochloric acid solution, and the acidic solution 
may have interfered with the assay.  
 
Figure 33 UV-Vis spectra of Exalg (in 1% DMSO in water) after phenol and sulphuric acid treatment, with background reading of 
1% DMSO in water solution treated with phenol and sulphuric acid.  
The calculated concentration of the ligand to polysaccharide ratio was compared for Exalg (Scheme 
23) to give the relative percentage modification. This gives values between 15 - 27% molar 
modifications for Exalg0.25 - Exalg1.25, reflecting possible error and variability in the synthesis and 
PSAA treatment (Table 6). The results suggest that the maximum modification is 27% for Exalg0.50, 
which indicates that there is a limiting factor to the ligand incorporation in Exalg.  
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Table 6 The calculated molar percentage modifications by PSAA for Exalg series showing highest modification for Exalg0.50. 
Entry Compound Ligand equiv % molar modification  by PSAA 
1 Exalg0.25 0.25 21 
2 Exalg0.50 0.50 27 
3 Exalg0.75 0.75 23 
4 Exalg1.00 1.00 15 
5 Exalg1.25 1.25 16 
4.5 X-Ray Photoelectron Spectroscopy 
X-Ray photoelectron spectroscopy (XPS) gives qualitative and quantitative information about 
surface elemental composition of the tested material. This technique is based on the photoelectric 
effect, which is the process of using photons to remove electrons from bulk material (Figure 34). 
 
Figure 34 The photoemission process used in XPS. 
When photons are directed at the surface of a material, the electrons can become excited from the 
ground state and can eventually escape into the vacuum by overcoming the work function (ϕ) of 
the material. The kinetic energy (Ek) of the escaped electrons are measured which can be used to 
calculate the binding energy (Eb) since the energy of the photons (hν) are also known (Equation 
4).143 The work function is the energy required to remove an electron from the excited state to the 
vacuum immediately outside the solid surface, and this is usually a fixed characteristic of the 
surface material.  
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𝐸𝑏 = ℎ𝑣 − 𝐸𝑘 − ∅ 
Equation 4 Binding energy Eb is calculated by subtracting kinetic energy Ek and work function ϕ from the energy of the photon hν, 
where h is Planck’s constant and ν is frequency of photons.  
Electrons are emitted with specific kinetic energy so that the calculated binding energies can be 
used to specifically identify the elemental composition of a sample, as emission lines are well 
tabulated for most elements. The normalised area under an elemental peak can be used to quantify 
elemental composition. Furthermore, qualitative data about the chemical state, hybridisation and 
chemical environment can also be elucidated by relative structure and shift of the elemental 
peaks.144  
This is a non-destructive technique from which a large amount of information can be gleaned, 
however it typically requires ultra-high vacuum and the detection limits mean that elements with a 
low mass such as hydrogen and helium cannot be detected. Also, since the instrument only 
measures the energy of the photoemitted electrons that reach the detector, this is suited to 
measuring the surface chemistry of a material. Electrons from deeper below the sample surface 
must travel through the sample to escape and can undergo inelastic collisions, recombination, and 
be trapped in an excited state which reduce the number of photoelectrons that reach the surface.143 
Measurements using XPS were obtained for all polymer samples and the high resolution spectra 
for carbon, nitrogen and oxygen are shown for Exkite and Exalg0.50 (Figure 35 and Figure 36). The 
peaks obtained were compared to literature values to assign relative shifts to different chemical 
environments. The integrated area under the peaks were used to calculate elemental ratios and the 
subsequent modifications of the polymers.   
The C 1s spectrum of alginate (Figure 35a) can be deconvoluted into three peaks corresponding to 
three carbon environments in the compound; C=O peak at 288.6 eV due to the carboxylic acid 
moiety, C-O peak at 286.9 eV and C-OH peak at 285.1 eV.145 
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Figure 35 XPS spectra of: a) alginate C 1s, b) Exalg0.50 C 1s both show three deconvoluted peaks for different carbon environments; 
c) alginate N 1s shows negligible nitrogen composition, d) Exalg0.50 N 1s shows peaks from triazole and amide nitrogen; e) alginate 
O 1s, f) Exalg0.50 O 1s both show carbonyl and alcohol oxygen species. 
Similarly, Exalg0.50 (Figure 35b) displays three peaks in the carbon region resulting from five 
carbon species. The peak at 287.0 eV is due to C=O of amide, peak at 286.6 eV is due to C-N and 
C-O species, and the peak at 285.0 eV is due to the remaining C-OH and C-C species.145 The 
nitrogen composition of alginate is negligible (Figure 35c), however Exalg0.50 shows N 1s peak at 
399.4 eV resulting from N-C of the triazole ring of the ligand146, and a peak at 401.6 eV due to the 
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amide nitrogen (Figure 35d).147 The O 1s spectra for both alginate (Figure 35e) and Exalg0.50 
(Figure 35f) show deconvoluted oxygen peaks at 531.3 eV and 530.6 eV respectively resulting 
from C=O of amide, and peaks at 532.9 eV and 532.2 eV respectively due to C-O and C-OH 
species.145  
 
Figure 36 XPS spectra of: a) chitosan C 1s, b) Exkite C 1s both show peaks from multiple carbon environments; c) chitosan N 1s 
shows peaks from amide and amine nitrogen, d) Exkite N 1s shows peaks from triazole and amide nitrogen; e) chitosan O 1s, f) 
Exkite O 1s both show peaks from carbonyl and alcohol oxygen environments. 
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The C 1s spectrum of chitosan (Figure 36a) consists of a peak at 287.0 eV resulting from C=O of 
the N-acylated glucosamine unit, and a peak at 285.7 eV which is attributed to the accumulation of 
C-N, C-O and C-OH species. However, the C 1s spectrum of Exkite (Figure 36b) can be 
deconvoluted into four peaks; the peak at 288.4 eV corresponds to C=O carbonyl, the peak at 286.9 
eV is due to C-N environment, the peak at 285.3 eV can be accredited to C-C and C-O species, and 
the final peak at 284.0 eV is a result of C-OH species.145 Chitosan shows two peaks in the resolved 
N 1s spectrum (Figure 36c) due to amide nitrogen at 400.3 eV and amine nitrogen at 398.2 eV.144 
Exkite also shows two peaks in the N 1s spectrum (Figure 36d); the peak at 401.2 eV is due to 
amide nitrogen and peak at 399.2 eV can be recognised as C-N environment of the ligand.147 The 
O 1s spectrum of chitosan (Figure 36e) is shown to consist of three peaks corresponding to three 
oxygen environments; C=O of acylated amide group at 530.6 eV, the peak at 531.7 eV is due to C-
OH species and the peak at 534.1 eV is a result of C-O species.144 Similarly, Exkite (Figure 36f) 
shows a peak at 531.5 eV resulting from C=O amide which is higher in intensity than in chitosan 
due to ligand incorporation, and a peak at 532.8 eV which is combination of C-OH and C-O 
environments.145  
The normalised area under the peak for each element was determined and used to calculate the 
graft ratio for the polymer material believed to be conjugated to the ligand, which is the ratio of 





Equation 5 General equation for graft ratio where y is the number of modified monomer units and x is the number of unmodified 
monomer units. 
A method described by Wang et al.94 was adopted for the derivation of graft ratio for Exalg and 
Exkite, using N/C ratio as determined by XPS analysis. In the graft ratio of Exalg (Equation 6), 6 
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and 27 are the number of carbon atoms in an alginate monomer unit and the ligand respectively, 
and 5 is the number of nitrogen atoms from the ligand.  






Equation 6 Graft ratio of Exalg based on N/C ratio 
Similarly, in the graft ratio of Exkite (Equation 7), 6 and 21 are the number of carbon atoms in a 
chitosan monomer unit and the ligand respectively, and 4 is the number of nitrogen atoms in a 
modified monomer unit.  






Equation 7 Graft ratio of Exkite based on N/C ratio 
The calculated N/C ratios from XPS analysis were used to determine the graft ratio for the modified 
polymers (Table 7).  
Table 7 The N/C ratio and graft ratio of polymers as calculated by XPS analysis. 
Entry Compound Ligand 
equiv 
N (Area) C (Area) N/C Graft ratio (% ) 
1 Chitosan - 0.01 0.07 - - 
2 Exkite 1.00 0.03 0.28 0.12 46 
3 Alginate - 0.00 0.16 - - 
4 Exalg0.25 0.25 0.03 0.27 0.13 48 
5 Exalg0.50 0.50 0.04 0.32 0.14 66 
6 Exalg0.75 0.75 0.03 0.21 0.14 62 
7 Exalg1.00 1.00 0.04 0.29 0.13 53 
8 Exalg1.25 1.25 0.04 0.28 0.14 67 
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This shows that Exkite is 46% modified with ligand, whilst Exalg modification ranges from 48% 
for Exalg0.25 to 67% for Exalg1.25. Although theoretically it is not possible to obtain a graft ratio of 
more than 25% for Exalg0.25 and 50% for Exalg0.50, this may be an artefact of alginate activated by 
NHS/EDAC.HCl as one equivalent of these reagents were used in all cases, thus increasing 
nitrogen content due to the activated species. However, as previously there is no significant 
increase in graft ratio with increasing ligand equivalence of Exalg. 
4.6 Summary 
Analysis by IR spectroscopy shows amide carbonyl peaks for the modified polymers, 1H NMR 
spectroscopy displays peaks corresponding to the polymer and ligand, and UV-vis spectroscopy 
revealed specific absorbance indicative of ligand incorporation for both polymers. Although the 
absolute values calculated for percentage incorporation from each method differed, with the 
exception of XPS the average incorporation calculated for Exalg is 20%. Analysis by all methods 
suggest that there is a limiting factor in the incorporation of ligand with alginate, as increasing 
ligand equivalence did not greatly affect polymer modification. This may be related to the number 
of carboxylic acid sites of alginate that were activated by NHS/EDAC.HCl coupling agents, or the 
number of active sites that were accessible to the ligand, as well as any tertiary structure features 
of alginate which may have affected incorporation.148 Additionally, the average percentage ligand 
incorporation calculated for Exkite is 40% when one equivalence of ligand was used.  
The synthesis of Exkite and Exalg were repeated and the characterisation results were compared. 
The IR spectra show similar absorbance at 3295 cm-1 and 3000 cm-1 for Exalg 2 corresponding to 
–OH and –CH absorption, and a carbonyl amide absorption at 1636 cm-1 resulting from C=O 
vibration (Figure 37). Although Exkite 2 also shows –OH absorption and overlapped –CH 
absorptions at 3380 cm-1 and 2985 cm-1, the carbonyl absorption is slightly higher at 1680 cm-1 
which may be due to the free ligand 6 in the salt form of Exkite. 
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Figure 37 UV-vis spectra of Exalg 2 and Exkite 2. 
Nevertheless, the 1H NMR spectra are similar to previous, showing aliphatic polymer peaks and 
aromatic ligand peaks for both Exalg 2 (Figure 38) and Exkite 2 (Figure 39).  
 
Figure 38 1H NMR spectra of Exalg 2 in d6-DMSO. 
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Figure 39 1H NMR spectra of Exkite 2 in d-TFA. 
The UV-vis spectra also exhibit similar absorbance at 247 nm and 302 nm for Exalg 2, and 248 nm 
and 305 nm for Exkite 2 indicative of ligand incorporation (Figure 40).    
 
Figure 40 UV-vis spectra of Exkite 2 (0.10% w/v in 1M HCl solution)) and Exalg 2 (0.01% w/v dissolved in 1% v/v DMSO in 
water). 
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Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry was also attempted but 
was unsuccessful in determining a change in molecular weight upon modification of the polymers 
due to the large polydispersity of the polymers. A range of molecular weights were observed for 
polymers before and after modification. Attempts to employ elemental analysis was also 
unsuccessful as comparison of theoretical C/N ratio to actual ratio obtained from elemental analysis 
was difficult due to the relatively small change in the theoretical C/N ratio of Exalg and Exkite with 
increasing modification. 
Diffusion NMR spectroscopy conducted as an addendum to the data shows that the ligand is 
covalently attached to alginate polymer in Exalg due to the similar self-diffusion coefficients 
obtained for ligand and polymer. However, the differing self-diffusion coefficients obtained for 
ligand and polymer in Exkite suggests that this sample is a mixture of chitosan and ligand 6 perhaps 
in a salt form. This is representative for the sample tested and hence the results must be interpreted 
with caution; more can be learnt about the synthesis if this is repeated on multiple batches of Exkite.  
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5 Iron binding studies 
5.1 Background 
Characterisation of the modified polymers demonstrated ligand attachment in Exalg by diffusion 
NMR spectroscopy and the presence of the ligand in Exkite in which ligand conjugation was more 
difficult to discern, and is likely to be present as Exkite salt according to diffusion NMR studies 
conducted after the data in this chapter was obtained (Chapter 4). The magnitude of iron binding 
of Exalg and Exkite were investigated in comparison to the native polymers to assess the change in 
iron binding properties upon addition of an iron chelator. This was principally assessed by two 
methods. Firstly, iron binding was probed by UV-vis spectroscopy in which polymer solutions 
were titrated with iron solutions to monitor a change or shift in absorbance in the UV-vis profile, 
which may be attributed to the formation of an iron complex species. Secondly, iron binding was 
assessed by dialysis which involves suspending the polymer solution in a semi-permeable 
membrane, placed in an iron solution for a period of time, after which the concentration of iron in 
polymer solution is measured to obtain the degree of iron uptake.  
5.2 Titrations by UV-vis spectroscopy 
Iron binding was studied by UV-vis spectroscopy by titrating a known quantity of iron solution 
into a solution of polymer to monitor a change in absorbance.149 Initially, iron chloride solution 
(10 mM FeCl3·6H2O) was titrated into water alone, which shows an increase in absorbance at 290 
nm due to the interaction of iron with water to form of [Fe(H2O)6]
3+ complex (Figure 41).150 Crystal 
field theory (CFT) states that this is due to an attraction between positively charged metal cation 
and electron rich ligand.151 However, as the ligand approaches the cation the electrons of the ligand 
and those in the d orbitals of the metal closest to the ligand repel causing a splitting of five 
degenerate d orbitals of Fe (III) to from a triply degenerate t2g and doubly degenerate eg sets of 
 77 
orbitals in an octahedral field with an energy difference of Δoct.
152 The t2g set consists of dxy, dxz and 






2 which have lobes pointing directly at the ligands so experience the greatest 
repulsion and are higher in energy.153 The absorption of energy from visible light allows an 
electronic transition to occur between the lower lying t2g set and eg set of crystal field orbitals giving 
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Figure 42 UV-Vis spectra of 10 mM FeCl3·6H2O titrations into chitosan (0.15% w/v dissolved in 1% v/v acetic acid in water) does 
not indicate any binding. 
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Iron binding of chitosan was probed by titrating iron chloride solution (10 mM FeCl3·6H2O) into 
chitosan solution (Figure 42). Although there seems to be the emergence of a peak at 330 nm, this 
is not significant suggesting poor iron binding by chitosan.  
Additionally, iron chloride solution (10 mM FeCl3·6H2O) was titrated into Exkite solution (Figure 
43), and a shift in absorbance was observed from 305 nm when there is no Fe (III) present, to 322 
nm suggesting the formation of an iron complex. This is likely due to be from a charge transfer 
within the complex which occurs when there is an electronic transition between a metal based 
orbital and a ligand based orbital. As the ligand has vacant low lying π* orbitals, the observed 
transition may be from the occupied metal t2g orbital to the ligand π* orbital.
155 Further titrations 
increased the absorbance at 322 nm due to increasing amounts of the iron complex species being 
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Figure 44 UV-vis spectra of 10 mM FeCl3·6H2O titrations into Exkite (0.10% w/v in 1M HCl solution) showing an increase in 
absorbance at high iron concentrations.  
In order to obtain a binding curve from this UV-vis data, it was necessary to know where the 
absorbance is at a maximum for each concentration of Fe (III) that was used in the titrations; i.e. at 
the stationary point where dy/dx = 0. Therefore, the position of maximum absorbance for each 
concentration of Fe (III) titration into Exkite was taken and a subsequent plot of the shift in 
wavelength, Δλ vs. final Fe (III) concentration for each titration enabled the plotting of a binding 

























Figure 45 Attempted fitting of binding curve for iron titrations into Exkite by measuring shift in λ. 
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Unfortunately, as the saturation point of binding was not reached, this resulted in a poor fit of the 
binding curve with an approximate binding constant of the order 105. An attempt to titrate higher 
concentrations of Fe (III) to obtain saturation resulted in precipitation of the iron complex which 
caused light scattering and interfered with the measurement of the UV-vis spectra. In addition, iron 
hydroxide complexes are known to undergo hydrolysis in solution to give insoluble complexes 
which precipitate out of solution.156 Similar titrations using iron sulphate solution (10 mM 
FeSO4·7H2O) to assess Fe (II) binding of Exkite was unsuccessful as there was no observed shift 
or increase in absorbance. This may be due to weak electronic transitions within the complex which 
cannot be observed by UV-vis spectroscopy.  
Iron titrations into alginate solution using iron chloride solution (10 mM FeCl3·6H2O) was also 
performed, which showed an increase in absorbance at 265 nm indicative of interaction of alginate 
with iron, however the increase in absorbance is not consistent with increase in iron concentration 
possibly due to the gelling of alginate in the presence of a cation which was visually observed in 
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Figure 46 UV-Vis spectra of 10 mM FeCl3·6H2O titrations into alginate (0.10% w/v in water) shows increase in absorbance at 265 
nm. 
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Iron titration into Exalg1.00 solution also showed a shift in the peak at 302 nm to 310 nm in the 
presence of Fe (III) which suggests the formation of an iron complex, and further titrations 
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Figure 47 UV-Vis spectra of 10 mM FeCl3·6H2O titrations into Exalg1.00 (0.01% w/v dissolved in 1% v/v DMSO in water) showing 
shift in absorbance upon iron titrations. 
However, as with alginate the increase in absorption at 310 nm does not increase directly in 
response to iron concentration.  
5.3 Dialysis methods 
The extent of iron binding can also be measured by dialysis, which involves the suspension of 
polymer solutions of known concentration in semi-permeable cellulose membrane, submerged in 
a supernatant at physiological concentrations of iron in the colon derived from an approximate 
dietary intake of 5 mg of elemental iron.158 Whilst the polymers are too large in size to escape the 
dialysis tubing, iron can move freely through the tubing to allow iron binding by polymers, and at 
the end of the experiment the concentration of iron within the polymer solutions can be measured 
by ferrozine assay or atomic absorption spectroscopy, which is a quantitative method of calculating 
the iron binding properties of polymers. Ferrous (0.20 mM FeSO4·7H2O) and ferric (0.20 mM 
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FeCl3·6H2O) binding of the polymers was investigated in the presence and absence of calcium 
(2.00 mM CaCl2·2H2O) at physiologically relevant concentrations. Calcium is known to be present 
in the human lumen,159 and alginate is recognised for binding calcium with good affinity forming 
egg box structures (Section 1.8.1). Therefore it is informative to understand if modification with 
an iron chelator altered this intrinsic calcium binding property as polymers need to be selective in 
iron binding in the presence of other cations. Potential calcium binding by Exalg modified from 
alginate may be problematic if this is significant as it will result in the removal of physiologically 
relevant non-target cation.  
Initial dialysis experiments were conducted in dilute acidic media in order to better solvate iron 
complexes and to prevent the precipitation of iron oxides during the experiment.160 Polymer 
solutions of chitosan, Exkite, alginate and Exalg1.00, which was chosen arbitrarily for comparison, 
were suspended in dialysis tubing and immersed in ferrous and ferric iron in the presence and 
absence of calcium for two hours with gentle agitation. Iron concentration was measured by flame 
atomic absorption spectroscopy (AAS), which utilises the principle that electrons can be promoted 
to an excited state by absorbing a defined quantity of energy, and the wavelength at which this 
occurs is specific to an electronic transition within an element.161 Therefore, the absorbance at a 
particular wavelength can be used to quantify elemental composition, which requires construction 
of a calibration curve to establish the relation between observed absorbance and iron concentration 
and hence relies on the Beer-Lambert law (Equation 3). The observed iron concentrations were 
used to calculate mg iron per mg polymer (Graph 4). This experiment shows a statistically 
significant increase (p < 0.006) in iron binding of Exkite compared to chitosan. Both ferrous and 
ferric binding has improved over 100 fold suggesting no selectivity between ferric and ferrous iron, 
and the presence of calcium does not have an effect. Iron binding of Exalg1.00 has also improved 
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compared to alginate alone (p < 0.002), however there is only a tenfold increase in ferrous and 
ferric binding in the presence and absence of calcium.  
 
Graph 4 Iron binding of polymers by dialysis in acidic media for two hours determined by AAS. Experiments were performed in 
triplicate, data is presented as mean ± SEM, * and # denote statistically significant difference calculated by Student’s t-test (p < 
0.05). 
The dialysis experiment in acidic media was repeated in which the polymer solutions in dialysis 
tubing were immersed in iron solutions for two hours followed by immersion in water for two 
hours. The subsequent washing step was conducted in order to determine the effective leaching of 
bound iron and any apparent selectivity between ferric and ferrous iron during this process, iron 
concentration was determined by AAS. Although there is still an increase in iron content of Exkite 
relative to chitosan (p < 0.004), and Exalg1.00 relative to alginate (p < 0.04), overall there is a 
decrease in total iron concentrations observed after washing due to leaching of iron (Graph 5). This 
is evident for Exkite in which ferrous iron concentration decreased from 0.422 ± 0.016 mg to 0.048 
± 0.0001 mg Fe per mg polymer after the washing step. However, there is greater retention of Fe 
(III) in Exkite which may be due to greater selectivity of the ligand towards ferric iron than ferrous 
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iron, which is unaltered in the presence of calcium. There is also a decrease in ferrous iron 
concentration of Exalg1.00 from 0.090 ± 0.003 mg to 0.017 ± 0.001 mg Fe per mg polymer after 
washing and a slight selectivity for ferric over ferrous iron is also observed. Despite conducting 
the washing step, Exkite whether present as conjugated polymer or salt, is still superior at iron 
binding relative to Exalg1.00. 
 
Graph 5 Iron binding of polymers after dialysis for two hours in acidic media followed by washing for two hours determined by 
AAS. Experiments were performed in triplicate, data is presented as mean ± SEM, * and # denote statistically significant difference 
calculated by Student’s t-test (p < 0.05). 
As former dialysis experiments had been conducted in dilute acidic media, it was proposed that 
this may affect the actual iron binding of the polymers as formation of the iron complex requires 
deprotonation of the phenolic oxygen of deferasirox ligand moiety. Hereafter further dialysis 
studies were done without acid in the supernatant in which polymer solutions were suspended in 
iron solutions for two hours with no further washing step, and iron concentration determined by 
AAS (Graph 6). In this instance, there is still a great increase in ferric and ferrous iron binding 
between chitosan and Exkite of over 100 fold (p < 0.0001) and calcium did not have an effect on 
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iron binding. However, alginate now shows good ferrous iron chelation which decreased in the 
presence of calcium (p = 0.004) due to competitive binding and affinity to form egg box structures, 
however ferric binding of alginate was poor. This correlates with reported pH dependency of 
calcium binding to alginate as the carboxyl groups of alginate are required to be deprotonated for 
effective cation binding, therefore calcium binding is improved at higher pH.162 Effective steady 
state binding of calcium by alginate was shown to be achieved above pH 6, which is consistent 
with a reported pKa for alginate of 3.4 – 4.4.80 Furthermore, the iron binding of Exalg1.00 not only 
seemed to be low but worse than that of alginate. This could be an artefact of incomplete 
combustion or may be due to the formation of metal oxides163 which reduces the sensitivity during 
AAS measurements giving an erroneous value that is lower than in reality.  
 
Graph 6 Iron binding of polymers after dialysis without acid in supernatant for two hours determined by AAS. Experiments were 
performed in triplicate, data is presented as mean ± SEM, * and # denote statistically significant difference calculated by Student’s 
t-test (p < 0.05). 
An alternate method of measuring iron concentration was sought: the ferrozine assay is a 
colorimetric assay164 in which the ferrozine molecule turns from colourless to purple upon binding 
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of iron so that the intensity of colour produced is directly proportional to the amount of iron in 
solution (Scheme 25).165 This works well for ferrous iron but can also be applied for the detection 
of ferric iron if a reducing agent such as sodium ascorbate is used.166  
 
Scheme 25 The ferrozine molecule which forms a purple coloured stable tris-iron complex utilised for the colorimetric determination 
of iron.  
Dialysis of polymers in iron solutions was conducted for two hours and subsequent iron 
concentration was measured by the ferrozine assay. As the ferrozine molecule is an iron chelator 
in itself with a ferrous iron binding constant167 of 3.65 × 1015 M−3, competitive binding is envisaged 
with the modified polymers in this assay. Therefore, hydrochloric acid and sodium ascorbate were 
added to samples to perturb iron binding with the ligand moiety and to retain iron in the reduced 
ferrous form to allow detection by ferrozine. The calibration samples were also prepared in the 
same way in order account for any effects from the addition of hydrochloric acid to the assay. The 
results of the ferrozine assay (Graph 7) show similar results as previously for chitosan and Exkite 
in that there is a marked increase in ferrous and ferric iron binding of Exkite relative to chitosan (p 
< 0.001). Alginate also shows similar iron content to that observed by AAS, however Exalg1.00 now 
displays improved iron binding relative to alginate that is statistically significant (p < 0.03).  
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Graph 7 Iron binding of polymers after dialysis without acid in supernatant for two hours determined by ferrozine assay. 
Experiments were performed in triplicate, data is presented as mean ± SEM, * and # denote statistically significant difference 
calculated by Student’s t-test (p < 0.05). 
The deferasirox ligand binds calcium poorly, with an approximate Ca (II) binding constant58 of the 
order 105. However, calcium is known to encourage gelling in alginate polymers which has been 
exploited previously to entrap cells for cell transplantation in which cells are mixed with an 
alginate/calcium solution.168  Therefore, whilst ferrous binding of alginate decreases in the presence 
of calcium due to competitive binding and the formation of egg-box structures, the increase in 
ferrous binding of Exalg1.00 in the presence of calcium may be due to gelling effects trapping iron 
in the polymer matrix rather than chelation of iron itself. Moreover, the ferric binding of alginate 
and Exalg1.00 is low which may be attributed to tertiary structure polymer effects as alginate is 
known to dimerise169 in the presence of cations contributing to the formation of egg-box structures. 
The cavities formed upon dimerization are ideally occupied by Ca (II) ions with an effective ionic 
radii of 100 pm.170 The Fe (II) ions are sufficiently similar in size at 78 pm to occupy the cavities 
of alginate, hence good ferrous iron binding is observed for alginate and Exalg. However, Fe (III) 
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has an effective ionic radii of 64 pm170 which may be too small to occupy the dimeric cavities, 
hence poor ferric iron binding is observed for alginate and Exalg. In addition, the poor ferric iron 
binding may be attributed to the formation of iron oxides during the process of dialysis in the 
absence of acid in solution, which precipitated160 out and therefore become unavailable for iron 
binding.  
Due to the poor iron binding of Exalg1.00 compared to Exkite, a series of Exalg polymers were 
synthesised by varying the ligand equivalence in the synthesis (Scheme 23) to determine whether 
the iron binding properties could be improved by altering the amount of ligand on the polymer. 
Iron binding studies of these polymers by dialysis and measurement of iron concentration by the 
ferrozine assay shows that iron binding is consistently similar throughout polymers Exalg0.25 - 
Exalg1.25 (Graph 8).  
 
Graph 8 Iron binding by dialysis for two hours determined by ferrozine assay of Exalg0.25- Exalg1.25. Experiments were performed 
in triplicate, data is presented as mean ± SEM, * and # denote statistically significant difference calculated by Student’s t-test (p < 
0.05). 
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Although iron binding of Exalg has improved moderately compared to alginate (p < 0.03), there is 
no variation in iron binding with increasing equivalence of ligand which correlates with the 
consistent ligand loading observed for these polymers, and supports the hypothesis that there is a 
limiting factor to the incorporation of ligand. Overall, the iron binding of the Exalg series is still 
low compared to Exkite, which is a result of low and consistent modification of the alginate polymer 
throughout the Exalg series so that there is only a small amount of attached ligands available for 
chelation. In addition, a modified version of deferasirox ligand was utilised for coupling onto 
alginate which may have affected its intrinsic iron binding properties compared to deferasirox alone 
which was used for coupling to chitosan. 
5.4 Summary 
Assessment of iron binding by UV-vis spectroscopy titrations showed a shift in absorbance for 
Exkite indicative of the formation of an iron complex. Although a shift in absorbance was also 
observed for Exalg1.00, this was not consistent with increasing iron concentration due gelling effects 
of alginate. Dialysis experiments showed Exkite to be superior at iron binding with an improvement 
of over 100 fold for both ferrous and ferric iron with and without calcium by AAS and ferrozine 
assay. However, Exalg showed comparatively poor iron binding which is similar throughout 
Exalg0.25 – Exalg1.25 polymers with only a tenfold increase in ferrous binding in the presence of 
calcium which is more likely due to entrapment of iron through gelling rather than iron chelation. 
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6 Cellular studies 
6.1 Background 
Iron binding studies by UV-vis spectroscopy and dialysis exhibited Exkite, whether present as 
conjugated polymer or salt, to be superior at iron chelation compared to Exalg and native polymers 
chitosan and alginate (Chapter 5). This was further probed by investigating in vitro iron binding 
properties of all polymers to assess intracellular iron binding activity. Cellular studies were 
conducted on RKO cells which is a poorly differentiated human colon carcinoma cell line.171  
In order to determine the appropriate concentration of compounds to use in the iron assessments, a 
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) assay was initially 
performed to assess cellular viability. This is a colorimetric assay in which MTT, a yellow tetrazole 
is reduced to purple formazan crystals in metabolically active cells by the action of mitochondrial 
reductase (Scheme 26).172 Upon application of different concentrations of a compound to cells 
followed by a MTT assay, a dose response curve can be constructed as the intensity of the purple 
colour corresponds to proportion of living cells, expressed as cellular viability normalised relative 
to the control.  
 
Scheme 26 The reduction of yellow MTT to purple formazan by living cells quantified by the MTT assay to assess cellular viability. 
Once the appropriate concentration of polymers to use was established by the MTT assay, 
intracellular iron binding was probed by stimulating RKO cells with iron in the presence and 
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absence of polymers to determine iron uptake. Ferritin was used as an internal biomarker as this is 
the ubiquitous intracellular iron storage protein of 450 kDa consisting of 24 subunits composed of 
light and heavy chain units with an apparent molecular weight of 19 kDa and 21 kDa 
respectively.173 Due to the toxic nature of free iron, ferritin serves to store excess iron in a non-
toxic form with each complex capable of storing up 4500 ferric iron ions.174 Serum ferritin 
concentrations correlate well with total body iron stores so are used clinically to assess iron stores 
for the diagnosis of iron deficiency or overload disorders.175  
Ferrous iron was used to stimulate cells as iron uptake by intestinal cells occurs through the action 
of divalent metal transporter 1 (DMT1) which transports ferrous iron into the enterocytes. Ferrous 
iron is also more soluble than ferric iron which can form iron oxides and precipitate out of solution. 
Moreover, sodium ascorbate functions both as a reducing agent to inhibit the oxidation of ferrous 
iron to ferric iron176 and also acts as a weak chelator forming an iron-ascorbate complex which also 
increases solubility of iron to enhance cellular iron uptake.177 Indeed, dietary ascorbate is known 
to increase iron absorption in the lumen and is often clinically co-administered with oral iron 
supplementation in individuals with iron deficiency diseases.178  
After a period of incubation of RKO cells at the desired experimental conditions, ferritin expression 
was measured by gel electrophoresis (western blot) in which proteins are separated according to 
their size and specific antibodies are applied to identify proteins, which can be semi-quantified by 
densitometry. Ferritin enzyme-linked immunosorbent assay (ELISA) was also used to quantify 
ferritin expression which is a colorimetric assay that uses ferritin specific antibodies to identify the 
protein. Finally, total intracellular iron was measured by the ferrozine assay which takes into 
account iron from ferritin, the labile iron pool and that being utilised in other functions of the cell.   
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6.2 MTT assay  
Dose response curves shown in this chapter were plotted by Haobo Ge using Logistic Fit on Origin software.  
Cellular viability of RKO cells in the presence of polymers was assessed by MTT assay. Due to 
the lack of differentiation in iron binding by dialysis observed for Exalg0.25 – Exalg1.25, Exalg0.50 
was arbitrarily chosen for further investigation by cellular studies and is henceforth referred to as 
Exalg. Cells were cultured with varying concentrations of chitosan, Exkite, alginate and Exalg for 
24 hours, followed by the addition of MTT for the determination of cellular viability.  
 
Figure 48 Dose response curve from MTT assay for a) chitosan and b) Exkite showing decreasing cellular viability of RKO cells 
with increasing Exkite concentration (% w/v is expressed as numerical decimal). Experiments were done in triplicate, data is 
presented as mean ± SEM. Student’s t-test to assess statistical significance for Exkite relative to control is p < 0.002, change in 
viability of cells treated with chitosan not statistically significant.  
The cellular viability of cells treated with chitosan and Exkite was compared as fold change relative 
to control normalised to one, which had no compound treatment so was taken to have optimum 
cellular viability. The dose response curve (Figure 48) shows that chitosan has little effect on RKO 
cells as there is no statistical effect on viability. However, Exkite shows decreasing viability with 
increasing concentration, with viability only a fifth of that compared to control at 0.09% w/v Exkite 
(p = 0.016). The concentrations 0.03% w/v and 0.05% w/v Exkite were taken forward into 
subsequent experiments as the cellular viability of Exkite at these concentrations shows that the 




















































application of Exkite is having some cytotoxic effects on cells which may be due to intracellular 
iron chelation, but there are enough cells viable in order to study this effect further.  
 
Figure 49 Dose response curve from MTT assay for a) alginate and b) Exalg showing decreasing cellular viability of RKO cells 
with increasing Exalg concentration (% w/v is expressed as numerical decimal). Experiments were done in triplicate, data is 
presented as mean ± SEM. Student’s t-test to assess statistical significance for Exalg relative to control is p < 0.05, change in 
viability of cells treated with alginate not statistically significant.  
The dose response curve for alginate and Exalg (Figure 49) shows that cellular viability is not 
statistically altered when cells were challenged with alginate. Conversely, viability is greatly 
reduced with increasing concentrations of Exalg on RKO cells, with viability reaching a tenth of 
that observed for control at 0.10% w/v Exalg (p = 0.001). Due to the significant drop in viability 
at higher concentrations, the concentrations of Exalg chosen for subsequent experiments were 
0.005% and 0.01% w/v. Although different experimental concentrations were chosen for alginate 
based and chitosan based polymers, this was determined by the toxicity of these polymers on RKO 
cells and the effective amount of viable cells that will be available for further experiments probing 
iron chelation. As Exalg seems to be more toxic towards RKO cells than Exkite, lower experimental 
concentrations of Exalg were chosen for subsequent experiments than Exkite as deemed fit by the 
MTT assay. The consequent purpose is to study intracellular iron chelation by these polymers 
which may contribute towards their toxic effects, whilst having enough viable cells for further 
assays.   
















































6.3 Ferritin western blot 
To ascertain whether the polymers are able to chelate iron in vitro, RKO cells were cultured in the 
presence and absence of aqueous iron sulphate (100 µM), sodium ascorbate (10 µM) and the 
appropriate concentration of polymer solution. Chitosan and Exkite were applied at 0.03% and 
0.05% w/v, whilst alginate and Exalg were applied at 0.005% and 0.01% w/v in cell culture media. 
Positive control was conducted in aqueous iron sulphate with sodium ascorbate in cell culture 
media, and negative control was treated with cell culture media alone.  
After incubation for 24 hours, the cell samples were lysed and analysed by western blot. This 
separates cellular proteins according to size, and the protein of interest is probed by antibodies. The 
blot produces an image of the proteins in which darker bands represent higher concentration of 
protein which can be analysed semi-quantitatively by densitometry.  
The western blot (Figure 50a) shows bands for ferritin at ~20 kDa and β-actin which is a highly 
conserved protein involved in cell structure and integrity with a molecular weight of 42 kDa. This 
is used in western blotting as an internal control to ensure equal amounts of protein overall is loaded 
onto the gel for electrophoresis.179 Since β-actin bands for all samples are equivalent, any 
differences in the concentration of ferritin observed is due to differences in cellular ferritin 
expression as a result of experimental conditions. 
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Figure 50 a) Ferritin western blot for cells cultured with iron in the presence of chitosan and Exkite, b) densitometric analysis of 
ferritin western blot as a ratio of ferritin to β-actin, expressed relative to control normalised to one.Experiments were done three 
times in triplicate for each concentration, data is presented as mean ± SEM, * and # represent statistical significance by Student’s 
t-test (p < 0.05). 
Stimulation of cells with iron elicits a seven fold increase in ferritin expression relative to negative 
control which had no iron treatment (Figure 50b). There is no statistically significant difference in 
the iron mediated ferritin induction in cells treated with chitosan 0.03% and 0.05% w/v suggesting 
that chitosan is poor at iron chelation as iron is available for intracellular uptake. However, ferritin 
protein expression is statistically repressed in cells co-cultured with iron and Exkite 0.03% w/v by 
an eighth or more compared to equivalent concentration of chitosan (p = 0.04) and iron only 




inhibiting ferritin expression. Cell lysates treated with Exkite 0.05% w/v did not contain enough 
protein for western blot analysis due to poor cellular viability. 
 
Figure 51 a) Ferritin western blot for cells cultured with iron in the presence of alginate and Exalg, b) densitometric analysis of 
ferritin western blot as a ratio of ferritin to β-actin, expressed relative to control normalised to one. Experiments were done three 
times in triplicate for each concentration, data is presented as mean ± SEM, # represent statistical significance by Student’s t-test (p 
< 0.05). 
Co-stimulation of RKO cells with iron and Exalg does not elicit a significant difference to iron 
mediated ferritin expression as this is similar to that observed for iron only positive control, 
suggesting that Exalg is poor at iron binding (Figure 51a). Cells challenged with iron and alginate 
show a suppression in ferritin protein expression compared to iron only positive control and cells 




significant for cells treated with alginate 0.01% compared to Exalg 0.01% w/v (p = 0.005) (Figure 
51b). Alginate displays inherent in vitro iron binding potential that is superior to that of Exalg 
despite modification of this polymer with an iron chelator. The superior iron chelation by alginate 
may be attributed to its greater solubility in aqueous media enabling it to chelate iron better out of 
solution. In addition, there is emerging interest in the use of alginate in colorectal cancer therapy180 
which may be effective due to its intracellular iron chelation properties.  
6.4 Ferritin ELISA 
Ferritin ELISA was used to support results of western blot by the colorimetric detection of ferritin 
in cell lysates by antibodies for quantitative analysis. Lysates prepared in an analogous manner to 
that described for western blots were also analysed by ferritin ELISA. 
 
Graph 9 Ferritin ELISA of cells stimulated with iron in the presence of chitosan and Exkite. Experiments were done three times in 
triplicate for each concentration, data is presented as mean ± SEM, * and # represent statistical significance by Student’s t-test (p < 
0.05). 
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The ferritin ELISA for cells challenged with iron (Graph 9) displays increased ferritin expression 
compared to negative control. The ferritin expression of RKO cells treated with iron and chitosan 
is unaltered compared to iron only positive control. The iron mediated ferritin expression is greatly 
supressed when cells were stimulated with iron and Exkite, which is a statistically significant 
reduction for cells treated with Exkite 0.03% and 0.05% w/v compared to treatment with chitosan 
at equivalent concentrations (p < 0.0002), and also with respect to iron only control (p < 0.0001).  
Furthermore, due to the heightened sensitivity of this assay, it can be observed that ferritin 
concentration of cell lysates treated with Exkite 0.03% and 0.05% w/v is 6.59 and 5.64 ng/mL 
respectively which is lower than that of negative control at 43.95 ng/mL which had no iron 
treatment. This suggests that not only is the iron chelation of the polymer preventing iron from 
entering cells, it is also chelating existing iron that is already within cells perhaps by entering cells 
or by being immobilised on the surface of cells. Modulation of intracellular iron in MCF-7 and 
MDA-MB-231breast cancer cells by DFO were indeed shown to disrupt a range of cell signalling 
pathways, activate apoptosis (programmed cell death), and enhance the sensitivity of the breast 
cancer cells to chemotherapeutics doxorubicin and cisplatin.181 Therefore, the chelation of 
intracellular iron in RKO cells is especially beneficial as it offers multiple mechanisms in which to 
retard or impede cancer cell growth. 
The ferritin ELISA of cells co-stimulated with iron in the presence of alginate and Exalg (Graph 
10) shows no significant effect on the iron mediated ferritin expression which is consistent with 
iron only control. This is indicative of poor iron chelation by these polymers as iron is freely 
available for uptake. 
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Graph 10 Ferritin expression by ELISA for RKO cells co-cultured with iron in the presence of alginate and Exalg Experiments 
were done three times in triplicate for each concentration, data is presented as mean ± SEM, * and # represent statistical significance 
by Student’s t-test (p < 0.05). 
However, it is of note that the western blot showed that ferritin expression was suppressed when 
cells were treated with iron and alginate. Although immunoassays are designed to be specific for 
the protein of interest by using protein specific antibodies, variation has been observed in practice 
due to interference which may result in a false-positive or false-negative result. This may arise 
from cross-reactivity of the detecting antibody with other proteins or endogenous substances in the 
sample with chemical differences but structural similarities, effects of buffer in the matrix and 
sample storage.182 In addition, proteins such as ferritin which are known to be present at a wide 
range of concentrations in cells are more susceptible to erroneous results in a one-step 
immunoassays such as the ELISA in which antigen, antibody and marker incubate 
simultaneously.183 This may be the cause of the differences observed between ferritin Western blot 
and ELISA as different antibodies were also used in the methods.      
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6.5 Intracellular iron by ferrozine assay 
Total intracellular iron was also measured by ferrozine assay following a period of cell culture at 
the chosen experimental conditions. Prior to stimulation in iron and polymer solutions, cells were 
serum starved by incubation in foetal calf serum (FCS) free media for one hour, which contains 
essential growth factors and nutrients required for cellular viability and proliferation.184 This was 
followed by stimulation for one hour at enhanced conditions using aqueous iron sulphate (100 µM), 
sodium ascorbate (500 µM) and predetermined concentrations of polymer solutions: chitosan and 
Exkite at 0.03% and 0.05% w/v, alginate and Exalg at 0.005% and 0.01% w/v. The serum starvation 
followed by stimulation is to maximise iron loading of the cells for heightened iron detection. 
Positive control was conducted in aqueous iron sulphate solution with sodium ascorbate in cell 
culture media, and negative control was treated with cell culture media alone. The cells were 
subsequently washed thoroughly with PBS, lysed and analysed by the ferrozine assay to measure 
total intracellular composition of elemental iron. This is a colorimetric assay in which the 
construction of calibration curves allows quantification of iron concentration expressed relative to 
protein concentration of cell lysates.185  
Following a period of cell culture, total intracellular iron has increased from 37 nM/µg protein in 
the negative control to 810 nM/µg protein in the positive iron only control (Graph 11) in accordance 
with greater iron uptake in an iron rich environment. Intracellular iron levels are not statistically 
different to cells co-stimulated with iron and chitosan 0.03% and 0.05% w/v. However total 
intracellular iron composition has statistically reduced upon co-stimulation with iron and Exkite 
0.03% and 0.05% w/v compared to co-stimulation with iron and chitosan (p < 0.004), and also with 
respect to iron only control (p < 0.0001). This is in agreement with results obtained for ferritin 
expression by western blot and ELISA indicative of intracellular iron binding by Exkite.  
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Graph 11 Ferrozine assay of RKO cells treated with iron in the presence Exkite and chitosan. Experiments were done twice in 
triplicate for each concentration, data is presented as mean ± SEM, * and # represent statistical significance by Student’s t-test (p < 
0.05). 
Cells challenged with iron and Exalg do not exhibit a statistically significant difference in 
intracellular iron accumulation compared to iron only control (Graph 12). Conversely, cells 
challenged with iron and alginate show a marked decrease in intracellular iron from 367 nM/µg 
protein in iron only positive control to 56 nM/µg protein in cells treated with iron and alginate 
0.005% w/v, and 43 ng/ µg protein in cells treated with iron and alginate 0.01% w/v. This is a 
statistically significant reduction compared to Exalg at similar concentrations of treatment and iron 
only control (p < 0.0001). This is in accordance with results from western blot ferritin analysis 




Graph 12 Ferrozine assay for RKO cells treated with iron, alginate and Exalg. Experiments were done three times in triplicate for 
each concentration, data is presented as mean ± SEM, * and # represent statistical significance by Student’s t-test (p < 0.05). 
6.6 Probing intracellular Exkite activity  
The iron assessments show that Exkite is able to chelate iron in an intracellular setting, preventing 
the uptake of iron to give reduced ferritin levels and overall iron status compared to cells treated 
with chitosan or iron only positive control. The ferritin ELISA in particular showed that Exkite was 
able to decrease iron induced ferritin expression to such an extent that it was lower than that of 
negative control with no iron treatment, suggesting scavenging of the existing iron within cells. 
This is possible if the chelator is able to enter cells, if Exkite is present in the salt form as indicated 
by diffusion NMR studies on a subsequent batch. Chitosan is known to enhance absorption of polar 
molecules and peptide drugs across mucosal epithelia when protonated. The proposed mechanism 
of action suggest that chitosan is able to do this by bioadhesion and transient widening of tight 
junctions in the membrane.186 Additionally, highly quaternised N-trimethyl chitosan was shown to 
greatly enhance absorption of mannitol across intestinal epithelial Caco-2 cells.187 Hence, the 
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superior iron chelation observed for cells treated with Exkite may arise from the salt form of Exkite, 
in which the protonated chitosan enhances the absorption of the anionic iron chelator across the 
RKO cell membrane.  
Therefore, investigations were conducted into the extent of ligand immobilisation within cells. Cell 
lysates were prepared for assessment by ferritin ELISA by sequential addition of aqueous iron 
solution and then polymer solution to cells. Firstly, aqueous iron sulphate (100 µM) with sodium 
ascorbate (10 µM) was added to RKO cells and incubated for 24 hours to allow prolonged iron 
uptake and ferritin expression. Subsequently, the iron solutions were removed, cells were washed 
with PBS and incubated with chitosan and Exkite 0.03% and 0.05% w/v solutions for 24 hours. 
The sequential addition of iron solutions followed by polymer solutions to the cells allows 
assessment of the capability of polymers to scavenge iron from within cells after iron uptake as 
opposed to iron chelation in an iron rich cellular environment. Cell lysates were prepared as 
previously and analysed by ferritin ELISA.  
The incubation of RKO cells with iron followed by chitosan and Exkite exhibit iron mediated 
ferritin expression that is comparable to that of iron only control at 348 ng/mL (Graph 13). In this 
instance, the addition of chitosan and Exkite after iron uptake does not dampen ferritin expression 
suggesting poor iron scavenging ability of these polymers once iron is bound in the ferritin 
complex. This is not entirely surprising as iron is known to be bound strongly by ferritin so removal 
of ferritin bound iron is a competitive process. However, siderophores have evolved to scavenge 
iron from cells of microorganisms and hence catechols, which are the predominant iron binding 
sub-unit of many siderophores, have been shown to release iron from ferritin by direct chelation.188 
In addition, naturally occurring dithiols DL-dihydrolipoate and DL-dihydrolipoamide have also 
been shown to remove ferritin bound iron when applied in excess,189 which was found to be 
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dependent upon the pH and the reduction of ferric iron to the ferrous form.190 Although the removal 
of ferritin bound iron was not observed in this case, it is possible by some small molecule chelators. 
 
Graph 13 Sequential addition of iron followed by polymer solution to RKO cells. Experiments were done twice in triplicate for 
each concentration, data is presented as mean ± SEM, * and # represent statistical significance by Student’s t-test (p < 0.05). 
6.7 Summary  
The cellular viability of RKO cells when incubated with the polymers was assessed by MTT assay 
which showed that alginate and chitosan are not particularly toxic towards RKO cells, however 
Exkite and Exalg exhibit decreasing cellular viability with increasing concentration of incubation. 
The concentrations of polymers chosen for further iron assays were 0.03% and 0.05% w/v for 
chitosan and Exkite, 0.005% and 0.01% w/v for alginate and Exalg. 
Stimulation of RKO cells with Exalg in the presence of iron does not affect ferritin expression or 
total intracellular iron concentration, which indicates that this is particularly poor at iron chelation 
in vitro. However, cells incubated with iron and alginate show suppression in ferritin expression 
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by western blot and reduction in total intracellular iron by ferrozine assay. Alginate is known to 
accommodate cations and is water soluble compared to the poor solubility of Exalg which may 
have contributed to the greater in vitro chelation activity observed. Previous dialysis experiments 
of Exalg showed that this polymer is capable of binding iron better than alginate, hence in vitro 
iron binding potential may be improved upon enhanced solubility of the polymer in conditions 
required for cellular analysis.  
Treatment of RKO cells with iron and chitosan does not inhibit cellular iron uptake owing to the 
poor solubility and chelation properties of chitosan. Incubation of cells with iron and Exkite shows 
significant reduction in ferritin protein expression by ferritin western blot and ELISA, and total 
intracellular iron is also reduced by the ferrozine assay. This is in accordance with the superior iron 
chelation properties of Exkite observed in UV-vis spectroscopy and dialysis studies.  
The reduction in ferritin expression when cells were stimulated with iron and Exkite was so great 
that it was comparable or lower than that of negative control with no iron treatment indicative of 
iron chelation within cells. This suggests that Exkite may be present in the salt form, consistent 
with NMR diffusion studies, in which protonated chitosan enhances the uptake of the iron chelator 
which inhibits intracellular iron uptake and ferritin expression. This was probed by stimulating 
cells sequentially by iron then Exkite, which showed good iron uptake and ferritin expression by 
cells but Exkite was unable to enter cells to scavenge iron out of the ferritin complex.  
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7 Mouse model studies 
The mouse experiments described in this chapter were conducted by Sorina Radulescu and Victoria Stavrou. This 
involved gavage of mice, monitoring of health, euthanasia and dissection. All mice experiments were conducted in 
accordance with Home Office project license 70/8198 under protocol 19b5 and 40/3613 under protocol 19b3. The 
preparation of microscope slides and H&E staining were provided by The Department of Cellular Pathology, Queen 
Elizabeth Hospital. Immunohistochemistry and scoring of slides were done by myself with assistance from Victoria 
Stavrou.  
7.1 Background 
The iron binding data by dialysis showed that Exkite material obtained as described was superior 
for the chelation of iron over Exalg (Chapter 5). Cellular studies using RKO colorectal cancer cells 
also showed that Exkite was able to chelate iron in an intracellular setting when cells were 
stimulated with iron in the presence of Exkite, inhibiting cellular iron uptake to reduce ferritin 
expression and total intracellular iron (Chapter 6). Although it is not conclusive whether the ligand 
is covalently attached to chitosan or whether Exkite exists in the salt form as a supramolecular 
aggregate, the overwhelming positive evidence towards the superior iron chelation properties of 
the Exkite material warranted further investigation. Furthermore, due to the prevalence of 
supramolecular drug carriers and the intestinal absorption enhancing properties of protonated 
chitosan,191 Exkite salt is potentially a better therapeutic compared to the conjugated counterpart. 
Therefore, regardless of whether the ligand is covalently or non-covalently attached to chitosan, 
the positive results of Exkite were followed into mouse model studies.  
In vivo activity of Exkite was probed by using mouse models of colorectal cancer that have similar 
genetic mutations to that found commonly in human colorectal cancer (CRC). The aim of this is to 
probe in vivo safety and tolerability of Exkite, and whether Exkite can extend the survival of mice 
predisposed to developing intestinal tumours as well as analysis of histological changes to intestinal 
epithelium of mice given Exkite.  
The tumour suppressor gene adenomatous polyposis coli (Apc) is essential for maintaining cellular 
homeostasis but is found to be mutated or inactive in 80% of CRC cases, which is regarded as a 
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key early event in the initiation of CRC.192 A germline heterozygous Apc mutation followed by a 
somatic mutation in the wild type Apc allele results in familial adenomatous polyposis (FAP) which 
gives rise to the development of numerous colonic polyps, which if left unchecked can go on to 
become cancerous. Sporadic CRC occurs with homozygous Apc mutations acquired during the 
lifetime of an individual.193 Many mouse models have been developed with mice carrying 
heterozygous Apc mutation, however homozygous mutations in mice leads to embryonic 
lethality.192 Therefore, cre-lox recombination technology is used to perform insertions or deletions 
at specific points of DNA in a particular cell type, which can be triggered by an external stimulus.194 
This allows targeted DNA modification of particular cells in an organism and is achieved by the 
Cre recombinase enzyme which recombines a pair of target (lox) sequences in the DNA. The lox 
sequence can be appropriately placed to allow for specific gene activation or repression. When a 
lox sequence is placed either side of a target gene, this is called a floxed gene.195 Therefore, 
homozygous inactivation of floxed genes can be induced in adult mice to mimic genetic aberrations 
of human diseases.196 As such, Apc Hom (Cre+ Apcf/f) mice is a transgenic inducible model of 
sporadic CRC with homozygous Apc inactivation in the intestinal epithelium.197 This results in 
multiple intestinal tumours as Apc is well conserved between humans and rodents, however Apc 
inactivation in mice leads to tumour formation predominantly in the small intestine as opposed to 
the large intestine in humans.198  
Similarly, phosphatase and tensin homolog (Pten) is also a tumour suppressor gene often found 
mutated in many sporadic cancers including CRC. Germline mutations in Pten gives rise to 
multiple hamartoma syndromes such as Cowden’s disease with individuals having an increased 
risk of cancer, especially cancer of the gastrointestinal tract. Apc Hom Pten Hom (Cre+ Apcf/f 
Ptenf/f) mice is also a transgenic inducible model with homozygous inactivation of Apc and Pten, 
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which gives rise to aggressive tumorigenesis of the small intestine due to the inactivation of both 
tumour suppressor genes.199   
The intestinal epithelium is ordered into crypts and villi in which cells produced in the crypts 
migrate up the villi until cell death or are shed into the gut lumen. Cell renewal is usually a tightly 
regulated process however, inactivation of tumour suppressor genes Apc and Pten results in 
uncontrolled mitosis (cell division) and reduced apoptosis (programmed cell death) of stem cells 
in intestinal crypts. This gives rise to enlarged crypts compared to wild type mice and the 
subsequent development of intestinal tumours (Figure 52).200 
 
Figure 52 Hematoxylin and Eosin (H&E) stained intestinal sections of control mouse (Vil-CreERT2 Apcf/+) and mutant mouse 
containing homozygous Apc inactivation along crypt-villus axis (Vil-CreERT2 Apcf/f  ) shows enlarged crypts compared to control 
mouse due to intense cellular proliferation from loss of Apc. (Copyright The Company of Biologists Publisher 2005). 
Apc Hom and Apc Hom Pten Hom mice were gavaged (Licence 40/3613 under protocol 19b3) 
with Exkite to study survival. As Exkite was administered as a suspension in water, this was 
compared to mice that were given water alone as the vehicle. Mice were euthanized when they 
showed symptoms of being sick such as weight loss, pale feet and hunched posture. The small 
intestine was dissected, preserved in paraffin block, and was submitted to histological staining to 
assess for mitosis and apoptosis to give an indication of tumour proliferation or suppression upon 
treatment.  
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7.2 Exkite safety and tolerability in mice 
Initial mice experiments were conducted with wild type mice to assess tolerability of Exkite and to 
find an appropriate dose to use for further in vivo experiments. Wild type mice were given daily 
200 µL gavages of Exkite for five days at varying concentrations: 0.01%, 0.10%, 0.25%, 0.50% 
and 1% w/v limited by the viscosity of the solution with 1% w/v being the highest concentration 
of Exkite that was able to be taken up by a gavage syringe. After five days, none of the mice showed 
any adverse symptoms such as weight loss or hunched posture so further mice experiments were 
conducted with 1% w/v Exkite. 
Wild type mice were also used to assess in vivo metabolism of Exkite, in particular to assess the 
possibility of absorption of non-conjugated ligand from Exkite salt into the blood stream which 
may cause anaemia by chelation of systemic iron.  
 
Figure 53 Analysis by MALDI spectrometry for presence of deferasirox at 374.11 Da, a) blood plasma of wild type mice gavaged 
Exkite or water control and b) intestinal crypts extracted from wild type mice gavaged Exkite or water control. Experiments were 
done with n = 3 mice, data is presented as mean ± SEM, * represent statistical significance by Student’s t-test (p < 0.05). 
Wild type mice were administered 200 µL of 1% w/v Exkite or water as control and were 
euthanized one hour after treatment. Blood plasma and intestinal crypts were collected and 
analysed by MALDI spectrometry for the presence of deferasirox or any of its known metabolites.59 
Analysis of blood plasma shows that there is an observable difference but this is not statistically 
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significant between mice gavaged with Exkite or water at 374.11 Da corresponding to the mass of 
deferasirox (Figure 53a, p = 0.174).  
However, analysis of intestinal crypt cells shows a three-fold increase in intensity at 374.11 Da for 
mice given Exkite relative to control (Figure 53b, p = 0.005), and although this is noticeable it is 
not substantial. This may be from free ligand in Exkite salt or from ligand detachment, but the 
relatively small amount found suggest that this will not pose a serious risk to chelation of systemic 
iron. Other metabolites of deferasirox as proposed by Bruin et al. in rats were not observed. This 
includes glucuronidation at the carboxylate group and at phenolic hydroxy groups, as well as 
hydroxylations catalysed by cytochrome P450 (Figure 54).59  
 
Figure 54 Major metabolites of deferasirox detected in plasma, urine, bile, and faeces of rats. 
7.3 Mouse survival 
Apc Hom and Apc Hom Pten Hom mice were utilised as models of sporadic CRC which were all 
placed on a control diet. After induction of tumorigenesis by tamoxifen injection at 6 weeks of age, 
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the mice were subject to a dose of 200 µL of 1% w/v Exkite or 200 µL of water as the vehicle 
control, administered by oral gavage on alternate days until they became sick.  
Previous studies by Radulescu et al. using an Apc hom mouse model (Lgr5creERT2+Apcf/f) showed 
increased survival of mice that were fed an iron deficient diet compared to a control diet with 
median survival of 89 days and 61 days respectively (p = 0.001).26 This was attributed to attenuated 
tumorigenesis with the iron deficient diet. Therefore, it would be expected that significant chelation 

























Survival Plot for Apc Hom mice
Kaplan-Meier Method
 
Figure 55 Apc Hom mice administered Exkite (n = 6) or vehicle (n = 3), survival plot shows no difference in survival for mice given 
Exkite or vehicle.  
The survival plot (Figure 55) shows that there is no difference in the survival of Apc Hom mice 
that were given Exkite compared to the vehicle comprising equivalent volume of water, with a 



























Survival Plot for Apc Hom PTen Hom mice
Kaplan-Meier Method
 
Figure 56 Apc Hom Pten Hom mice administered Exkite (n = 13) or vehicle (n = 16), Survival plot shows no difference in survival 
for mice given Exkite or vehicle.  
There is no apparent change in the survival of Apc Hom Pten Hom mice that were given Exkite 
with a median of 28 days compared to the vehicle control mice with a median of 32 days (Figure 
56, p = 0.55). This suggests that chelation of dietary iron by Exkite is not profound enough to 
prolong survival of mice in both models used.  
7.4 Histology 
At the end of the survival study, histological sections of the small intestine of the mice were taken. 
These slides were then stained by hematoxylin and eosin (H&E) which is a non-specific stain to 
show cellular morphology from which mitotic and apoptotic cells can be identified.201  
Slides were also stained by immunohistochemistry in which phosphohistone (PHT) was utilised as 
a marker for mitosis as histone is specifically phosphorylated in the mitotic cycle during chromatin 
condensation.202 Caspase 3 is a serine protease that induces apoptosis, such that activation of this 
protease is an unambiguous indicator of this cell suicide mechanism.203 The use of specific 
antibodies for the detection of phosphohistone and caspase 3 results in positive staining of mitotic 
and apoptotic cells. The extent of mitosis or apoptosis was assessed by scoring 25 continuous crypts 
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by counting positively stained cells and the total number of cell in the crypt. This is expressed as 
an index which is the average percentage of cells in mitosis or apoptosis relative to the total number 
of cells per crypt.  
 
Figure 57 Representative images of intestinal tissue sections from Apc Hom mice stained by H&E, arrows indicate mitotic cells in 
crypts: a) H&E section of mouse treated with Exkite (magnification x 20), b) Enlarged magnification (x 40) H&E section of mouse 
treated with Exkite, c) H&E section of mouse treated with vehicle (magnification x 20), d) Enlarged magnification (x 40) H&E 
section of mouse treated with vehicle, e) Mitotic index from H&E stain shows no difference between treatments. Data is presented 





Figure 58 Representative images of intestinal tissue sections from Apc Hom mice for PHT and caspase 3 stains, arrows indicate 
mitotic or apoptotic cells in crypts, magnification x 20 for all: a) PHT section of mouse treated with Exkite, b) Caspase 3 section of 
mouse treated with Exkite, c) PHT section of mouse treated with vehicle, d) Caspase 3 section of mouse treated with vehicle, e) 
Mitotic index from PHT stain shows no difference between treatments, f) Apoptotic index from caspase 3 stain shows no difference 





Figure 59 Representative images of intestinal tissue sections from Apc Hom Pten Hom mice stained by H&E, arrows indicate 
mitotic cells in crypts: a) H&E section of mouse treated with Exkite (magnification x 20), b) Enlarged magnification (x 40) H&E 
section of mouse treated with Exkite, c) H&E section of mouse treated with vehicle (magnification x 20), d) Enlarged magnification 
(x 40) H&E section of mouse treated with vehicle, e) Mitotic index from H&E stain shows statistically significant decrease in 
mitosis of mice treated with Exkite relative to vehicle. Data is presented as mean ± SEM, * represent statistical significance by 





Figure 60 Representative images of intestinal tissue sections from Apc Hom Pten Hom mice for PHT and caspase 3 stains, arrows 
indicate mitotic or apoptotic cells in crypts, magnification x 20 for all: a) PHT section of mouse treated with Exkite, b) Caspase 3 
section of mouse treated with Exkite, c) PHT section of mouse treated with vehicle, d) Caspase 3 section of mouse treated with 
vehicle, e) Mitotic index from PHT stain shows reduction in mitosis for mice treated with Exkite relative to vehicle, f) Apoptotic 
index from caspase 3 stain shows increase in apoptosis for mice treated with Exkite relative to vehicle. Data is presented as mean ± 
SEM, * represent statistical significance by Student’s t-test (p < 0.05) 
Scoring slides for Apc Hom mice revealed that there is no appreciable difference in mitotic index 
between mice that were administered Exkite or vehicle water control, by H&E staining (Figure 57e, 
p = 0.813) or PHT expression (Figure 58e, p = 0.518). Likewise, there is no difference in the 
apoptotic index between the two treatments as calculated from caspase 3 immunostained tissue 
sections (Figure 58f, p = 0.282).  
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However, Apc Hom Pten Hom mice showed statistically significant reduction in mitosis in mice 
treated with Exkite compared to vehicle alone by both H&E staining (Figure 59e, p = 0.022) and 
PHT immunostained sections (Figure 60e, p = 0.026). This is complimented by an increase in 
apoptosis by amplified caspase 3 expression in mice treated with Exkite relative to vehicle (Figure 
60f, p = 0.004). In this mouse model, the inactivation of tumour suppressor genes Apc and Pten 
results in intense cellular proliferation of intestinal crypts leading to enlarged crypts and 
tumorigenesis. Therefore, the observation that Exkite reduces cellular proliferation by mitosis 
whilst simultaneously increasing cell death by apoptosis indicates an attenuation of tumorigenesis. 
This result is supported by previous studies in which scoring intestinal crypts of AHCre+Apcf/f mice 
that were fed an iron deficient diet showed a decrease in mitotic index and increase in apoptotic 
index (p = 0.015), and associated decrease in tumour burden compared to mice on a control diet, 
whereas mice fed an iron rich diet showed the opposite trend.26 This was attributed to iron levels 
directly affecting intestinal crypt cells to survive and proliferate. Furthermore, deferasirox induces 
early apoptosis by increasing expression of caspase 3 in human malignant lymphoma cells204 and 
myeloid leukemia cells205 by chelation of iron inhibiting cellular proliferation. Hence, it is likely 
that the reduced mitotic index and increased apoptotic index of mice treated with Exkite in this 
model is a result of iron chelation in vivo, as it is well known that iron is essential for cellular 
division.  
7.5 Summary  
Safety and tolerability of Exkite towards mice was assessed by subjecting wild type mice to daily 
gavage of varying concentrations of Exkite for five days from which the optimal dose was deemed 
to be 200 µL of 1% w/v Exkite. Subsequently, wild type mice administered Exkite indicated minute 
amounts of free deferasirox ligand in intestinal crypt cells which may be ligand from Exkite salt as 
determined by diffusion NMR or ligand cleavage from decomposition of ligand conjugated Exkite. 
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Nevertheless, administering Exkite to CRC mouse models did not extend survival in either Apc 
Hom or Apc Hom Pten Hom mice. Histological analysis of intestinal tissue for Apc Hom mice did 
not show any difference in apoptotic or mitotic index in mice treated with Exkite compared to water 
vehicle control. However, Apc Hom Pten Hom mice treated with Exkite showed reduced mitosis 
and increased apoptosis of intestinal crypt cells compared to control. Although this did not translate 
into increased survival of mice treated with Exkite, this suggests in vivo activity of Exkite material 




8 Conclusion and Future work 
8.1 Conclusion 
The ligand deferasirox was identified as an appropriate iron chelator for investigation in this project 
owing to its safety and tolerability profile, and its superior iron binding properties relative to other 
chelators. This was synthesised in two steps from commercially available starting materials, and 
various modifications were attempted which demonstrated the chemical versatility of this ligand, 
and allowed the accumulation of a library of deferasirox related ligands. In particular, 
modifications to deferasirox were focused upon incorporating suitable functionalities for attaching 
onto non-absorbable backbones alginate and chitosan. These biopolymers were chosen for their 
non-toxicity and are already used in the food industry so are safe for oral consumption. 
Carbodiimide chemistry was utilised to attempt to attach deferasirox 6 to chitosan to yield Exkite 
43, and modified ligand 33 was attached to alginate to yield Exalg 42. In addition, the ligand 
loading of Exalg was probed by reacting alginate with varying amount of ligand 33 to yield 
Exalg0.25 – Exalg1.25.  
Characterisation of polymers by IR, NMR and UV-vis spectroscopy confirmed ligand 
incorporation of polymers. Attempts to quantify ligand incorporation of Exkite by 1H NMR 
spectroscopy and XPS indicated modification of 40%. Quantification of modification of Exalg0.25 
– Exalg1.25 polymers by 
1H NMR spectroscopy and phenol/sulphuric acid assay suggest 
modification of 20% for all Exalg polymers. Analysis by XPS suggest higher modification on 
account of observed nitrogen composition but this may be an artefact of activated NHS/EDAC.HCl 
species as opposed to the ligand. Modification of all Exalg polymers was similar despite varying 
ligand equivalence in the synthesis. This suggests a restrictive factor to ligand incorporation which 
may arise from steric bulk or tertiary structure effects as incorporation of some ligands onto 
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alginate may prevent the approach of other ligand molecules due to steric hindrance on the polymer. 
This may also be related to the extent of activation of carboxylic acid sites by coupling agents. 
Further probing by diffusion NMR spectroscopy confirmed that the modified ligand 33 was indeed 
attached to alginate in Exalg owing to similar self-diffusion coefficients between the polymer and 
the ligand. However, significantly different self-diffusion coefficients were observed between the 
ligand and polymer in Exkite which suggests that the ligand is not associated with the polymer. 
This can be attributed to Exkite salt in which the electrostatic interactions between protonated 
chitosan and deprotonated ligand 6 give rise to a supramolecular aggregate, and may indicate batch 
to batch variation in the synthesis of Exkite.  
Iron binding upon ligand incorporation of modified polymers was probed by the titration of iron 
solution into polymer solutions to measure a change in absorbance by UV-vis spectroscopy. 
Titrations into Exkite and Exalg revealed a shift in absorbance indicative of iron complex formation. 
Iron binding was also investigated by dialysis methods, and iron concentrations measured by AAS 
and ferrozine assay. Exkite elicited 100-fold increase in ferrous and ferric iron binding in the 
presence and absence of calcium relative to native polymer chitosan. Exalg only presented a 
moderate increase in iron binding; ferrous binding is greater in the presence of calcium, possibly 
due to gelling in the presence of Ca+ to form egg box structures and trapping of iron. Iron binding 
of Exalg0.25 – Exalg1.25 was consistent due to similar modification of all Exalg polymers.   
In vitro cellular studies were conducted using RKO colorectal cancer cells. Incubation of cells with 
iron and Exkite elicited a suppression in iron induced ferritin expression by western blot and ELISA. 
Exkite was shown to prevent the uptake of ambient iron as total intracellular iron was also reduced 
by ferrozine assay relative to iron only control and cells treated with iron and chitosan. However, 
stimulation of cells with iron and Exalg failed to have an effect on ferritin expression or total 
intracellular iron concentration, indicating poor in vitro iron chelation of Exalg. Surprisingly, cells 
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stimulated with iron and alginate itself supressed iron mediated ferritin expression by western blot, 
and total intracellular iron is reduced by ferrozine assay compared to iron only control. The greater 
aqueous solubility of alginate may have contributed to the superior in vitro iron chelation observed. 
In vivo chelation properties of Exkite was probed by using mouse models of CRC in which 
uncontrolled growth of intestinal crypt cells leads to the formation of intestinal tumours. Although 
Apc Hom mice that were administered Exkite did not display any positive effects, Apc Hom Pten 
Hom mice that were administered Exkite showed reduced mitotic index and increased apoptotic 
index of intestinal crypt cells relative to vehicle control. Despite the fact that this did not extend to 
an increase in mouse survival, the anti-neoplastic effects observed demonstrate in vivo activity of 
Exkite, and contribute to the growing evidence that in the background of CRC, iron chelation in 
the intestine has the potential to supress carcinogenesis.   
8.2 Future work 
The modified polymers Exkite and Exalg investigated in this project represent the first generation 
of non-absorbable iron chelators which allowed the development of synthesis, characterisation and 
iron binding testing methods. Although the ligand conjugation of Exkite is not conclusive, the 
delivery of Exkite in the salt form requires further investigation. The development of the polymer 
Chemistry is on-going in the Fossey group in collaboration with the Fernandez-Trillo group. It was 
established that iron chelation properties of polymers can be improved by incorporation of a ligand, 
and these can be applied for effective iron chelation in an in vitro and in vivo setting. However, 
there were some important factors that became apparent during the course of this project which 
need to be taken into account if non-absorbable iron chelators are to be progressed into a clinical 
setting.  
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The physical properties of modified polymers such as solubility are important as this can directly 
influence iron binding. The in vitro and in vivo iron binding of Exkite and Exalg may be improved 
by increasing the aqueous solubility of the polymers so that it is more readily available to chelate 
iron out of solution. This will also enable easier characterisation by the use of traditional polymer 
characterisation techniques such as gel permeation chromatography and rheology. In addition, the 
precipitation of iron-polymer complex during UV-vis spectroscopy titrations meant that an 
accurate binding constant could not be elucidated from a binding curve. Increasing the solubility 
of modified polymers will allow better quantification of iron binding as isothermal titration 
calorimetry (ITC) can be used to calculate binding constants.  
The aqueous solubility of Exkite and Exalg can be improved by the incorporation of water soluble 
polyethylene glycol (PEG) groups to offset the hydrophobic nature of the deferasirox ligand moiety. 
Alternatively, the ligand loading can be limited to be low by using stoichiometric control with 
respect to ligand to polymer ratio in the synthesis so that the aqueous solubility of the polymer 
backbone is retained. Despite the use of water soluble ligand 33 in reaction with alginate, the 
product Exalg was still poorly water soluble. Therefore, other ligands may be investigated for 
attachment onto a non-absorbable backbone. In particular, desferrioxamine (DFO) is water soluble 
and contains a free amine that is not utilised in iron binding, which can be used to react with alginate 
(Scheme 27).  
DFO-polymer conjugates have been previously synthesised and applied to improve the vascular 
retention and toxicity of the ligand when administered intravenously. It is possible to investigate 
these polymers such as starch-DFO70 7 and PEG-DFO71 8 conjugates in the context of CRC. Their 
iron binding properties can be determined by application to RKO cancer cells and CRC mouse 




Scheme 27 Proposed synthesis of alginate-DFO conjugate. 
The synthesis of Exalg0.25 – Exalg1.25 allowed the identification of a limiting factor to the 
incorporation of the ligand to polymer backbone resulting in similar iron binding of all the Exalg 
polymers, although the nature of the limiting factor remains elusive. This can be probed by altering 
the amount of coupling agents as well as the ligand in the synthesis, and can also be applied to 
Exkite to see how varying ligand equivalence in the synthesis affects iron binding of this polymer.  
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Surprisingly alginate performed well in intracellular iron binding experiments, and further 
investigations into the use of alginate alone in CRC therapy is on-going. Different types of alginate 
from different sources, the effects of molecular weight and M/G ratio upon iron binding are all 
being considered. Alginate therapy offers a non-toxic and practical alternative to synthetic 
chelators for CRC therapy, however the potential drawback is that alginate has a higher affinity 
towards calcium than iron. The removal of a non-target cation such as calcium may cause a 
deficiency of a physiologically important metal leading to complications. In addition, calcium has 
been shown to have protective properties in the context of CRC in epidemiological studies so 
removal of this metal should be avoided.206  
The mode of delivery of an active agent is also an important consideration. Delivery of Exkite 
material in the salt form may increase the intracellular uptake of the iron chelator due to the 
intestinal absorption enhancing properties of chitosan.191 Matrix metalloproteinases (MMPs), 
which are known to be overexpressed in cancer cells, are zinc dependant endopeptidases207 which 
are capable of degrading extracellular matrix (ECM) proteins208 so are capable of cleaving peptide 
bonds of conjugated ligands. Additionally, oral administration of the active agent means that it has 
to withstand drastic pH changes in the GI tract from pH 1.0 - 3.0 in the stomach to pH 6.0 - 7.0 in 
the large intestine.209 Essential nutritional iron is absorbed in the small intestine so it is also vital 
that chelation of dietary iron does not happen too early in the GI tract. One method to overcome 
these problems is to encapsulate the active compound for controlled release in the large intestine. 
This could be in a pH responsive coating210, 211 or degradation of the capsule by gut microbiota for 
site specific release.212 Larger beads or microparticles that are large enough not to be absorbed in 
the GI tract can also be used instead of a non-absorbable backbone, to have chelators adsorbed onto 
the surface.  
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The current course of treatment for CRC is surgery and chemotherapy alone. Assuming that the 
correct drug delivery method for the iron binding active is found, this should offer a safer and less 
expensive adjuvant therapy to the clinical management of the disease with a view of prolonging 





9.1 General Chemical Experimental 
Proton nuclear magnetic resonance (1H NMR) spectra were recorded on a Bruker AVIII 300 (300 
MHz) spectrometer. All spectra were obtained at 22 °C and reported relative to residual solvent 
peaks in CDCl3 (δH 7.26 ppm), d6-DMSO (δH 2.50 ppm), CD3OD (δH 3.31), D2O (δH 4.79) or d-
TFA (δH 11.3 ppm).
213 All coupling constants are expressed as J, data is reported as follows: 
chemical shift (multiplicity, number of protons, coupling constants, assignment). Chemical shift is 
quoted to the nearest 0.01 ppm, and coupling constants to the nearest 0.1 Hz. Multiplicity is 
reported according to the following convention: s = singlet, d = doublet, t = triplet, q = quartet, dd 
= doublet of doublets, m = multiplet. All spectra were processed with MestReNova (version 6.0.2-
5475). 
Carbon nuclear magnetic resonance (13C [1H] NMR) spectra were recorded on a Bruker AVIII 400 
(101 MHz) spectrometer which was proton decoupled. Chemical shifts are quoted to the nearest 
0.1 ppm relative to residual solvent peaks in CDCl3 (δC 77.2 ppm), d6-DMSO (δC 39.5 ppm) or 
CD3OD (δC 49.0 ppm).
213  
Diffusion NMR experiments were performed on a Bruker DMX300 spectrometer equipped with a 
7 T superconducting magnet, operating at a proton resonance frequency of 300.13 MHz. Diffusion 
coefficients were measured using the 1H NMR pulsed gradient stimulated echo (PGSTE) 
experiment at 293 ± 0.3 K. An observation time of Δ = 100 ms was used and the gradient strength 
was varied over 32 gradient steps with Gmax  = 1 T m 
-1. A repetition time of 2 s was used and δ was 
kept constant at 2 ms. The signal loss with increasing gradient strength was fitted to the Stejskal-












  is the signal decal,  𝛾 is the gyromagnetic ratio and 𝐷 is the self-diffusion coefficient. 
Where a monoexponential fit was poor, a biexponential fit was performed, producing two diffusion 
coefficients. The data were fitted to the minimum number of components necessary. 
Flash column chromatography was conducted using silica gel 60F under positive pressure. TLC 
visualisation was with UV (254 nm), KMnO4 or Ninhydrin on F254 plates. 
Mass spectra were recorded with electrospray MS Waters LCT Time of Flight mass spectrometer 
and with synapt G2-HDMS mass spectrometer in both positive and negative mode. 
Melting points were conducted in triplicate and reported as the average and expressed as a range 
using Melting Point apparatus Stuart Scientific SMP10.  
All IR spectra were recorded on a Perkin Elmer Spectrum 100 FT-IR spectrometer with Universal 
Attenuated Total Reflection Sampling Accessory as an average (10 scans) with the background (10 
scans) subtracted. 
UV-vis spectra were recorded on a Varian Cary50 spectrophotometer at 22 °C in water using 2.00 
mL sample solution in a quartz cuvette with a path length of 1.00 cm.   
Elemental analysis was conducted at Warwick Analytical Service on a CE 440 Elemental Analyser. 
XPS measurements were obtained at Leeds Nanoscience and Nanotechnology Research Equipment 
Facility (LENNF) with support from EPSRC for funding towards travel and subsistence to take 
samples to the facility. XPS measurements were performed using a VG Escalab 250 XPS with 
monochromated aluminium K-alpha X-ray source. The spot size was 500 μm with a power of 150 
W. Detailed spectra of individual peaks were taken at energy of 20 eV with a step size of 0.1 eV. 
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Binding energy was calibrated by setting the carbon 1s peak to 285 eV. Detailed spectra had a 
Shirley or linear background fitted to them and peaks were fitted using mixed Gaussian-Lorentzian 
fits (using CASAXPS).  
All purchased chemicals were used as received from Sigma Aldrich.  
9.2 Compounds synthesised 
9.2.1  2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one 
 
Salicylic acid 19 (6.04 g, 43.75 mmol), salicylamide 20 (5.00 g, 36.46 mmol) and pyridine (0.37 
mL, 4.63 mmol) were heated at reflux in xylene (18.00 mL) for 15 minutes. Thionyl chloride (5.83 
mL, 80.21 mmol) was added with vigorous stirring over a period of 4 hours, with further stirring 
for 16 hours at room temperature. Xylene was removed by concentration in vacuo, and resulting 
solid residue was suspended in ethanol (15.00 mL) and acetic acid (0.36 mL). The mixture was 
heated to reflux and cooled to room temperature. The solid precipitate was isolated and dried to 
yield 21 (6.59 g, 27.54 mmol, 76%) as yellow solid. Rf 0.37 (3:1 hexane/ ethyl acetate). 1H NMR 
(300 MHz, d6-DMSO) δH 12.94 (s, 1H, OH), 8.21 (dd, 1H, J = 8.4, 1.6 Hz, H3), 8.07 (dd, 1H, J = 
7.8, 1.6 Hz, H10), 7.95 (ddd, 1H, J = 8.7, 7.4, 1.6 Hz, H5), 7.80 (d, 1H, J = 8.7 Hz, H6), 7.69 – 7.55 
(m, 2H, H12, H13), 7.16 – 7.03 (m, 2H, H4, H11). 13C NMR (100 MHz, d6-DMSO) δC 164.8 (C1), 
163.4 (C14), 161.8 (C7), 153.8 (C8), 136.7, 136.0, 129.0, 127.2, 126.7, 119.5, 117.9, 117.8, 117.4 
(C2), 111.4 (C9). MS m/z 262.1 [M+Na
+]. IR 1690 (C=O), 1604 (C=N), 1540 (C=C), 1464 (C=C), 
1445 (C=C), 1352 (C=C) cm-1. Melting point range 198 - 201 °C. 
 129 
9.2.2 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoic acid 
 
4-Hydrazino-benzoic acid (1.40 g, 9.19 mmol), and triethylamine (1.28 mL, 9.19 mmol) were 
added to ethanol (40.00 mL) and refluxed for 15 minutes until all components were dissolved. To 
the clear solution was added 21 (1.40 g, 9.19 mmol) which was further refluxed for 2 hours. After 
cooling to room temperature, water (5.00 mL) was added until perturbation was observed. The 
mixture was concentrated to 50% of total volume under reduced pressure, and aqueous 6 M HCl 
(31.00 mL) was added. The resulting precipitate was isolated and dried to yield 6 (3.12 g, 8.36 
mmol, 99%) as dark yellow solid. Rf 0.27 (5% MeOH, 2% NEt3 in CHCl3). 1H NMR (300 MHz, 
d6-DMSO) δH 13.20 (s, broad, 1H, OH), 10.82 (s, 1H, OH), 10.07 (s, 1H, OH), 8.06 (dd, 1H, J = 
7.8, 1.6 Hz, H8), 7.99 (d, 2H, J = 8.7 Hz, 2H3), 7.61 – 7.53 (m, 3H, 2H4, H15), 7.46 – 7.34 (m, 2H, 
H10, H17), 7.08 – 6.95 (m, 3H, H9, H16, H11 ), 6.87 (d, 1H, J = 8.2 Hz, H18). 13C NMR (100 MHz, 
d6-DMSO) δC 166.4 (C1), 159.9 (C13), 156.4 (C12), 155.2 (C19), 152.0 (C6), 141.2 (C5), 132.5, 131.4, 
131.0, 130.5, 130.2 (C2), 126.7, 123.2, 119.6, 119.4, 117.0, 116.2, 114.4 (C7), 113.6 (C14). MS m/z 
372.3 [M+]. IR 2971 (O-H), 1683 (C=O), 1616 (C=N), 1603 (C=C), 1560 (C=C), 1532 (C=C), 





To a solution of 6 (0.100 g, 0.268 mmol) in DCM (40.00 mL) was added NHS (0.037 g, 0.322 
mmol) and DCC (0.066 g, 0.322 mmol), and solution was refluxed for 30 minutes. Isopropylamine 
(0.032 g, 0.536 mmol) was added and solution was further refluxed for 3 hours. The medium was 
concentrated in vacuo and resulting residue was purified by flash column chromatography (1:1 
hexane: ethyl acetate), to yield 29a as white crystalline powder (0.093 g, 0.224 mmol, 83%). Rf 
0.50 (1:1 hexane: ethyl acetate). 1H NMR (300 MHz,CDCl3) δH 11.40 (s, 1H, OH), 9.59 (s, 1H, 
OH), 8.14 (dd, 1H, J = 7.8, 1.6 Hz, H10), 7.95 (d, 2H, J = 8.6 Hz, 2H5), 7.60 (d, 2H, J = 8.6 Hz, 
2H6), 7.44 – 7.30 (m, 2H, H11, H18), 7.14 (dd, 1H, J = 8.4, 1.0 Hz, H17), 7.11 – 7.01 (m, 2H, H12, 
H13), 6.93 (dd, 1H, J = 8.0, 1.5 Hz, H20), 6.71 – 6.62 (m, 1H, H19), 4.34 (m, 1H, H2), 4.01, (d broad, 
1H, J = 7.9 Hz, NH), 1.32 (d, 6H, J = 6.5 Hz, 6H1). 13C NMR (100 MHz, CDCl3) δC 165.1 (C3), 
159.6 (C15), 158.1 (C14), 156.5 (C21), 152.2 (C8), 140.3 (C4), 136.6, 133.0, 131.9, 128.6, 127.7, 
127.5, 126.3, 119.9, 119.1. 118.4, 117.2, 113.2, 109.9, 42.4 (C2), 22.8 (C1). MS: m/z 437.3 [M + 
Na+]. IR 3304 (O-H), 1621 (C=O), 1587 (C=N), 1543 (C=C), 1505 (C-C), 1472 (C-C), 1493 (C-




To a solution of 21 (1.000 g, 4.180 mmol) in methanol (20.00 mL) was added 4-
nitrophenylhydrazine (0.700 g, 4.600 mmol), which was refluxed for 2.5 hours. Upon cooling, the 
product precipitates as dark yellow solid which was collected and washed with methanol to yield 
27 (0.778 g, 2.080 mmol, 50%). Rf 0.38 (3:1 hexane: ethyl acetate). 1H NMR (300 MHz, d6-
DMSO) δH 10.70 (s, 1H, OH), 10.11 (s, 1H, OH), 8.34 (d, 2H, J = 9.1 Hz, H2), 8.06 (dd, 1H, J = 
7.8, 1.5 Hz, H7), 7.73 (d, 2H, J = 9.1 Hz, H3), 7.62 (dd, 1H, J = 7.8, 1.5 Hz, H14), 7.47- 7.35 (m, 
2H, H9, H16), 7.09 – 6.97 (m, 3H, H8, H15, H10), 6.88 (d, 1H, J = 8.0 Hz, H17). 13C NMR (100 MHz, 
d6-DMSO) δC 160.2 (C12), 156.3 (C11), 155.0 (C18), 152.4 (C1), 148.1 (C5), 142.8 (C4), 132.8, 131.6, 
131.1, 126.9, 124.7, 124.1, 119.7, 119.6, 117.1, 116. 2, 114.2, 113.5. MS m/z 373.2 [M - H+]. IR 
3010 (O-H), 1652 (C=N), 1593 (N-O), 1482 (N-O), 1328 (C=C), 1306 (C=C), 1273 (C-C), 1254 
(C-O), 1112 (C-N) cm-1. Melting point range 179 – 181 °C.  
9.2.5 Tert-butyl (2-(2-(2-aminoethoxy)ethoxy)ethyl)carbamate 
 
Boc anhydride (1.000 g, 1.053 mL, 4.582 mmol) in DCM (5.00 mL) was added portion wise over 
2 hours at room temperature to 2,2 (ethylenedioxy) bis(ethylamine) (4.074 g, 4.01 mL, 27.489 
mmol) in DCM (10.00 mL). This was further stirred at room temperature for 5 hours and solvent 
was removed. Water (30.00 mL) was added to the residue and extracted with DCM (6 x 20.00 mL), 
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the combined organic extracts were dried (MgSO4) and concentrated in vacuo to yield 31 as pale 
yellow oil (0.982 g, 3.957 mmol, 86 %). 1H NMR (300 MHz, CDCl3) δH 5.66 (s, 1H, NH), 3.59 – 
3.50 (m, 4H, 2H5, 2H8), 3.50 – 3.40 (m, 4H, 2H6, 2H7), 3.27- 3.17 (m, 2H, 2H9), 2.79 (t, J = 5.2 Hz, 
2H, 2H4), 1.48 (s, 2H, 2NH), 1.36 (s, 9H, 9H1). 13C NMR (100 MHz, CDCl3) δC 154.0 (C3), 78.5 
(C2), 73.2, 69.9, 41.5 (C4), 40.1 (C9), 28.2 (C1). MS m/z 249.1 [M + H
+], 271.1 [M + Na+]. IR: 
3364 (N-H), 2975 (N-H), 2868 (C-H), 1696 (C=O), 1516 (C-C), 1454 (C-C), 1365 (C-O) cm-1. 
9.2.6  4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoyl chloride 
 
Thionyl chloride (0.20 mL, 2.687 mmol) was added to 6 (0.100 g, 0.268 mmol) in DCM (20.00 
mL), and solution refluxed for 22 hours. The residue was concentrated in vacuo to yield 32 as dark 
brown solid (0.104 g, 0.268 mmol, 99%). Rf 0.20 (5% MeOH, 1% NEt3 in CHCl3). 1H NMR (300 
MHz, d6-DMSO) δH 8.04 (dd, 1H, J = 7.8, 1.6 Hz, H8), 7.99 (d, 2H, J = 8.7 Hz, 2H3), 7.60 – 7.51 
(m, 3H, J = 8.7 Hz, 2H4, H15), 7.45 – 7.32 (m, 2H, H10, H17), 7.07 – 6.94 (m, 3H, H9, H11, H16), 
6.90 (d, J = 8.2 Hz, 1H, H18). 13C NMR (100 MHz, d6-DMSO) δC 166.4 (C1), 159.6 (C13), 156.3 
(C12), 155.3 (C19), 152.0 (C6), 141.1 (C5), 132.6 (C2), 131.6, 131.1, 130.6, 130.3, 126.9, 123.4, 
119.7, 119.4, 1171, 116.2, 114.4 (C7), 113.6 (C14). MS m/z 414.8 [M + Na
+]. IR 2954 (O-H), 1777 
(C=O), 1737 (C=N), 1613 (C=C), 1598 (C=C), 1534 (C-C), 1460 (C-C) cm-1. Melting point range 





Compound 32 (0.090 g, 0.230 mmol) was added to 31 (0.077 g, 0.310 mmol) in DCM (20.00 mL), 
followed by triethylamine (0.032 mL, 0.230 mmol). The reaction mixture was stirred for 18 hours 
at room temperature, quenched by the addition of saturated NaHCO3 solution (20.00 mL) and 
extracted with DCM (3 x 20.00 mL). The combined organic extracts were dried (MgSO4), 
concentrated and purified by silica plug (5% MeOH, 1% NEt3 in CHCl3) to yield boc protected 33-
boc as pale yellow solid (0.100 g, 0.166 mmol, 72%). Rf 0.29 (5% MeOH, 1% NEt3 in CHCl3). 1H 
NMR (300 MHz, CDCl3) δH 9.68 (s, 1H, OH), 8.59 (s, 1H, OH), 8.06 (dd, 1H, J = 7.8, 1.6 Hz, H17), 
7.91 (d, 2H, J = 7.5 Hz, 2H12), 7.51 (d, 2H, J = 7.5 Hz, 2H13), 7.37 – 7.22 (m, 2H, H18, H23), 7.11 
– 6.82 (m, 4H, H19, H20, H25, H27), 6.63 (m, 1H, H26), 4.94 (s, 1H, H2), 3.75 – 3.41 (m, 10H, 2H7, 
2H6, 2H5, 2H4, 2H8), 3.29 – 3.14 (m, 2H, 2H4), 2.80 (s, 1H, NH), 1.33 (s, 9H, 9H1). 13C NMR (100 
MHz, CDCl3) δC 166.6 (C10), 166.2 (C3), 157.7 (C28), 152.1 (C21), 140.5 (C22), 135.8 (C15), 132.9 
(C11), 133.8 (C14), 129.3, 128.7, 128.0, 127.6, 125.8, 119.9, 119.2, 118.2, 117.2 (C16), 113.3 (C23), 
77.4 (C2), 70.2 (C6), 69.7 (C7), 46.0 (C5), 40.3 (C8), 40.0 (C9), 28.4 (C4), 9.7 (C1). MS m/z 604.3 
[M + H+], 626.3 [M + Na+]. IR 3312 (O-H), 2975 (N-H), 2930 (C-H), 1688 (C=O), 1611 (C=C), 





A solution of TFA (2.00 mL) was added to 33-boc (0.052 g, 0.086 mmol) in DCM (2.00 mL) and 
stirred at room temperature for 4 hours. Saturated NaHCO3 solution (20.00 mL) was added and 
subsequently extracted with DCM (3 x 10 mL), dried (MgSO4) and concentrated in vacuo to yield 
33 as yellow solid (0.041 g, 0.081 mmol, 96%). 1H NMR (300 MHz, CDCl3) δH 8.13 (dd, 1H, J = 
7.8, 1.6 Hz, H14), 7.95 (d, 2H, J = 7.5 Hz, 2H9), 7.52 (d, 2H, J = 7.5 Hz, 2H10), 7.41 – 7.27 (m, 2H, 
H21, H15), 7.21 (dd, 1H, J = 7.9, 1.5 Hz, H17), 7.13 – 6.96 (m, 2H, H16, H23), 6.92 (d, 1H, J = 8.2 
Hz, H24), 6.78 (t, 1H, J = 7.6 Hz, H22), 3.82 – 3.54 (m, 10H, 2H2, 2H6, 2H5, 2H4, 2H3), 3.47 (t, 2H, 
J = 4.6 Hz, 2H1), 2.75 (s, 2H, NH). 13C NMR (100 MHz, CDCl3) δC 166.5 (C7), 160.1 (C19), 157.0 
(C18), 156.7 (C25), 152.2 (C12), 140.8 (C8), 135.2, 132.8, 131.6, 129.0, 128.5, 127.4, 125.0, 119.8, 
119.3, 117.7, 117.2, 113.5, 112.1 (C2), 71.6 (C3), 69.9 (C4), 69.3 (C5), 40.9 (C1), 39.8 (C6). MS m/z 
504.2 [M + H+], 526.1 [M + Na+]. IR 3053 (O-H), 2869 (N-H), 1644 (C=O), 1624 (C=C), 1586 
(C=C), 1461 (C-C), 1247 (C-O) cm-1. Melting point range 100 – 104 °C.  
9.2.9 Methyl 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate 
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Compound 6 (0.055 g, 0.015 mmol) was added to methanol (2.00 mL) and sulphuric acid (12 M, 
0.01 mL), and refluxed for 18 hours. Solvent was removed in vacuo to yield 34 as dark brown solid 
(0.060 g, 0.015 mmol, 99%). Rf 0.30 (2:1 hexane: ethyl acetate). 1H NMR (300 MHz, CD3OD) δH 
8.09 (d, 2H, J = 8.8 Hz, 2H4), 7.99 (dd, 1H, J = 7.9, 1.6 Hz, H9), 7.66 (d, 2H, J = 8.8 Hz, 2H5), 7.54 
– 7.41 (m, 3H, H16, H18, H11), 7.08 (dd, 1H, J = 8.3, 0.6 Hz, H12), 7.05 – 6.92 (m, 3H, H10, H19, 
H17), 3.87 (s, 3H, H1). 13C NMR (100 MHz, CD3OD) δC 167.0 (C2), 157.8 (C14), 157.6 (C13) 153.7 
(C20), 151.2 (C7), 141.2 (C6), 136.6 (C3), 135.3, 133.3, 132.2, 131.9, 130.4, 126.1, 121.5, 121.3, 
117.8, 111.5 (C15), 108.7 (C8), 53.19 (C1). MS m/z 388.1 [M + H
+]. IR 3213 (O-H), 1718 (C=O), 
1607 (C=N), 1545 (C=C), 1521 (C=C), 1478 (C-C), 1428 (C-C) cm-1. Melting point range: 147 
– 150 °C.  
9.2.10 Ethyl 4-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)benzoate 
 
Compound 6 (0.100 g, 0.268 mmol) was added to ethanol (4.00 mL) and sulphuric acid (12 M, 
0.01 mL), and refluxed for 23 hours. Solvent was removed in vacuo to yield 35 as dark brown solid 
(0.105 g, 0.267 mmol, 99%). Rf 0.41 (2:1 hexane: ethyl acetate). 1H NMR (300 MHz, CD3OD) δH 
8.14 (d, 2H, J = 8.7 Hz, 2H5), 8.05 (dd, 1H, J = 7.9, 1.6 Hz, H10), 7.71 (d, 2H, J = 8.7 Hz, 2H6), 
7.60 – 7.46 (m, 3H, H12, H19, H17), 7.17 – 6.96 (m, 4H, H11, H13, H20, H18), 4.39 (q, 2H, J = 7.1 Hz, 
2H2), 1.39 (t, 3H, J = 7.1 Hz, 3H1). 13C NMR (100 MHz, CD3OD) δC 166.5 (C3), 157.8 (C15), 157.6 
(C14), 153.7 (C21), 151.2 (C8), 141.2 (C7), 136.6 (C4), 135.9, 135.3, 133.7, 132.2, 131.8, 130.4, 
126.0, 121.5, 121.3, 117.7, 111.5 (C9), 108.8 (C16), 62.8 (C2), 14.6 (C1). IR 3105 (O-H), 1707 
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2-Hydroxyethylhydrazine 36 (0.55 mL, 8.360 mmol) was added to 21 (1.000 g, 4.180 mmol) in 
methanol (30.00 mL) and solution was refluxed for 2 hours. Upon cooling, water (10.00 mL) was 
added to precipitate product which was collected, washed with water (10.00 mL) and dried to yield 
37 as white crystalline solid (0.527 g, 1.770 mmol, 43%). Rf 0.26 (2:1 hexane: ethyl acetate). 1H 
NMR (300 MHz, CD3OD) δH  8.03 (dd, 1H, J = 7.8, 1.6 Hz, H5),  7.50 (dd, 1H, J = 7.8, 1.6 Hz, 
H12), 7.46- 7.37 (m, 1H, H7), 7.33- 7.25 (m, 1H, H14), 7.08- 6.89 (m, 4H, H6, H8, H15, H13), 4.29 (t, 
2H, J = 5.6 Hz, 2H2), 3.94 (t, 2H, J = 5.6 Hz, 2H1), 3.35 (s, 1H, OH). 13C NMR (100 MHz, CD3OD) 
δC 161.5 (C10), 157.9 (C9), 156.8 (C16), 154.8 (C3), 133.5, 132.5, 132.0, 127.9, 120.9, 120.6, 117.9, 
117.3, 115.7, 61.1 (C1), 52.9 (C2). MS m/z 298.3 [M + H
+]. IR 3163 (O-H), 2974 (C-H), 1617 
(C=N), 1596 (C=C), 1585 (C=C), 1452 (C-C) cm-1. Melting point range: 150 – 152 °C.  
9.2.12 2-(3,5-bis(2-hydroxyphenyl)-1H-1,2,4-triazol-1-yl)ethyl benzoate 
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Benzoic acid (0.020 g, 0.168 mmol) was dissolved in DCM (20 mL), DCC (0.041 g, 0.202 mmol) 
and DMAP (0.007 g, 0.057 mmol) were added and solution was stirred at room temperature for 30 
minutes, 37 (0.050 g, 0.168 mmol) was added and solution was further stirred for 18 hours. The 
medium was concentrated in vacuo and purified by flash column chromatography (2:1 hexane: 
ethyl acetate) to yield 38 as a white solid (0.012 g, 0.030 mmol, 18%). Rf 0.3 (2:1 hexane: ethyl 
acetate). 1H NMR (300 MHz,CDCl3) δH 10.65 (s, 1H, OH), 9.66 (s, 1H, OH), 8.01 (dd, 1H, J = 
7.8, 1.6 Hz, H12), 7.77 (dd, 2H, J = 8.4, 1.3 Hz, H3, H5), 7.65 (dd, 1H, J = 7.9, 1.5 Hz, H19), 7.52 – 
7.40 (m, 1H, H1), 7.37 – 7.24 (m, 4H, H2, H6, H14, H21), 7.08 – 6.85 (m, 4H, H13, H15, H22, H20), 
4.86 – 4.74 (m, 4H, 2H8, 2H9). 13C NMR (100 MHz, CDCl3) δC 166.1 (C7), 159.5 (C17), 157.4 
(C16), 156.5 (C23), 153.1 (C10), 133.4, 132.8, 131.6, 129.7, 129.0, 128.4, 127.5, 126.9, 119.8, 119.7, 
118.4, 117.1, 113.5, 110.7, 62.4 (C8), 49.5 (C9). MS m/z 401.2 [M + H
+]. IR 3209 (O-H), 1711 
(C=O), 1624 (C=N), 1584 (C=C), 1512 (C=C), 1496 (C-C), 1473 (C-C), 1464 (C-N), 1453 (C-O) 




Compound 37 (0.150 g, 0.505 mmol) was added to tosyl chloride (0.115 g, 0.605 mmol) and 
triethylamine (0.102 g, 0.141 mL, 1.010 mmol) in DCM (30.00 mL), and stirred at room 
temperature for 70 hours. The reaction mixture was washed with water (3 x 20.00 mL), dried 
(MgSO4) and concentrated in vacuo. The resulting residue was purified by flash column 
chromatography (1:5 hexane: ethyl acetate) to yield 39 as white crystalline solid (0.093 g, 0.206 
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mmol, 20%). Rf 0.25 (1:5 hexane: ethyl acetate). 1H NMR (300 MHz,CDCl3) δH 7.87 (dd, 1H, J = 
7.8, 1.6 Hz, H20), 7.63 – 7.50 (m, 2H, H12, H13), 7.44 (dd, 1H, J = 7.7, 1.2 Hz, H10), 7.41 – 7.35 (m, 
1H, H11), 7.25 (ddd, 1H, J = 8.7, 7.3, 1.6 Hz, H18), 7.21 – 7.15 (m, 2H, 2H4), 6.96 – 6.89 (m, 1H, 
H17), 6.89 – 6.82 (m, 3H, H19, 2H3), 4.16 – 4.08 (m, 2H, 2H7), 4.02 – 3.94 (m, 2H, 2H6), 1.91 (s, 
3H, 3H1). 13C NMR (100 MHz, CDCl3) δC 160.6 (C21), 156.8 (C15), 149.9 (C8), 146.4 (C14), 146.3 
(C2), 132.5 (C12), 131.8 (C10), 131.3 (C18), 130.8 (C5), 129.9 (C3), 127.8 (C11), 127.5 (C4), 126.4 
(C20), 124.8 (C13), 121.0 (C9), 119.4 (C19), 117.3 (C17), 113.2 (C16), 60.9 (C6), 51.6 (C7), 21.1 (C1). 
MS m/z 474.2 [M + Na+]. IR 3541 (O-H), 3084 (C-H), 1616 (C=N), 1582 (C=C), 1524 (C=C), 




Compound 37 (0.150 g, 0.505 mmol) was added to tosyl chloride (0.115 g, 0.605 mmol) and 
triethylamine (0.102 g, 0.141 mL, 1.010 mmol) in DCM (30.00 mL), and stirred at room 
temperature for 70 hours. The reaction mixture was washed with water (3 x 20.00 mL), dried 
(MgSO4) and concentrated in vacuo. The resulting residue was purified by flash column 
chromatography (1:5 hexane: ethyl acetate) to yield 40 as yellow oil (0.082 g, 0.135 mmol, 12%). 
Rf  0.46 (1:5 hexane: ethyl acetate). 1H NMR (300 MHz,CDCl3) δH 7.76 (dd, 1H, J = 7.8, 1.6 Hz, 
H25), 7.70 – 7.62 (m, 1H, H12), 7.58 (d, 1H, J = 8.0 Hz, H13), 7.54 – 7.42 (m, 4H, H10, H11, 2H4), 
7.37 – 7.29 (m, 1H, H23), 7.19 (d, 2H, J = 8.0 Hz, 2H16), 7.07 (d, 2H, J = 8.0 Hz, 2H3), 7.01 (dd, 
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1H, J = 8.3, 0.9 Hz, H22), 6.98 – 6.91 (m, 1H, H24), 6.88 (d, 2H, J = 8.0 Hz, 2H17), 4.40 (t, 2H J = 
4.8 Hz, 2H6), 4.29 (t, 2H, J = 4.8 Hz, 2H7), 2.13 (s, 3H, 3H1), 1.96 (s, 3H, 3H19). 13C NMR (100 
MHz, CDCl3) δC 160.7 (C26), 156.6 (C20), 150.4 (C8), 146.2 (C14), 146.2 (C18), 145.3 (C2), 132.6 
(C12), 131.8 (C10), 131.7 (C5), 131.2 (C23), 130.8 (C15), 129.9 (C17), 129.7 (C3), 128.0 (C11), 127.5 
(C16), 127.4 (C4), 126.5 (C25), 124.6 (C13), 120.7 (C9), 119.3 (C24), 117.3 (C22), 113.5 (C21), 66.8 
(C6), 48.2 (C7), 21.2 (C19), 21.1 (C1). MS m/z 628.2 [M + Na
+]. IR 3064 (O-H), 1776 (C=N), 1737 
(C=C), 1613 (C=C), 1596 (C=C), 1461 (C-C), 1355 (S=O) cm-1.  
9.2.15  Alginate-deferasirox conjugate Exalg 
 
A solution of sodium alginate LFR5/60 (FMC Biopolymer, 0.250 g, 1.262 mmol), EDAC.HCl 
(0.242 g, 1.262 mmol), and NHS (0.145 g, 1.262 mmol) in MES buffer (30.00 mL, 0.1 M, pH 6) 
was prepared. To this was added 33 (Table 8) dissolved in MES buffer (10.00 mL, 0.10 M, pH 6) 
and the reaction mixture was stirred at room temperature for 16 h. The precipitate was isolated, 
washed with water (3 x 10.00 mL) and dried to yield 42 Exalg as off-white solid. 1H NMR (300 
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MHz, d6-DMSO) δH 10.84 (s, 1H), 8.63 (s, 1H), 8.20 – 7.70 (m, 4H), 7.70 – 7.17 (m, 4H), 7.17 – 
6.54 (m, 4H), 4.00 – 2.25 (m, xH). IR 3295 (O-H), 3000 (C-H), 1636 (C=O), 1628 (C=C), 1608 
(C=C), 1586 (C=C), 1505 (C-C), 1461 (C-C), 1090 (C-O), 1028 (C-N) cm-1. UV/vis (H2O, 25 °C): 
λmax = 247, 302 nm.  
Table 8 Details of ligand equivalence, amount used and mass of isolated product. 
Entry Eq 33 mmol 33 Mass 
33 (g) 







NMR spec, m) 
1 0.25 0.315 0.159 Exalg0.25 0.107 13 30 
2 0.50 0.631 0.318 Exalg0.50 0.309 37 38 
3 0.75 0.946 0.476 Exalg0.75 0.531 64 48 
4 1.00 1.262 0.635 Exalg1.00 0.785 94 39 
5 1.25 1.578 0.794 Exalg1.25 0.961 115 40 
 
Percentage ligand incorporation by 1H NMR spectroscopy was calculated by equating 12 aromatic 
protons (8.70 – 6.00 ppm) to one ligand equivalent. The number of x aliphatic protons (4.00 – 2.25 
ppm) was subtracted twelve aliphatic protons corresponding to the linker to give the number of 
protons that are from the alginate alone. This was divided by 7 protons per alginate monomer unit 
to get the number of alginate monomer equivalents. One ligand equivalent was divided by the 






Elemental analysis (Nitrogen/Carbon/Hydrogen) calculated for 100% modification N 10.58: C 
59.09: H 5.33, found (Table 9).  
Table 9 Results of elemental analysis of alginate polymers 
Compound C (% w/w) H (% w/w) N (% w/w) 
Alginate 30.62 4.09 0.00 
Exalg0.25 52.86 5.53 9.79 
Exalg0.50 51.78 5.76 9.74 
Exalg0.75 51.78 5.64 9.88 
Exalg1.00 51.82 5.67 9.87 
Exalg1.25 52.89 5.60 10.04 
 
9.2.16 Chitosan-deferasirox conjugate Exkite 
 
A solution of EDAC. HCl (0.062 g, 0.322 mmol) and NHS (0.038 g, 0.322 mmol) in deionised 
water (50.00 mL) was added to 6 (0.100 g, 0.269 mmol) dissolved in a few drops of DMSO. 
Chitosan was then added (0.044 g, 0.268 mmol of monomer units) and solution stirred at rt for 17.5 
h. Reaction solution was transferred to semi-permeable cellulose membrane (14 kDa molecular 
weight cut off, 76 mm flat width, Sigma Aldrich D9402) and dialysed in deionised water for three 
days, with the water changed twice daily. Water was removed in vacuo to yield 43 Exkite as pale 
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brown film (0.109 g, 90%). 1H NMR (300 MHz, d-TFA) δH 8.50 – 8.27 (m, 2H), 8.18 – 8.05 (m, 
1H), 7.70 – 7.60 (m, 2H), 7.30 – 7.48 (m, 2H), 7.09 – 6.92 (m, 4H), 6.82 – 6.91 (m, 1H), 5.30 – 
2.50 (m, 9H). IR: 3379 (O-H), 2985 (N-H), 1623 (C=O), 1591 (C=C), 1506 (C=C), 1493 (C-C), 
1472 (C-C), 1462 (C-C), 1369 (C-O) cm-1. UV/vis (H2O, 25 °C): λmax = 248, 305 nm.  
Percentage ligand incorporation by 1H NMR spectroscopy was calculated by equating 12 aromatic 
protons (8.50 – 6.00 ppm) to one ligand equivalent. The number of aliphatic protons (5.30 – 2.50 
ppm) was divided by 7 protons per chitosan monomer unit to get the number of chitosan monomer 
equivalents. One ligand equivalent was divided by the number of chitosan monomer equivalents 
and expressed as a percentage. 
Elemental analysis (Nitrogen/Carbon/Hydrogen) calculated for 100% modification N 10.85: C 
62.79: H 4.68, found (Table 10). 
Table 10 Elemental analysis results for chitosan polymers 
Compound C (% w/w) H (% w/w) N (% w/w) 
Chitosan 42.31 6.53 7.46 
Exkite 55.34 4.77 9.31 
 
9.2.17 Alginate-catechol conjugate 
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A solution of sodium alginate LFR5/60 (0.176 g, 1.000 mmol), dopamine hydrochloride (0.190 g, 
1.000 mmol), EDC.HCl (0.192 g, 1.000 mmol) and NHS (0.116 g, 1.000 mmol) in MES buffer 
solution (50.00 mL, 0.1 M, ph 6) was stirred at rt for 16 h. The reaction mixture was dialysed 
through a semi-permeable cellulose membrane (14 kDa molecular weight cut off, 76 mm flat width, 
Sigma Aldrich D9402) in aqueous media, the media was changed twice a day for three days. 
Compound 45 was obtained as white solid by freeze drying (0.125 g, 49%). IR 3252 (O-H), 1732 
(C=O), 1673 (C=C), 1610 (C=C), 1520 (C=C), 1406 (C-C), 1092 (C-C), 1031 (C-O) cm-1. 
Elemental Analysis (Nitrogen/Carbon/Hydrogen) calculated for 100% modification N 4.5: C 
54.02: H 5.50, found: N 5.28: C 38.99: H 6.01.  
9.2.18 Chitosan-catechol conjugate 
 
A solution of hydrocaffeic acid (0.500 g, 2.745 mmol), EDAC.HCl (0.631 g, 3.294 mmol) and 
NHS (0.379 g, 3.294 mmol) was prepared in water: ethanol mixture (1:1 15.00 mL: 15.00 mL). To 
this was added a solution of chitosan (0.445 g, 2.745 mmol) in acidic aqueous media (60.00 mL 
water acidified by HCl to pH 5), and the resulting reaction mixture was stirred at room temperature 
for 16 h. Reaction solution was transferred to semi-permeable cellulose membrane (14 kDa 
molecular weight cut off, 76 mm flat width, Sigma Aldrich D9402) and dialysed in acidic aqueous 
media (pH 5) for three days, with the aqueous media changed regularly. The dialysed solution was 
freeze dried to yield 47 as a brown solid (0.784 g, 70%). IR: 3347 (O-H), 1631 (C=O), 1527 (C=C), 
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1441 (C-C), 1069 (C-O) cm-1. Elemental Analysis (Nitrogen/Carbon/Hydrogen) calculated for 
100% modification N 4.31: C 55.38: H 5.89, found: N 5.50: C 38.06: H 6.21.  
9.3 Phenol/Sulphuric acid assay 
9.3.1 Ligand concentration 
Deferasirox ligand 6 was dissolved in 0.1 M NaOH solution and UV-vis spectroscopy readings 
were taken at varying concentrations using Varian Cary50 spectrophotometer at 22 °C. A 
calibration curve was constructed by plotting absorbance vs. concentration at 245 and 315 nm.  
Modified ligand 33 was dissolved in water and UV-vis spectroscopy readings were taken at varying 
concentrations using Varian Cary50 spectrophotometer at 22 °C. A calibration curve was 
constructed by plotting absorbance vs. concentration at 245 and 300 nm. 
Exalg solutions were made by dissolving polymers in DMSO and diluting in water (0.010 g 
polymer/2.00 mL DMSO diluted up to 140.00 mL in water), and Exkite solutions were dissolved 
in 1M HCl (0.010 g polymer/150.00 mL 1M HCl). These polymer solutions were used for further 
iron binding studies. UV-vis spectra of polymers were taken and absorbance at 245 and 315 nm 
for Exkite, 245 and 300 nm for Exalg were compared to ligand calibration curves to determine 
amount of ligand in polymer.  
9.3.2 Polymer concentration 
Alginate solutions were made in water and chitosan solutions were made in 1% v/v acetic acid at 
varying concentrations. Exkite and Exalg solutions were used as prepared above. Polymer solution 
(2.00 mL) was decanted into a glass vial and 80% w/w phenol solution (0.05 mL) was added and 
solutions mixed by shaking. Concentrated sulphuric acid (5.00 mL) was added rapidly and solution 
was allowed to stand at room temperature for 10 minutes, then mixed by shaking. The solutions 
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were placed in a water bath at 30 °C for 20 minutes and readings were taken by UV-vis 
spectroscopy.142 Calibration curves for alginate were constructed by plotting absorbance vs. 
concentration at 480 nm and for chitosan at 490 nm. Exkite and Exalg were treated in the same 
way; chitosan concentration in Exkite was determined by comparing absorbance at 490 nm to 
chitosan calibration curves, and alginate concentration in Exalg was determined by comparing 
absorbance at 480 nm to calibration curves.  
9.3.3 Percentage modification 
The percentage modification of polymers was calculated by comparison of the ligand concentration 
to polymer concentration as determined by phenol/sulphuric acid assay and UV-vis spectroscopy 
in the same volume of polymer (2.00 mL/cuvette). All readings were taken in triplicate, and 
background readings of solutions that polymers were dissolved in were also obtained to ensure no 
background interference.  
9.4 UV-Vis spectroscopy iron titration experiments 
Polymer solutions 0.15% w/v chitosan, 0.10% w/v Exkite, 0.10% w/v alginate, 0.01% w/v Exalg 
were titrated with sequential addition of 10 µL iron chloride solution (10 mM FeCl3.6H2O) into 
2.00 mL polymer solution in quartz cuvette. The solution was mixed between each addition and 
UV-vis spectra recorded. A gradual shift or increase in absorbance at λmax was taken to indicate 
iron chelation by polymers.  
9.5 Iron binding by polymer dialysis 
9.5.1 Dialysis experiments 
Polymer solutions 0.10% w/v chitosan, 0.10% w/v alginate, 0.007% w/v Exalg (0.010 g polymer/ 
2.00 mL DMSO diluted up to 140.00 mL in water), and 0.007% w/v Exkite (0.010 g polymer/ 
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150.00 mL 1M HCl), were sealed (3 x 10.00 mL) into a dialysis membrane (14 kDa molecular 
weight cut off, 76 mm flat width, Sigma Aldrich D9402). Polymer solutions in dialysis membrane 
were incubated in ferrous iron (0.20 mM FeSO4·7H2O, 750.00 mL), ferrous iron with calcium (0.20 
mM FeSO4·7H2O, 2.00 mM CaCl2·2H2O, 750.00 mL), ferric iron (0.20 mM FeCl3·6H2O, 750.00 
mL), and ferric iron with calcium (0.20 mM FeCl3·6H2O, 2.00 mM CaCl2·2H2O, 750.00 mL) for 
2 hours with agitation. Dialysis in acidic supernatant required addition of concentrated 
hydrochloric acid (12 M HCl, 0.75 mL in 750.00 mL). When washing step was conducted, the 
sealed dialysis membrane was washed in deionised water (750.00 mL) for 2 hours. All experiments 
were performed in triplicate. 
9.5.2 Ferrozine assay of polymers 
Ferrozine stock solution was prepared by adding sodium ascorbate (0.911 g), ferrozine (0.089 g), 
and sodium acetate (13.776 g) to deionised water (152.50 mL). After dialysis, each polymer sample 
(200 µL) was mixed with ferrozine stock (600 µL) and concentrated hydrochloric acid (12 M HCl, 
50 µL). Calibration curve for iron was constructed by preparing varying concentrations of ferrous 
iron solutions in 0.1% v/v HCl at 0.75 mM, 0.50 mM, 0.25 mM, 0.125 mM and 0.10 mM that were 
also treated in the same way. All samples were plated out in triplicate (3 x 200 µL) into a flat-
bottomed clear 96 well plate and absorbance read at 550 nm on Victor 2 Wallac 1420 microplate 
reader. Iron binding of polymers was determined by comparison to calibration curve. 
9.5.3 Atomic absorption spectroscopy 
Dialysed samples (10.00 mL) were concentrated in vacuo and re-dissolved in nitric acid (16 M 
HNO3, 0.50 mL) and hydrochloric acid (3 M HCl, 9.50 mL). Samples were heated to 80 °C and 
sonicated for 2 – 4 hours. Calibration standards were prepared by serial dilutions of 1000 ppm iron 
in 1 M nitric acid (Fischer J803005) at 0.5 ppm, 1 ppm, 5 ppm, 10 ppm, 15 ppm and 20 ppm. Iron 
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content of samples were analysed by Perkin Elmer Instruments Analyst 300 atomic absorption 
spectrophotometer, equipped with iron specific hollow cathode lamp with maximum current of 10 
mA. The samples were atomised using an acetylene-air flame. Iron binding of polymers was 
determined by comparison to calibration curve.  
9.6 Cell culture 
Human colorectal carcinoma RKO cells obtained from ATCC were stored in liquid nitrogen and 
thawed for use. The cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, Sigma 
Aldrich) supplemented with 10% v/v foetal calf serum (FCS, Gibco Life Technologies), 100 units/ 
mL penicillin and 0.1 mg/ mL streptomycin. Cells were incubated at 37 °C and 5% CO2.  
Cells were routinely maintained as adherent monolayers, and were passaged at 80% confluence by 
aspirating the culture medium, washing with sterile phosphate buffered saline (PBS) and incubating 
with Trypsin (TrypLETM Express (1x), Gibco Life Technologies, 5.00 mL for 5 minutes) until cells 
had detached. Culture media (5.00 mL) was added and then centrifuged at 1500 rpm for 5 minutes. 
The cell pellet was re-suspended in culture media and reseeded into tissue culture flasks and 
cultured in the standard manner. All cell culture procedures were performed in a laminar flow tissue 
culture cabinet using aseptic technique. 
9.7 MTT cell viability assay 
RKO cells (1 x 105 cells/mL) were seeded into 6-well plates (Corning) at 2.00 mL/well. After cells 
were allowed to adhere for 24 hours, the medium was replaced with stimulation medium and further 
incubated for 24 hours. This consisted of varying concentrations of chitosan, Exkite, alginate or 
Exalg diluted from 1% w/v stock solutions into modified DMEM (10% FCS, 100 units/mL 
penicillin and 0.1 mg/mL streptomycin). Experiments were done in triplicate for each concentration 
and control was conducted in cell culture media alone. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-
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diphenyltetrazolium bromide] (Sigma-Aldrich) was dissolved into sterile PBS (0.005 g/mL) and 
further filtered sterilised to remove any insoluble particles. MTT solution (100 µL) was added to 
each well and incubated for 3 hours. The media was aspirated and replaced with DMSO (1.00 
mL/well) to dissolve accumulated formazan crystals. After 10 - 15 minutes at room temperature, 
DMSO solution from each well of 6-well plate was transferred in triplicate to 96-well plate (100 
µL x 3 from each well). Plates were read at 490 nm on Victor 2 Wallac 1420 microplate reader. 
The resulting optical densities were used to calculate viability as fold change with respect to control. 
9.8 Western blot 
9.8.1 Sample preparation 
RKO cells (1 x 105 cells/mL) were seeded into 6-well plates at 2.00 mL/well and allowed to adhere 
for 24 hours. Iron stock solution was made by dissolving iron sulphate (10 mM FeSO4·7H2O, 
0.1112 g) and sodium ascorbate (1 mM, 0.008 g) into deionised water (40.00 mL), which was 
further filtered sterilised to remove any insoluble particles. The stock solution was added to 
modified DMEM (100 µL/10.00 mL DMEM) to give final concentrations of 100 µM iron sulphate 
and 10 µM sodium ascorbate. Polymer solutions were added to iron loaded modified DMEM, 
diluted from 1% stock solutions to achieve final concentrations of 0.03% w/v Exkite and Chitosan 
(0.30 mL polymer stock/10.00 mL DMEM), 0.05% w/v Exkite and Chitosan (0.50 mL polymer 
stock/10.00 mL DMEM), 0.005% w/v alginate and Exalg (0.05 mL polymer stock/10.00 mL 
DMEM), 0.01% alginate and Exalg (0.10 mL polymer stock/10.00 mL DMEM).  
The media was aspirated and replaced with stimulation medium containing iron sulphate (100 µM), 
sodium ascorbate (10 µM) and the appropriate concentration of polymer in DMEM (2.00 mL/well) 
and further incubated for 24 hours. Experiments were done in triplicate for each polymer 
 149 
concentration, positive control was conducted in iron loaded modified DMEM (100 µM FeSO4· 
7H2O, 10 µM sodium ascorbate), negative control was conducted in modified DMEM alone. 
At the end of the incubation period, the media was removed and cells washed with ice cold PBS 
buffer (3 x 1.00 mL/well), and lysed with radioimmunoprecipitation assay (RIPA) buffer (100 
µL/well) whilst being kept on ice. RIPA buffer contains 1% v/v NP40 detergent, 0.5% w/v sodium 
deoxycholate, 0.1% w/v sodium dodecyl sulphate (SDS) and a mixture of proprietary protease 
inhibitors (1 protease inhibitor tablet (Roche) dissolved per 50.00 mL RIPA buffer). 
Cell lysates were subject to probe sonication (10 seconds, Soniprep 150 MSE Sonyo). The amount 
of protein in each sample was quantified using PierceTM BCA Protein Assay Kit, according to 
manufacturer’s instructions using 96-well plate done in triplicate for each sample (3 x 10 µL). The 
plate was read at 550 nm using Victor 2 Wallac 1420 microplate reader. Standard calibration curves 
were constructed for the determination of protein content. The volume of cell lysate containing 20 
µg of protein was calculated and this volume was added to 5 µL of 5x SDS sample loading buffer 
(0.0625 M Tris HCl pH 6.7, 10% v/v glycerol, 2% w/v SDS, 1% v/v β-mercaptoethanol and 0.001% 
w/v bromophenol blue). Samples were then heated to 100 °C for 5 minutes and centrifuged briefly 
to bring samples to bottom of tubes.  
9.8.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
Stacking and resolving gels for SDS-PAGE were prepared according to recipe (Table 11). A 
BioRad Protean–II mini-gel apparatus was used, and resolving gel was poured between two glass 
plates. Isopropanol was added to the top to form a thin layer to ensure uniformity of resolving gel. 
After leaving gel to set (5 - 10 minutes), isopropanol was poured out and stacking gel applied to 
the top of resolving gel with immediate insertion of miniprep combs (1.5 mm combs for 10 lanes). 
After stacking gel was set (5 - 10 minutes), combs were removed and wells equilibrated with 
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electrophoresis running buffer (0.192 M glycine, 0.01% w/v SDS, 25 mM Tris HCl pH 8.3).One 
well per gel was loaded with an aliquot of pre-stained protein ladder (5 µL, Thermo Scientific 
26619). The remaining wells were loaded with prepared cell lysates at the predetermined volume 
containing 20 µg protein. Electrophoresis was conducted at 100 V (15 minutes), and then increased 
to 180 V (45 minutes) until the dye front reached the bottom of the gel. 
Table 11 Composition of SDS-PAGE stacking and resolving gels, sufficient for the preparation of two gels. 
Reagent Resolving gel (12.5%) Stacking gel 
dH2O 1.90 mL 3.70 mL 
Buffer 10.00 mL (0.2% w/v SDS, 
0.75 M Tris HCl, pH 8.8) 
5.00 ml (0.2% w/v SDS, 0.25 
M Tris HCl, pH 6.8) 
Acrylamide 8.10 mL 1.30 mL 
Ammonium persulphate 30 mg 30 mg 
TEMED (add last for gelling) 60 µL 60 µL 
 
9.8.3 Transfer of gels 
Proteins separated by SDS-PAGE were transferred directly onto Hybond hydrophobic 
polyvinylidene diflouride membranes (GE Healthcare, RPN2020F). Membranes were cut to size 
and activated by soaking in methanol (30 seconds) and placed in transfer buffer (48 mM Tris HCl, 
39 mM glycine, 20% v/v methanol, 0.0375% w/v SDS). The gels were removed from resolving 
apparatus, stacking gel at top and dark bands at the bottom were disposed. Gels were placed on top 
of the membrane and inserted into transfer cartridges ensuring that this was placed in between 
sponges and filter paper soaked in transfer buffer. The transfer tank was filled with transfer buffer 
and an ice pack to offer constant cooling, and was run at 100 V for 70 minutes.  
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9.8.4 Blocking membranes 
Membranes were removed from transfer tanks and blocked by placing in 5% w/v milk solution, 
prepared from skimmed milk powder dissolved in tris-buffered saline tween (TBST) (10 mM Tris-
Cl pH 8.0, 150 mM NaCl, 0.05% tween-20). Membranes were incubated for 1 hour at room 
temperature on a plate shaker.  
9.8.5 Primary antibody 
Blocking milk was removed and membranes were cut into two sections along 35 kDa line by using 
the pre-stained protein ladder as a guide. The top sections of the membranes were incubated with 
anti-β-action primary antibody (Abcam, ab8226), and bottom sections were incubated with anti-
ferritin primary antibody (Abcam, ab69090). Both antibodies were diluted at ratio 1:5000 in 5% 
w/v skimmed milk powder in TBST, which was added to membranes and incubated at 4 °C 
overnight on plate shaker.   
9.8.6 Secondary antibody 
Primary antibody was removed followed by a brief wash of membranes with TBST. Membranes 
were further washed with TBST (3 x 10 minutes) accompanied by agitation on plate shaker. 
Secondary peroxidase conjugated antibodies were prepared by diluting antibodies 1: 10,000 in 5% 
w/v skimmed milk powder in TBST; anit-mouse antibody used for β-actin and anti-rabbit antibody 
used for ferritin (Abcam). This was applied to membranes and incubated for 1 hour at room 
temperature on plate shaker. Secondary antibodies were removed and membranes washed by TBST 
(3 x 10 minutes).  
9.8.7 Developing blots 
Membranes were placed in a plastic bag sealed on three sides and enhanced chemiluminescence 
(ECL) reagent was added (5.00 mL/membrane, GE Healthcare, RPN2106 prepared according to 
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manufacturer’s instructions.) The bag was sealed and exposed to ECL reagent (5 minutes), after 
which the bag was unsealed, ECL reagent removed and placed in an imaging cassette. The blots 
were developed in a darkroom using Amersham HyprfilmTM (GE Healthcare, 28-9068-46) on a 
Xograph X2 automatic developer.  
Blots were scanned and densitometry was analysed using ImageJ software and Microsoft Excel, in 
which ferritin bands were normalised relative to β-actin bands. 
9.9 Ferritin ELISA 
Cell lysates prepared for western blots were also used for analysis by ferritin ELISA. After lysis of 
cells in RIPA buffer, samples were stored at -20 °C until use and were subsequently thawed on ice. 
Ferritin ELISA was conducted using a Spectro ferritin ELISA kit (Ramco Laboratories Inc, S-22) 
according to manufacturer’s instructions, using the pre-coated 96-well plate provided. Absorbance 
of samples were read at 490 nm and 595 nm on Victor 2 Wallac 1420 microplate reader. Results 
were processed using Microsoft Excel by construction of calibration curves as instructed in the kit.  
9.10  Intracellular ferrozine assay  
9.10.1 Sample preparation  
RKO cells (3 x 105 cells/mL) were seeded into 6-well plates at 2.00 mL/well and allowed to adhere 
for 24 hours. Iron stock solution was made by dissolving iron sulphate (10 mM FeSO4·7H2O, 
0.1112 g) and sodium ascorbate (50 mM, 0.396 g) into deionised water (40.00 mL), which was 
further filtered sterilised to remove any insoluble particles. Serum-free DMEM was prepared (100 
units/mL penicillin and 0.1 mg/ mL streptomycin only). The stock solution was added to serum-
free DMEM (100 µL/10.00 mL DMEM) to give final concentrations of 100 µM iron sulphate and 
500 µM sodium ascorbate. Polymer solutions were added to iron loaded serum-free DMEM, 
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diluted from 1% stock solutions to achieve final concentrations of 0.03% w/v Exkite and Chitosan 
(0.30 mL polymer stock/10.00 mL DMEM), 0.05% w/v Exkite and Chitosan (0.50 mL polymer 
stock/10.00 mL DMEM), 0.005% w/v alginate and Exalg (0.05 mL polymer stock/10.00 mL 
DMEM), 0.01% alginate and Exalg (0.10 mL polymer stock/10.00 mL DMEM).  
The media was aspirated and replaced with serum-free DMEM and incubated for 1 hour to serum 
starve cells. Serum-free media was removed and replaced with stimulation medium containing iron 
sulphate (100 µM), sodium ascorbate (500 µM) and the appropriate concentration of polymer in 
serum-free DMEM (2.00 mL per well) and further incubated for 1 hour. Experiments were done in 
triplicate for each polymer concentration, positive control was conducted in iron loaded serum-free 
DMEM (100 µM FeSO4·7H2O, 500 µM sodium ascorbate), negative control was conducted in 
serum-free DMEM alone. 
At the end of the incubation period, the media was removed and cells washed with ice cold PBS 
buffer (3 x 1.00 mL/well), and lysed with HEPES saline buffer (10 mM 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) in 0.9% w/v sodium chloride at pH 7.4, 150 µL/well) 
whilst being kept on ice.  
9.10.2 Protein assay 
The amount of protein in each sample was quantified using PierceTM BCA Protein Assay Kit, 
according to manufacturer’s instructions, using 96-well plate done in triplicate for each sample (3 
x 10 µL). The plate was read at 550 nm using Victor 2 Wallac 1420 microplate reader. Standard 
calibration curves were constructed for the determination of protein content.  
9.10.3 Ferrozine assay  
Cell lysate (90 µL) was added to TCA solution (200 µL, 20% w/v trichloroacetic acid (TCA) in 
4% w/v sodium pyrophosphate) and heated to 100 °C for 10 minutes. The tubes were centrifuged 
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to bring solutions to the bottom. Ferrozine stock solution was prepared by adding sodium ascorbate 
(0.911 g), ferrozine (0.089 g), and sodium acetate (13.776 g) to deionised water (122.00 mL). The 
cell lysate and TCA solution (200 µL) was added to ferrozine stock solution (600 µL) and 
thoroughly mixed. This solution was plated out in triplicate in a flat bottomed clear 96-well plate 
(3 x 200 µL). Calibration solutions were made using iron sulphate in 0.1% v/v HCl at 0.75 mM, 
0.50 mM, 0.25 mM, 0.125 mM, 0.10 mM and were mixed (200 µL) with ferrozine stock solution 
(600 µL) and plated out in triplicate. The plate was read at 550 nm using Victor 2 Wallac 1420 
microplate reader. Standard calibration curves were constructed for the determination of iron 
content, which was normalised to protein content in each sample.  
9.11  Preloading cells with iron  
In order to determine in vitro Exkite activity and possible ligand cleavage, RKO cells were 
preloaded with iron, then treated with polymers. RKO cells (2 x 105 cells/mL) were seeded into 6-
well plates (2.00 mL/well) and allowed to adhere for 24 hours. Iron stock solution was made by 
dissolving iron sulphate (10 mM FeSO4·7H2O, 0.1112 g) and sodium ascorbate (1 mM, 0.008 g) 
into deionised water (40.00 mL), which was further filtered sterilised to remove any insoluble 
particles. The stock solution was added to modified DMEM (100 µL/ 10.00 mL DMEM) to give 
final concentrations of 100 µM iron sulphate and 10 µM sodium ascorbate. The media was 
aspirated and replaced with iron loaded modified DMEM (2.00 mL/well), and further incubated 
for 24 hours.  
Polymer solutions were added to modified DMEM, diluted from 1% stock solutions to achieve 
final concentrations of 0.03% w/v Exkite and chitosan (0.30 mL polymer stock/10.00 mL DMEM), 
0.05% w/v Exkite and chitosan (0.50 mL polymer stock/10.00 mL DMEM). Iron loaded media was 
aspirated and cells were washed with PBS (3 x 1.00 mL/well). Stimulation medium containing 
polymer solutions was added (2.00 mL/well) and incubated for 24 hours. Experiments were done 
 155 
in triplicate for each polymer concentration, positive control was conducted in iron loaded modified 
DMEM (100 µM FeSO4·7H2O, 10 µM sodium ascorbate), negative control was conducted in 
modified DMEM alone. The media was removed and cells washed with ice cold PBS buffer (3 x 
1.00 mL/well), and lysed with RIPA buffer (100 µL/well) whilst being kept on ice. 
Samples were analysed by ferritin ELISA which was conducted using a Spectro ferritin ELISA kit 
(Ramco Laboratories Inc, S-22) according to manufacturer’s instructions, using the pre-coated 96-
well plate provided. Absorbance of samples were read at 490 nm and 595 nm on Victor 2 Wallac 
1420 microplate reader. Results were processed using Microsoft Excel by construction of 
calibration curves as instructed in the kit.  
9.12  Murine studies 
Wild type mice have no genetic modifications. Mice used in experiments were at least 6 weeks of 
age weighing a minimum of 20.00 g.  
Apc Hom (Cre+ Apcf/f) mice is a transgenic inducible model of sporadic CRC with homozygous 
Apc inactivation in the intestinal epithelium. Mice were induced at 6 weeks of age after they 
weighed a minimum of 20.00 g by tamoxifen (Sigma Aldrich) injection of 4 x 3.00 mg given on 
consecutive days.  
Apc Hom Pten Hom (Cre+ Apcf/f Ptenf/f) mice is a transgenic inducible model with homozygous 
inactivation of Apc and Pten. Mice were induced at 6 weeks of age after they weighed a minimum 
of 20.00 g by tamoxifen (Sigma Aldrich) injection of 1 x 3.00 mg. 
All mouse experiments were performed according to UK Home Office Guidelines and approved 
by University of Birmingham Ethics Committee in accordance with project licence 70/8198 under 
protocol 19b 5 and 40/3613 under protocol 19b3. 
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9.13  Exkite activity in mice 
9.13.1 Exkite safety and tolerability 
Wild type mice (n = 1 per dose) were given daily 200 µL gavages of Exkite for five days at varying 
concentrations: 0.01%, 0.10%, 0.25%, 0.50% and 1% w/v, using gavage needle and luer lock 1.00 
mL syringe. After the allotted treatment period the mice were culled under humane conditions. 
9.13.2 Deferasirox detection in blood plasma 
Wild type mice (n = 3) were administered a single dose of 200 µL 1% w/v Exkite by oral gavage, 
control mice (n = 3) were subject to 200 µL water using gavage needle and luer lock 1.00 mL 
syringe. After one hour, the mice were culled under humane conditions. Blood samples were 
obtained by direct cardiac puncture and aliquoted into Capiject® blood tubes. The blood was 
allowed to clot and centrifuged at 5000 rpm for 10 minutes after which the serum was aspirated. 
Blood serum was diluted in water (1:2 ratio) and analysed by MALDI spectroscopy by plating 
sample (2 µL) with α-cyano-4-hydroxycinnamic acid (CHCA) matrix (1 µL), analysed on Bruker 
Ultraflextreme MALDI spectrometer.  
9.13.3 Deferasirox detection in crypt cells 
Wild type mice (n = 3) were administered a single dose of 200 µL 1% w/v Exkite by oral gavage, 
control mice (n = 3) were subject to 200 µL water using gavage needle and luer lock 1.00 mL 
syringe. After one hour, the mice were culled under humane conditions.  
The small intestine was dissected and placed in cold PBS (10.00 mL), and cut into small pieces. 
The intestine was repeatedly agitated and washed with cold PBS (10 x 10.00 mL) and supernatant 
discarded until supernatant was clear. After the final wash, cold PBS (25.00 mL) was added with 
EDTA (100 µL) and incubated on ice for 30 minutes. The EDTA supernatant was discarded, and 
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intestines were washed gently with PBS (10.00 mL). The intestines were mechanically agitated by 
hard pipetting of cold PBS (10.00 mL) and the supernatant was decanted to obtain the first fraction 
of crypt cells. This was repeated three more times to obtain four crypt fractions. The fractions were 
checked under the microscope and crypt enriched fractions were combined, and made up to 50.00 
mL by the addition of Advanced DMEM/F12 (ADF). The solution was centrifuged at 1200 rpm 
for 5 minutes to obtain a cell pellet. The supernatant was discarded and pellet was re-suspended in 
Advanced DMEM/F12 (10.00 mL) and passed through a 70 µm cell strainer, which was washed 
with additional DMEM (5.00 mL). This was centrifuged at 600 rpm for 2 minutes, supernatant 
discarded and pellet re-suspended. This process was repeated two more times and supernatant was 
discarded. To the cell pellet, PBS (1.00 mL) was added, cells re-suspended and centrifuged at 1300 
rpm for 5 minutes. The PBS supernatant was discarded and ethanol (100 µL) added and thoroughly 
mixed. This was centrifuged at 1300 rpm for 5 minutes and ethanol supernatant was aspirated and 
allowed to air dry. Samples were re-dissolved in ethanol (10 µL) and deionised water (10 µL) and 
thoroughly mixed.  
Samples were analysed by MALDI spectrometry by plating sample (2 µL) with α-cyano-4-
hydroxycinnamic acid (CHCA) matrix (1 µL), analysed on Bruker Ultraflextreme MALDI 
spectrometer. 
9.14  Mouse survival studies 
Mouse survival studies were conducted with Apc Hom (Cre+ Apcf/f) mice and Apc Hom Pten Hom 
(Cre+ Apcf/f Ptenf/f) which were used immediately following induction by tamoxifen injection. The 
mice were administered 200 µL of 1% w/v Exkite (n = 6 Apc Hom, n = 13 Apc Hom Pten Hom) 
or 200 µL of water as the vehicle control (n = 3 Apc Hom, n = 16 Apc Hom Pten Hom), 
administered by oral gavage using gavage needle and luer lock 1.00 mL syringe on alternate days 
(Mon/ Wed/ Fri) until they became sick. Mice were presumed sick when they showed symptoms 
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of weight loss (< 20% pre-experimental weight), hunched posture, pale feet, pinched face, 
piloerection, lack of movement and isolation in cage. All mice were culled under humane 
conditions, small intestines were dissected and fixed in 10% v/v neutral buffered formalin and 
embedded in paraffin.  
9.15  Immunohistochemistry 
9.15.1 De-wax and rehydrate slides 
Archived small intestine tissue from mouse survival studies were sectioned at 5 μm intervals and 
applied to SuperFrost glass. Slides were washed in xylene for 2 minutes for removal of excess 
paraffin wax, and hydrated by sequential submersion in 100% ethanol followed by 80% v/v ethanol.  
9.15.2 Antigen retrieval 
A solution of citric acid (10.50 g) in deionised water (0.50 L) was made, and a solution of sodium 
citrate (29.40 g) in deionised water (1.00 L) was made. Citric acid solution (27.00 mL) was added 
to sodium citrate solution (123.00 mL) and total volume was made up to 1.50 L by the addition of 
deionised water. This solution was added to a pressure cooker and slides were submerged, pressure 
cooker was heated in a microwave for 20 minutes until pressure was optimised for 10 – 15 seconds 
and allowed to cool.  
9.15.3 Prevention of endogenous staining/Blocking 
Slides were blotted dry and outlined by a hydrophobic delineating pen (Dako). A solution of 3% 
w/v hydrogen peroxide was added to cover surface of slides (100 – 200 µL) for 10 minutes. Slides 
were washed in PBS (3 x 1.00 mL/slide) and incubated for 30 minutes with 1% w/v albumin in 
PBS.  
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9.15.4 Primary antibody 
Anti-caspase 3 antibody (R&D Systems, AF 835) was diluted into 1% w/v albumin at 1:800 ratio, 
and anti-phosphohistone antibody (R&D Systems) was diluted into 1% w/v albumin at 1:500 ratio. 
The slides were tapped dry and antibodies applied to ensure surface coverage (100 – 200 µL) and 
incubated overnight at 4 °C. Slides were then washed in PBS (3 x 1.00 mL/slide).  
9.15.5 Secondary antibody 
Secondary antibody was applied (Dual – link Dako kit HRP Yellow) at 2-3 drops per slide for both 
caspase 3 and phosphohistone slides and incubated at room temperature for 30 minutes. Slides 
were tapped dry and washed in PBS (3 x 5 minutes).  
9.15.6 Visualisation of positivity 
A visualisation kit (DAB) was used according to the manufacturer’s instructions. The premixed 
solution was added to each slide (200 µL) and incubated for 30 seconds – 5 minutes until positive 
brown staining was observed, and washed thoroughly in water. Slides were counterstained in 
haematoxylin for 20 seconds and washed sequentially in water twice, Scott’s Tap water (Sigma 
Aldrich), then water again. Slides were dehydrated by washing in 80% w/v ethanol, then 100% 
ethanol and finally in xylene. Slides were mounted by the application of a cover slip using DPX 
Mountant (Sigma Aldrich).  
9.15.7 Scoring of slides 
H&E sections were stained by a service provided by The Department of Cellular Pathology, Queen 
Elizabeth Hospital.  
The slides were scored by counting 25 continuous crypts for positive staining per mouse, with 6 
mice taken per group. Slides stained by H&E were scored for mitosis by identification of cells 
undergoing division. The extent of mitosis is expressed as mitotic index, which is the percentage 
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of cells in mitosis relative to total number of cells per crypt. The extent of apoptosis is expressed 
as apoptotic index, which is the percentage of cells in apoptosis relative to total number of cells per 
crypt. 
Images were visualised using a Nikon Eclipse E600 microscope and digital image captured using 
a Nikon DXM1200F camera, with the use of Nikon ACT-1 2.62 software for image acquisition.  
9.16  Statistical analysis 
Data was analysed using Microsoft Excel Professional 2010. Data is expressed as an average of 
triplicate readings in most cases ± the standard error in the mean (SEM). Statistical significance 
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